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Abstract 
Cardiomyocyte apoptosis is an important contributory factor towards 
the progression of ischaemic heart disease. Signal Transducer and 
Activator of Transcription 3 (STAT3) is a transcription factor has that 
been implicated in normal heart development and function. Most 
interestingly, STAT3 also appears to playa role in cardioprotection, 
including hypoxic preconditioning. In this thesis the levels and 
activities of ST A T3 were measured in response to hypoxic insult in 
primary rat cardiomyocytes (RCMs) and two cardiomyocyte cell lines 
(H9c2 and P19CL6 cells). P19CL6 cells were extremely sensitive to 
hypoxia-induced apoptosis whereas RCMs and H9c2 cells were highly 
resistant. 
Apoptosis in P19CL6 cells correlated with loss of ST AT3 DNA 
binding, which was preceded by serine phosphorylation and followed 
by loss of tyrosine phosphorylation. Treatment with LIF partially 
protected P19CL6 cells from hypoxia-induced apoptosis, as did 
exogenous expression of ST A T3 but not a redox-insensitive ST AT3 
mutant (STAT3C3s). Moreover, STAT3 expressIOn rescued 
mitochondrial ATP production during hypoxia whereas the redox-
insensitive mutant did not. These data indicate that the contribution of 
STAT3 to cardiomyocyte survival under hypoxic stress involves the 
maintenance of mitochondrial function by a redox-dependent 
mechanism. 
Understanding how STAT3 is regulated in cardiomyocytes will be 
important for the development of therapeutic approaches for ischaemic 
heart disease in the future. 
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Chapter 1. Introduction 
1.1. Cardiovascular disease 
1.1.1. The statistics 
Cardiovascular disease (CVD) is responsible for the highest morbidity 
rates worldwide, accounting for approximately 17 million deaths each 
year. Ischaemic heart disease (lHD) resulted in 12.2% of total deaths in 
2004 (table 1) and this figure is estimated to rise to 14.2% by 2030 
(WHO, 2008). In the UK, CVD accounts for almost 191 ,000 deaths 
each year - one in three of all deaths (Scarborough, 2010). As well as 
human losses, CVD places a great financial burden on the UK and is 
estimated to cost the economy £30.7 billion a year. Of the total costs of 
CVD to the UK, around 47% is due to direct health care costs, 27% to 
productivity losses and 26% to the informal care of people with CVD 
(Scarborough, 2010). 
Table 1 Top 5 causes of death worldwide. Data taken from (WHO, 
2008) 
Disease causing death Deaths Percent of 
(Millions) total deaths 
1. Ischaemic heart Disease 7.2 12.2 
2. Cerebrovascular disease 5.7 9.7 
3. Lower respiratory infections 4.2 7.1 
4. Chronic obstructive pulmonary 3.0 5.1 
disease 
5. Diarrhoeal diseases 2.2 3.7 
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1.1.2 Structure and function of the heart 
The heart is a powerful muscle that pumps blood throughout the body 
through coordinated contraction. The heart is composed of four 
chambers; two thin-walled atria that receive blood returning to the heart 
and two thick-walled ventricles consisting of multiple layers of muscle 
to aid contraction - pumping deoxygenated blood to the lungs and 
oxygenated blood rest of the body (Selzer, 1992). The heart consists of 
three layers; an inner lining (endocardium), the heart muscle 
(myocardium) and the outer layer (pericardium). The endocardium 
consists of a single layer of endothelial cells which lines the surface of 
heart valves and the inner lining of the chambers. The s u b e ~ d o c a r d i a l l
(layer between the endocardium and myocardial) contains fibroblasts, 
elastic and collagen fibres, nerves and branches of the conducting 
system that are required for normal function of the heart (Selzer, 1992). 
The myocardium is the thickest layer consisting of highly organised 
rod-shaped branching striated muscle cells (cardiomyocytes) that are 
attached to adjacent myocytes (Gregorio and Antin, 2000). Working 
cardiomyocytes usually contain a single centrally located nucleus and 
are rich in mitochondria - occupying -40% of myocyte cell volume 
(Figure 1.1) (Katz, 2006). A prominent and unique feature of cardiac 
muscle is the presence of irregularly spaced dark bands between 
myocytes. These are known as intercalated discs, and are due to areas 
where the membranes of adjacent myocytes come very close together 
(figure 1.1). The intercalated discs help to 'glue' the myocytes together 
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and allow an electrical connection between the cells, which is required 
for contraction of the heart muscle. 
Figure 1.1. Schematic representation of cardiomyocytes. Rod-shaped 
branching striated muscle cells (cardiomyocytes) that are attached to adjacent 
myocytes via intercalated discs. 
Finally the third layer external to the myocardial layer is composed of 
connective and adipose tissue through which pass the larger blood 
vessels and nerve supply to the heart (Selzer, 1992). 
1.1.2 What is ischaemic heart disease? 
IHD is characterised by ischaemia (reduced blood supply) to the 
myocardium, usually due to atherosclerosis of the coronary arteries. 
Endothelial cell injury and inflammation are thought to be the first steps 
in the development of atherosclerosis, which can lead to the 
accumulation of lipids in the injured area of the artery (figure 1.2). 
Atherosclerosis is attributed to a western life style, whereby a high fat 
3 
and salt diet are combined with low levels of physical activity, high 
levels of alcohol consumption and tobacco smoking. Diet is implicated 
because the deposits on arterial walls contain high levels of fat and 
cholesterol; studies of both animals and humans have shown links 
between dietary habits and atherosclerosis (Thorpe et aI., 1996, McGill 
et aI., 2002). Other risk factors that are associated with the onset and 
progression of atherosclerosis, include age (Stout, 1987), diabetes 
(Grundy et aI., 1999) and hypertension (Stamler et aI., 1989). 
During atherosclerosis, increased adhesion of macrophages to the 
injured lipid-lined endothelial cells leads to the formation of lipid-
engorged "foam cells" and together with T lymphocytes these become 
"fatty streaks", which ultimately lead to the formation of fibrous 
plaques. A coronary vessel occlusion can be caused by the formation of 
arterial thrombi (blood clot), which is induced by atherosclerotic 
plaques. Thrombi formation is induced by platelet adhesion and platelet 
aggregation on the collagenous plaque components, followed by the 
formation of thrombin and fibrin by activated coagulation (Lippi et aI., 
2011 ). 
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Plaque 
Figure 1.2. The progression of atherosclerosis. Plaque formation during 
atherosclerosis can lead to occluded arteries. Image modified from 
(MedicaISymptomsGuide, 2009) 
The heart, like any other muscle requires an oxygenated blood supply 
in order to maintain function. During a coronary vessel o.cclusion, 
blood flow is severely restricted to the heart and myocardial tissue 
becomes deprived of oxygen (hypoxia) and nutrients. Under these 
conditions, the myocardial tissue is unable to function appropriately 
and cardiomyocytes cease to beat. When the blood flow is restricted for 
a significant period of time, the cardiomyocytes become damaged and 
begin to die leading to a myocardial infarction (MI) or more commonly 
known as a heart attack (Selzer, 1992). The severity of an MI depends 
on three factors: the level of the occlusion in the coronary artery, the 
length of time of the occlusion, and the presence or absence of 
collateral circulation. The longer the period of vessel occlusion, the 
greater the chances of irreversible myocardial damage distal to the 
occlusion (Selzer, 1992). Antithrombotic (anticoagulants and anti-
platelet) drugs or surgical intervention can restore blood flow to the 
ischaemic cardiac tissue. Although critical to re-establish cardiac 
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function, restoration of blood flow and oxygen can actually result in 
enhanced levels of cellular damage (Eefting et ai., 2004). This 
phenomenon of Ischemia/reperfusion (I/R) injury has been linked to the 
generation of reactive oxygen species (ROS), which in tum lead to 
tissue damage through induction of apoptosis (Zorov et ai., 2006). 
Principal mediators of myocardial reperfusion injury are ROS and 
neutrophils, which are reintroduced by reperfusion into the previously 
ischaemic cardiac tissue. Oxygen radicals are very reactive chemical 
species that are capable of inducing oxidative modification of other 
molecules and formed by various mechanisms, that can overwhelm 
cellular defenses and induce tissue damage (discussed in more detail in 
section 1.3.2) Neutrophils are also important contributors to UR injury 
by releasing ROS and proteolytic enzymes, which can directly induce 
tissue damage (Duilio et ai., 2001). 
1.1.3 Modes of cell death 
The death of a cell can be defined as an irreversible loss of plasma 
membrane (Kroemer et ai., 2005). Cell death is an important aspect of 
normal organ development and cellular regulation and plays a role in a 
wide range of physiological and pathological conditions. Three modes 
of cells death have been identified which include, necrosis and 
apoptosis. 
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1.1.3.1 Necrosis 
Necrosis derived from the Greek "nekros" for corpse, is a rapid and 
irreversible process that occurs when cells are severely damaged. 
Necrosis is characterised by swelling of the cell and its organelles, 
mitochondrial disruption and breakdown of the plasma membrane. It is 
a destructive process, as the release of cellular content into the 
surrounding environment can cause further damage or kill neighbouring 
cells (Searle et aI., 1982). There is accumulating evidence showing that 
several signal transduction cascades are involved in the propagation of 
necrotic cell death. In particular, the serine/threonine kinase RIPI 
(Receptor-Interacting Protein 1) has been described as one of the key 
mediators of necrotic cell death (Festjens et aI., 2007). 
1.1.3.2. Apoptosis 
A third mode of cell death is apoptosis, which is an evolutionarily 
conserved "programmed cell death process" and plays fundamental 
roles in many biological processes including embryonic development 
(Brill et aI., 1999), inflammation (Haanen and Vermes, 1995) and the 
development and regulation of the immune system. Kerr and colleagues 
first described the loss of cells through programmed cell death looking 
at ischaemic injury of rat liver (Kerr, 1965). This was later termed 
apoptosis and characterised by cellular shrinkage, blebbing, 
condensation of nuclear chromatin, DNA fragmentation, protein 
cleavage and cytoplasmic vacuolisation (Kerr et aI., 1972). 
Dysregulation of apoptosis has been implicated in many diseases 
(Thompson, 1995). For example, excessive apoptosis is associated with 
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neurodegenerative diseases such as Parkinson's or Alzheimer's diseases, 
as apoptosis is thought to account for much of the cell death and the 
progressive loss of neurons (Mattson, 2000). However insufficient 
apoptosis may participate in carcinogenesis (Wyllie, 1997) and playa 
role in the progression of many auto-immune diseases. For example, in 
the case of rheumatoid arthritis, excessive proliferation of synovial cells 
is thought to be due to the resistance of these cells to apoptotic stimuli 
(Perlman et aI., 2001). 
Apoptosis is mediated by two central pathways: the extrinsic (death 
receptor) pathway and the intrinsic (mitochondrial) pathway (Danial 
and Korsmeyer, 2004). Successful apoptotic signaling requires the 
activation of intracellular pro-caspases and the disabling of 
mitochondrial function. 
Caspases are aspartate-specific cysteine proteases that are highly 
homologous to the c.elegans cell death gene CED-3 (Hengartner and 
Horvitz, 1994). Fourteen human caspases have been identified to date 
and are numbered in the order in which they were discovered. Caspases 
are synthesized as inactive pro-caspases and regulated at a post-
translational level, to ensure rapid activation. Caspases are sub-divided 
into upstream signaling caspases (Caspases 2, 8, 9, 10 and 11) that are 
activated by dimerisation and downstream executioner caspases 
(Caspases 3, 6 and 7) that are activated by proteolytic cleavage and 
responsible for the proteolytic destruction to the cell (Fischer et aI., 
2003). 
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Figure 1.3. Apoptotic signaling pathways. The extrinsic pathway is 
triggered by death receptor activation and the formation of the death-inducing 
signaling complex (DISC). which initiates a signaling cascade mediated by 
caspase-8 activation. Caspase-8 directly activates caspase-3 and indirectly 
stimulates the release of cytochrome c from the mitochondria. Activated 
caspase-3 degrades cellular proteins necessary to maintain cell survival and 
integrity. leading to apoptosis. The intrinsic pathway occurs when apoptotic 
stimUli triggers the release of cytochrome c from the mitochondria 
(independently of caspase-8 activation) . Cytochrome c interacts with Apaf-1 
and caspase-9 to promote the activation of caspase-3. Various intermediary 
signaling molecules and proteins inhibiting the apoptotic cascade are also 
shown. Apaf-1 (apoptosis-activating factor 1). Bak (bacille Calmette-Guerin). 
Bax. (BCL-2-associated x protein). Bid. (proapoptotic BcI-2 family member). 
Bim (proapoptotic Bcl-2 family member). DIABLO (direct lAP binding protein 
with low PI). FADD (Fas-associated death domain protein). lAP (inhibitors of 
apoptosis). Smac (second mitochondria-derived activator of caspase) tBid 
(truncated beta interaction). Modified from (Mak and Yeh. 2002). 
The extrinsic pathway is initiated by the binding of a death ligand 
trimer to its specific cell surface receptor (Ashkenazi and Dixit, 1998). 
A number of death receptors have been identified such as Fas, Tumor 
Necrosis Factor Receptor 1 (TNFR1) and TNF-Related Apoptosis 
Inducing Ligand Receptor l(TRAILRl). The ligand may be an integral 
membrane protein on the surface of another cell (e.g. Fas ligand) or a 
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soluble extracellular protein (e.g. Tumour Necrosis Factor-a). Using the 
Fas death receptor as an example, the binding of Fas ligand allows the 
recruitment of the adaptor protein F ADD ( E a s - ~ s s o c i a t e d d via geath 
gomain) through interactions involving death domains in both proteins 
(Chinnaiyan et aI., 1995). This enables the recruitment of procaspase-8, 
leading to a multi-protein complex called the Death Inducing Signaling 
Complex (DISC) (Kischkel et aI., 1995). Complex formation leads to 
the dimerisation and activation of procaspase-8 (Boatright et aI., 2003). 
Once activated caspase-8 cleaves and activates downstream procaspase-
3 and Bid (BH3 interacting gomain death agonist), a proapoptotic Bcl-2 
protein (Luo et aI., 1998) that links the extrinsic and intrinsic pathways 
(figure 1.3). 
Procaspases are also activated through a mitochondrial-dependent 
pathway (Intrinsic Pathway) through apoptotic stimuli such as oxidative 
stress or DNA damage, which regulate the permeability of the 
mitochondrial membrane. Changes in mitochondrial membrane 
permeability allow the release of pro-apoptotic effectors such as 
cytochrome c (Liu et aI., 1996). Cytochrome c can directly activate 
some upstream procaspases (e.g. procaspase-9) or form a multimeric 
protein complex called the apoptosome by oligomerising with Apaf-I 
(Apoptotic frotease Activation Eactor-l). The apoptosome facilitates 
the dimerisation and activation of procaspase-9, which leads to the 
activation of downstream executioner caspases (Li et aI., 1997a) and 
ultimately the proteolytic destruction to the cell. The control and 
regulation of these pro-apoptotic mitochondrial events occur through 
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members of the Bcl-2 family of proteins (Cory and Adams, 2002) 
(figure 1.3). The Bcl-2 family of proteins governs mitochondrial 
membrane permeability and can either be pro-apoptotic (Bax, Bid and 
Bad) or anti-apoptotic (Bcl-2 and BclxL). It is thought that the main 
mechanism of action of Bcl-2 family members is regulation of 
cytochrome c release from the mitochondrial via alteration of 
mitochondrial membrane permeability (figure 1.3). 
Cardiomyocyte apoptosis has been documented as a significant form of 
cell death during I1R damage, with reports stating an apoptotic rate of 
2-12% in the boarder-zone of the myocardial infarct (Ottaviani et aI., 
1999, Olivetti et aI., 1996). I/R injury have to been shown to activate 
activates both the extrinsic and intrinsic pathways (Jeremias et aI., 
2000) 
1.1.4 Cardiovascular disease and cell death 
Although apoptosis was first documented in 1972 by Kerr and 
colleagues (Kerr et aI., 1972), apoptosis in cardiomyocytes was not 
reported until 1994 (Gottlieb et aI., 1994). In rabbit hearts, IIR injury 
was induced and apoptosis identified using TUNEL, DNA 
fragmentation and electron microscopy (Gottlieb et aI., 1994). 
There is accumulating evidence from both animal and human studies 
strongly suggesting that apoptosis occurs in various cardiovascular 
diseases (Gottlieb et aI., 1994, Sharov et aI., 1998). Animal studies have 
demonstrated that IIR injury and myocardial infarction both lead to the 
onset of apoptosis in cardiomyocytes (Gottlieb et aI., 1994). Gottlieb 
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and colleagues identified nucleosomal ladders of DNA fragments 
(approx. 200 base pairs) from ischaemic reperfused rabbit myocardial 
tissue - a characteristic indicative of apoptosis (Gottlieb et aI., 1994). 
Also studies performed on left ventricular tissue obtained from dogs 
with chronic heart failure demonstrated that loss of cardiomyocytes by 
apoptosis led to the progressive deterioration of heart function. 
Apoptosis was analysed using transmission electron microscopy 
(morphological characteristics of apoptosis) and in situ 
immunohistochemical labeling of nuclear DNA fragments (Sharov et 
aI., 1998). Apoptosis has also been identified in human studies; (ltoh et 
aI., 1995, Saraste et aI., 1997) DNA fragmentation was described in the 
infarcted myocardium using DNA electrophoresis (ltoh et aI.,. 1995). 
Also studies from hearts obtained at autopsy from subjects who 
suffered from coronary artery thrombosis (in which reperfusion of the 
occluded artery had been achieved) revealed apoptotic myocytes found 
in the border zone between viable myocardium and infarcted tissue 
(Saraste et aI., 1997). 
It is clear that apoptosis plays a critical role in the pathogenesis of 
cardiovascular disease and that inhibition promises to be an important 
target for potential therapies. However, more work is required to 
understand the molecular mechanisms that govern these processes. For 
example, although caspase inhibition has been shown to reduce the loss 
of cardiomyocytes due to I1R injury in various animal models (Yaoita et 
aI., 1998, Laugwitz et aI., 2001), it may not be completely effective in 
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blocking apoptosis, due to a significant contribution of caspase-
independent apoptotic cell death (Okamura et aI., 2000). 
1.1.5 Cellular and molecular adaptations to cardiac 
cell death 
The heart undergoes cellular and molecular adaptations in response to 
stresses associated with CVD. At the cellular level maladaptation is 
associated with elevated levels of fibrosis. As cardiomyocytes are 
terminally differentiated, once lost they are replaced by non-specialised 
cardiac fibroblasts. In fibrosis, the excessive production of extracellular 
matrix proteins alters the structure, architecture and shape of the heart. 
Such changes have marked effect on ventricular contractility, valvular 
function and electrical conduction (Weber and Brilla, 1991). 
Myocyte cell loss also causes regional myocardial wall thinning which 
impairs cardiac function. Compensatory hypertrophy occurs as an 
adaptive mechanism whereby cardiomyocytes increase in size (cell 
enlargement) as a mean of compensating for damaged heart tissue in 
order to increase cardiac output (Sonnenblick et aI., 1983). This cardiac 
adaptation leads to changes in gene expression - fetal cardiac genes are 
activated, including the up-regulation of fetal gene isoforms whose 
products regulate cardiac contractility and calcium handling while a 
down-regulation of adult isoforms is often observed (i.e., up-regulation 
of B-MHC and down-regulation of a-MHC) (Iemitsu et aI., 2001). 
Compensatory hypertrophy has been described in pigs exposed to 
chronic episodes of reversible ischaemia to induce myocyte cell loss. 
Myocyte nuclear density decreased to 71 %; however, the myocyte 
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volume was maintained by regional compensatory hypertrophy as 
manifested by a 65% increase in myocyte size (Lim et aI., 1999). 
Compensatory hypertrophy has also been identified in humans with 
end-stage congestive heart failure due to ischaemic cardiomyopathy 
(Beltrami et aI., 1994, Olivetti et aI., 1997). Although compensatory 
hypertrophy is an initial adaptive mechanism in response to myocyte 
cell loss it subsequently leads to myocardial ischaemia, heart failure 
and even death (Weber, 1991). 
Ischaemic preconditioning (IPC) is a phenomenon by which brief 
exposures to ischaemia protect against subsequent, prolonged 
ischaemia. The protective effect of IPC in the myocardium was first 
demonstrated by Murry and colleagues (Murry et aI., 1986). Their data 
shows that brief, intermittent episodes of ischaemia (four 5 minute 
circumflex coronary occlusion, each separated by 5 minute reperfusion) 
have a protective effect on the myocardium that is subjected to 
subsequent more prolonged ischaemic insult (40 minutes sustained 
occlusion). They reported that IPC resulted in infarct sizes that were 
approximately 25% of those observed in untreated hearts. The complex 
signal transduction cascade of IPC has not yet been fully elucidated, but 
is known to involve activation of receptors in the plasma membrane, 
which transduces signals via the activation of many kinases. Liu and 
colleagues were the first to identify a signal transduction element as 
part of the precondioning mechanism (Liu et aI., 1991). They 
discovered that stimulation of the Oi-coupled adenosine AI receptor 
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was necessary to trigger IPC's protection and an adenosine receptor 
antagonist could abolish this protection. Other signal transduction 
pathways implicated in this process include PI3-Kinase/AKT pathway 
(Tong et aI., 2000, Mocanu et aI., 2002) and the JAKISTAT pathway 
(section 1.2.7.1) (Xuan et aI., 2001, Smith et aI., 2004). Protein kinase 
C (PKC) isoforms have also been shown to play a pivotal role in 
mediating both the early and late phases of IPC (Yellon and Dana, 
2000, Tong et aI., 2000). The evidence supporting PKCo in the role of 
IPC is somewhat contradictory. For example, Wang and colleagues 
demonstrated that mitochondrial translocation of PKCo is related to 
cardioprotection induced by IPC (Wang and Ashraf, 1999); whereas 
Fryer and colleagues reported that PKCo plays an important .role in 
pharmacological-induced preconditioning but not IPC (Fryer et aI., 
2001). A later study using PKCo knockout mice demonstrated that the 
cardioprotection observed in IPC is abolished in hearts lacking PKCo 
(Mayr et aI., 2004). 
A molecular mechanism in the defence against ischaemic injury utilises 
an oxygen-sensing pathway that involves the hypoxia-inducible 
transcription factor I (HIF-I). This pathway mediates gene expression 
to allow adaption to a hypoxic environment. HIF was initially identified 
as a hypoxia-inducible DNA-binding activity capable of interacting 
with a hypoxia response element in the 3' region of the erythropoietin 
gene (Pugh et aI., 1991). HIF is a heterodimer consisting of an (1-
subunit and a ~ - s u b u n i t , , which induces a variety of genes in the acute 
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and chronic adaption to hypoxia. Examples include genes that regulate 
angiogenesis, survival, and glycolysis (Safran and Kaelin, 2003). 
Although HIF-P is ubiquitously expressed, HIF-a is tightly regulated by 
oxygen through post-translational hydroxylation by oxygen-dependant 
prolyl hydroxy lases (PHD) and asparaginyl hydroxy lases (Ivan et aI., 
2001). Under normoxic conditions, HIF-a is hydroxylated at either of 
two conserved prolyl residues enabling its recognition by the von 
Hippel-Lindau (VHL) tumour suppressor protein, a component of the 
E3 ubiquitin ligase complex that leads to the ubiquitination and 
subsequent proteasome-dependent degradation of the HIF-a subunit. 
Hydroxylation of an asparaginyl residue in the C-terminal 
transactivation domain of HIF -a directly prevents its interaction with 
the co-activator p300 from the transcription complex. Hydroxylation is 
intrinsically oxygen dependent because the oxygen atom of the 
hydroxyl group is derived from molecular oxygen (McNeill et aI., 
2002). Under hypoxic conditions, levels of HIF-a rise, allowing its 
dimerisation with HIF -P and enabling transcriptional activation. 
In swine models of coronary artery occlusion, myocardial ischaemia 
induces VEGF expression and collateral blood vessel development 
(White et aI., 1992, Banai et aI., 1994). More recently, a study has used 
the adenoviral (Ad) intramyocardial vascular endothelial growth factor 
(VEGF)-B I86 gene transfer and shown it is capable of inducing 
myocardium-specific angiogenesis and arteriogenesis in both pigs and 
rabbits (Lahteenvuo et aI., 2009). After acute myocardial infarction, 
AdVEGF-B I86 increased blood vessel area, perfusion, collateral artery 
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formation which induced changes towards an ischeamic-resistant 
myocardial phenotype (Lahteenvuo et aI., 2009). 
Human patients with coronary artery stenosis (abnormal narrowing of 
the coronary artery) have an impaired development of collateral 
vessels. Due to the inverse correlation between infarct size and 
collateral blood flow (Sabia et aI., 1992) such adaptations in response to 
ischaemia could determine the risk and severity of myocardial 
infarction. 
1.2 Signal Transducers and Activators of Transcription 
1.2.1 Discovery 
In 1992 Darnell and colleagues (Schindler et aI., 1992a) identified a 
91kDa protein (and an 84kDa form, lacking 39 C-terminal amino acids) 
and a 113kDa protein through the study of interferon-a (lFN-a) and 
IFN-y induction of transcription. The identified proteins became 
tyrosine phosphorylated upon treatment of cells with IFN-a (Schindler 
et aI., 1992b), whereas only the 91kDa protein was also phosphorylated 
in response to INF-y (Shuai et aI., 1992). These proteins serve a dual 
function as signal transducers and activators of transcription and were 
later named accordingly in the order they were characterised. Thus, the 
91 kDa and 84kDa proteins were designated Signal Transducers and 
Activators of Transcription I-a (STATla) and S T A T l ~ ~ respectively 
and the 113kDa protein named STAT2. Due to the fact that IFN-a and 
IFN-y transcriptional responses used different STA Ts that share -40% 
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amino acid identity with each other, it seemed plausible that additional 
family members might direct the formation of distinct DNA binding in 
response to other signaling(Saraste et aI., 1997) molecules. STAT3 was 
initially identified as the acute response factor (APRF) activated by 
interleukin- 6 (IL-6) (Wegenka et aI., 1993). STAT3 cDNA was cloned 
a year later by Akira and colleagues (Akira et aI., 1994), which 
exhibited 53.5% overall homology with STATlu cDNA. The STAT3 
protein was also tyrosine phosphorylated and activated as a DNA-
binding protein in response to epidermal growth factor (EGF) or IL-6 
but not IFN-y (Zhong et aI., 1994). STAT4 was first cloned and 
characterised due to its similarity to STATI (52% identical) and shown 
to be predominantly expressed in the spleen, thymus and testis. and is 
differentially regulated during differentiation (Yamamoto et aI., 1994). 
ST AT5 was originally identified as a prolactin-response factor termed 
mammary gland factor (MGF) and confers the prolactin response 
(Wakao et aI., 1994). Later, two STAT5 homologues were identified, 
named ST AT5a and ST A T5b that were encoded by two highly related 
genes and activated by IL-3, granulocyte-macrophage colony-
stimulating factor (GM-CSF) and IL-5 (Azam et aI., 1995, Mui et aI., 
1995). The last transcriptional family member to be identified was 
ST AT6, which was initially termed IL-4 STAT due to its activation by 
IL-4, a cytokine secreted by activated T lymphocytes, basophils, and 
mast cells (Hou et aI., 1994). 
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1.2.2 Structure of STATs 
All STAT proteins consist of approximately 750-850 amino acids and 
have several conserved domains that are critical for protein function 
(figure 1.4). 
ND Coiled-coil DNA-binding Linker SID TAD 
STAT! N c 
~ - - - - - - ~ - - ~ ~ ~
STAT2 N 
~ - - - - - - ~ - - - - - - - - ~ ~
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___ - ' - _ ~ L . . . . . . . J J C 
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pY 
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Figure 1.4. STAT protein family members. Schematic diagram representing 
the conserved domains present in STAT proteins. N; amino-terminus, C; 
carboxy-terminus, pY; phospho-tyrosine site, pS; phospho-serine site 
Modified from (Yu and Jove, 2004). 
1.2.2.1 The N-Domain 
The N-domain is located to the amino terminus of STAT proteins and is 
important for protein-protein and dimer-dimer interactions to form 
tetrameric ST AT molecules. Many promoters contain closely spaced 
tandem STAT binding sites (-20bp apart). When two such sites are 
occupied with STATs, dimer-dimer interactions exist that are mediated 
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through the N-domain (Xu et aI., 1996, Vinkemeier et aI., 1998). 
Protein interactions between the N-terminus of STATI and histone 
acetyltransferases CBPIP300 have also been reported which may 
contribute to transcriptional activation (Paulson et aI., 1999). Recently 
it has been reported that the N-domain of STATI is required for the 
paracrystals formation. Cytokine-induced paracrystals prolong the 
activity of STATI by regulating SUMO conjugation (section 1.2.5.6) 
(Droescher et aI., 2010). 
1.2.2.2 The Coiled-Coil Domain 
Adjacent to the N-domain is the coiled-coil domain. It contains four 
long a-helices that enable ST A Ts in interact with other proteins 
(Bromberg and Darnell, 2000). The coiled-coil domain mediates the 
interaction of STATI and STAT2 with p48 (lSGF3 complex) and is 
required for DNA binding and transcriptional activation (Veals et aI., 
1992). STAT3 interacts with c-Jun via the coiled-coil domain to aid co-
operative transcriptional activation (Zhang et aI., 1999). Also, it has 
been demonstrated that the coiled-coil domain of ST AT3 is also 
essential for SH2 domain mediated recruitment to its receptor and 
subsequent tyrosine phosphorylation. Single point mutations of 
Asp170, or to a lesser extent Lys177, diminish STAT3 receptor binding 
and tyrosine phosphorylation (Zhang et aI., 2000). 
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1.2.2.3 The DNA-Binding Domain 
The DNA binding domain contains several ~ - s h e e t s s and intervening 
loops that determine DNA specificity (figure 1.5). All STATs can bind 
to an element similar to GAS (gamma-interferon activated sequence) 
(TTNs_6AA), which is probably due to the highly conserved amino acid 
composition within this domain. However, DNA binding analysis using 
activated STA Ts and synthetic oligonucleotides yielded different DNA 
binding affinities between STAT members (Lamb et aI., 1995). The 
experiments demonstrated that spacing between the palindromic TT-
AA core influences DNA binding affinity. For example, the palindrome 
TT -AA separated by 6bp resulted in selective binding of ST A T6 
dimers, whereas a spacing of 4bp preferentially favoured ST AT3 
dimers. Also DNA binding might depend on the composition of the 
S TAT dimers, since S TAT liS T A T3 heterodimers appear to bind to 
different response elements compared to STAT 1 and STAT3 
homodimers (Lamb et aI., 1995). Several years later, Ehret and 
colleagues described experiments in which they quantified the relative 
affinity of a series of weak DNA binding sites for STATl, STAT5a, 
ST A T5b and ST A T6. Clear differences observed in the fine specificity 
between STAT proteins are reflected amongst the natural target sites of 
different STAT proteins, indicating they contribute to the selective gene 
activation by these proteins (Ehret et aI., 2001). 
21 
... 
Monomer I I Monomer 2 
I DNA 
Domain 
Phospho-tyrosine 
Figure 1.5. Three-dimensional structure of STA T1 protein. The core 
structure (amino acids 130-712) shows binding of a STAT1 dimer to DNA. 
Various domains are indicated . Modified from (Levy and Darnell, 2002) 
Mutations within the DNA-binding domain of STAT3 are associated 
with the autosomal-dominant mUltisystem immuno-deficiency disease 
known as Hyper IgE syndrome (HIES). HIES presents with elevated 
serum IgE levels, dermatitis and recurrent skin and lung infections. 
Minegishi and colleagues identified missence and single codon in-
frame deletions ofSTAT3 located in the STAT3 DNA-binding domain 
of familial and sporadic cases of HIES (OMIM; 147060) (Minegishi et 
al.,2007). 
1.2.2.4 The Linker Domain 
Carboxy-terminal to the DNA binding domain is the highly conserved 
EF-hand-like linker domain consisting of approximately 100 amino 
acids. The linker domain may contribute to transcriptional activity, 
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since mutations in the linker region of STAT 1 abolished transcriptional 
responses to IFN-y (Yang et aI., 1 999b). More recently, de novo 
mutation (Lys531Glu) in the linker domain of the STAT3 gene has also 
been linked to the multisystem immunodeficiency disease - Hyper IgE 
syndrome (Kim et aI., 2009). 
1 .. 2.2.5. The SH2 Domain 
The Src-homology 2 (SH2) domain is a well-studied structural motif 
that modulates STAT dimerisation via SH2-phosphotyrosine peptide 
interactions (Shuai et aI., 1994). The negatively charged phosphate on 
the tyrosine residue (Y701 for STATI and Y705 for STAT3) located at 
the C-terminal end of the SH2 domain is stablised by a positively 
charged arginine residue located at the N-terminal region of the SH2 
domain STAT partner molecule. Mutations of either the tyrosine or 
arginine residue completely abolishes STAT dimerisation (Reviewed in 
(Schindler and Darnell, 1995». 
1.2.2.6 The Transcriptional Activation Domain 
The carboxyl-terminal domain of all STAT proteins contains the 
transcriptional activation domain (TAD), which is the least conserved 
domain among STAT family members. However, STAT1, STAT3, 
ST AT4 all share a conserved stretch of amino acids in their C-terminal 
T ADs (LPMSP) that includes a phosphorylated serine residue 
(described in detail in section 1.2.5.1.) that is important to achieve 
maximal transcriptional activity (Wen et aI., 1995, John et aI., 1999, 
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Decker and Kovarik, 2000). The C-tenninal region is also important for 
protein-protein interactions. For example, the C-tenninal region of both 
STAT 1 and STAT2 interact with the histone acetyltransferase, 
CBP/p300 (Paulson et aI., 1999) and STATI also associates with the 
mini chromosome maintenance protein (MCM)-5 (Zhang et aI., 1998). 
1.2.3 STAT isoforms 
Naturally occurring splice variants have been identified for all STAT 
proteins, with the exception of ST AT2. These splice variants lack 
regions of the C-tenninal transactivation domain. This leads to a 
competitive negative effect on gene induction, counteracting the 
transcriptional activation of full-length STATs. The splice variants are 
known as S T A T 1 ~ , , S T A T 3 ~ , , S T A T 4 ~ , , S T A T 5 ~ ~ and S T A T 6 ~ ~
(Schindler et aI., 1992a, Caldenhoven et aI., 1996, Hoey et aI., 2003, 
Shennan et aI., 1999, Wang et aI., 1996) and can be generated by two 
distinct mechanisms: alternative mRNA splicing and proteolytic 
processing. ST AT3 ~ ~ is generated from alternative splicing, which 
arises from the alternative-splice acceptor sties in exon 23, which 
differs from STAT3a by the lack of 50 amino acids from the C-tenninal 
domain (Schaefer et aI., 1995). In the case of proteolytic processing, 
STAT5 is truncated at the transactivation domain (Azam et aI., 1995). 
Cathepsin G has been identified as the protease that cleaves full length 
STAT5 (STAT5a) to generate a C-tenninally truncated fonn in 
immature myeloid cells (Lee et aI., 1999), however there is some 
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controversy over whether this cleavage occurs in vivo (Garimorth et aI., 
1999). 
1.2.4 Activation of ST ATs 
ST ATs are activated in response to a variety of cytokines and growth 
factors, each initiating signal transduction by association with their 
appropriate receptor (figure 1.6). The various receptor families include 
transmembrane receptors lacking an intrinsic protein tyrosine kinase 
domain (non-RTK receptors), single transmembrane receptors with an 
intrinsic protein tyrosine kinase domain (RTK receptors), and seven 
transmembrane receptors (G-protein coupled-receptors) (figll!e 1.5). 
Cytokines 
LIF 
Growth 
factors 
EGF 
t 
Peptides 
\ ~ / /
STAT1.3-6 
STAT 
homodimer 
STATpY(-700) 
1,2,4,5a,5b,6 
STAT1 : STAT2 
STAT1 : STAT3 
STAT 
betrodimer 
Nucleus 
Figure 1.6 Overview of STAT signaling. STAT proteins can be activated by 
a variety of cytokines, growth factors and peptides. Acivated STAT proteins 
(STATpY) are able to dimerise and bind to specific DNA sequences to bring 
about transcription. LlF; Leukemia Inhibitory Factor, LlFR; Leukemia Inhibitory 
Factor Receptor, EGF; Epidermal Growth Factor, EGFR; Epidermal Growth 
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Factor Receptor, AT1; Angiotensin II Receptor Type I. Adapted from (Levy 
and Darnell, 2002). 
1.2.4.1 Non-RTK receptors 
Non-RTK (cytokine) receptors can be subdivided into two groups on 
the basis of conserved amino acids in their extracellular domain, termed 
class I and class II receptors (Schindler and Darnell, 1995). Class I 
receptors can be further divided into four families (gp130, IL-2, IL-
3/IL-5/GM-CSF (gpI40) and growth hormone (GH) family), which all 
share four conserved cysteine residues, an extracellular (WSXWS) 
motif and a variable intracellular domain. Class II receptors bind 
interferons including IFN-a, INF-y and IL-IO. These receptors share 
sequence homology with type I receptors, but have additional cysteine 
pairs and several conserved proline and tyrosine residues (Novick et aI., 
1994, Ho et aI., 1993). 
Leukemia inhibitory factor (LIF) belongs to the family of interleukin 
(lL )-6-type cytokines, which signal through the common receptor 
subunit gp 130 in association with a ligand-specific receptor subunit, the 
low-affinity LIF receptor (LIFR). The binding of LIF to the LIFR 
induces its heterodimerisation with gp130 (figure 1.7). Giese and 
colleagues demonstrated herterodimeriastion between LIFR and gp 130 
by using Fluorescence Resonance Energy Transfer (FRET) (Giese et 
aI., 2005). An increase in FRET signal was observed between CFP-
tagged LIFR and YFP-tagged gp130 upon stimulation with LIF (Giese 
et aI., 2005). Like all non-RTKs, the LIFRlgp130 receptor complex 
lacks an intrinsic protein kinase domain, but are able to signal through 
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the association with Janus Kinase (JAK) family members, a group of 
receptor associated tyrosine kinases (Darnell, 1997). 
Figure 1.7. JAK/STAT3 pathway via the LlF receptor. LlF binding rapidly 
induces the LlF receptor (LlFR) and gp130 subunits to form a heterodimer 
receptor complex. Receptor complex formation leads to autophosphorylation 
of receptor-associated JAK2, followed by tyrosine phosphorylation of the 
receptor's cytoplasmic domain and recruitment of STAT proteins to the 
receptor complex. Subsequent tyrosine phosphorylation of STATs enables 
homo- or heterodimerisation of STAT proteins. STAT dimers translocate to the 
nucleus and bind to specific STAT-binding elements in the promoter region of 
various genes. Modified from (Auernhammer and Melmed, 2001). 
In mammalian cells the family consists of four members; Jakl, Jak2, 
Jak3 and Tyk2, which are phosphorylated via activated non-PTK 
receptors. JAKs consist of seven JAK homology domains, which share 
high sequence similarity. At the C-terminus, they contain a tyrosine 
kinase domain (JHl), which is preceded by a pseudo-kinase domain 
(JH2). The activated JAKs phosphorylate specific tyrosine residues on 
the cytoplasmi_c tails of the cytokine receptors thus, providing docking 
sites for STAT proteins via their SH2 domains. The recruited STAT 
monomers are then phosphorylated on their specific tyrosine residues 
by JAKs, which allows the formation of active STAT dimers through 
reciprocal phosphotyrosine-SH2 interactions (Darnell, 1997). It has also 
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been shown that SRC kinases can also facilitate in this process (Reddy 
et aI., 2000). STAT dimers can translocate to the nucleus in a regulated 
manner where they bind to promoters and enhancer regions of their 
target genes. 
1.2.4.2 RTK-receptors 
STATs can also be activated by growth factor receptors, which contain 
an intrinsic tyrosine kinase domain (Silvennoinen et aI., 1993, Zhong et 
aI., 1994, Schaefer et aI., 2002). These RTK-receptors include 
epidermal growth factor receptor (EGFR), platelet derived growth 
factor receptor (PDGFR) and vascular endothelial growth factor 
receptor (VEGFR). STAT activation by various RTKs can be JAK-
dependant or JAK-independent as both models are present in the 
literature (Vignais and Gilman, 1999, Paukku et aI., 2000, Olayioye et 
aI., 1999, Schaefer et aI., 2002). EGFR, VEGFR and PDGFR all 
possess an intrinsic tyrosine kinase domains and can phosphorylate 
STATs directly (Vignais and Gilman, 1999, Paukku et aI., 2000). 
However, under some conditions RTKs require the presence of JAK or 
Src for STAT phosphorylation (Olayioye et aI., 1999, Schaefer et aI., 
2002). 
1.2.4.3 G protein-coupled receptors 
G protein-coupled receptors have also been reported to activate STAT 
proteins (figure 1.6). These receptors span the cell membrane seven 
times and activate GTP-binding proteins. In rat aortic smooth-muscle 
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cells, angiotensin II induces phosphorylation and activation of JAK2, 
leading to the rapid tyrosine phosphorylation of STAT1, STAT2, 
STAT3 and STAT5 (Marrero et aI., 1995). In cardiomyocytes, 
Mc Whinny and colleagues showed that angiotensin II, acting through 
the AT! receptor could induce STATI and STAT3 phosphorylation, 
translocation to the nucleus and induction of gene transcription 
(McWhinney et aI., 1997). Although it is established that the AT! 
receptor activated the JAKIST AT pathway, the sequence of events 
leading to the association of AT! receptor and STAT proteins has yet to 
be defined. 
1.2.4.4 Non-receptor kinases 
In addition, non-receptor cytoplasmic tyrosine kinases such as activated 
Src and Abelson Leukemia Protein (ABL) (Danial and Rothman, 2000) 
can directly phosphorylate STAT proteins in the absence of ligand-
induced receptor activation. Src-transformed NIH3T3 cells were found 
to contain a phosphorylated tyrosine form of STAT3 in a constitutive 
manner (Yu et aI., 1995) and studies have shown that v-src is able to 
bind to and phosphorylate STAT3 in vitro (Cao et aI., 1996). 
These pathways ultimately lead to the tyrosine phosphorylation of 
STAT proteins that results in homo and heterodimerisation through 
reciprocal interactions between SH2 domains and phosphotyrosines. 
STATl, STAT3, STAT4, STAT5a and STAT5b form homodimers 
whereas STATl:STAT2 and STATl:STAT3 heterodimers are also 
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capable of fonning. STAT dimers translocate to the nucleus where they 
bind to response elements in the promoters of target genes to initiate 
transcription. It was initially thought that STAT proteins would only 
translocate to the nucleus upon activation, however it has been shown 
that nucleocytoplasmic shuttling of STATI and STAT3 is a dynamic 
process and was first demonstrated using the fluorescence recovery 
after photobleaching (FRAP) approach. Constitutive shuttling of 
ST AT3 was observed in the absence of cytokine stimulation and IL-6 
induction resulted in nuclear accumulation of STAT3 (Pranada et aI., 
2004). 
1.2.5 Regulation of STATs through post-translational 
modification 
Post-translational modification IS a common mechanism to regulate 
protein function, activity and localisation. Post-translational 
modifications include phosphorylation, acetylation, methylation, 
glutathionylation, and sumoylation and ubiquitylation. 
1.2.5.1 Serine phosphorylation 
All STAT proteins contain a tyrosine phosphorylation site that is 
required for dimerisation and ultimately activation. However, most 
STAT proteins (STATI, STAT3, STAT4, STAT5a and STAT5b) can 
also be phosphorylated at a serine residue present in their C-tenninal 
TAD. Serine phosphorylation was first identified for STAT! and 
STAT3 by isolation of proteins from 32P-Iabelled cells after stimulation 
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with appropriate cytokines and then subjected to phospho-amino acid 
analysis (Eilers et at. , 1995, Wen et at. , 1995). Zhang and colleagues 
first reported the role of serine phosphorylation for STAT 1 and STAT 3 
activities, showing its requirement for DNA binding and transcriptional 
activation (Zhang et at. , 1995). These conserved sites consist of a 
LPMSP motif (Ser727 in STATl , 3 and Ser72 1 in STAT4) (Wen et at. , 
1995) and LPSP motif (Ser725 in STAT5a and Ser730 in STAT5b 
(Yamashita et at., 1998) (figure 1.8). 
STAT! evhpSr l qTt D n l. l PMSP e e • f d ems 
STATJ pttcS •• nTi D l PMSP r t • L d s 1 s 
STAT4 ti.rSd s t e pqs p s d 1 l PMSP s a • ya V 1 r e. 
STATSa tdagas.aTymD q a. • P • S P V v c p. 
STATSb tdagSg.aTymD q a . • P • S P V 1 c p . 
Figure 1.8 Comparison of human STATs containing the P(M)SP 
phosphorylation site. The P(M)SP motif is highlighted in red. Uppercase 
letters denotes amino acids conforming consensus sequences. Modified from 
(Decker and Kovarik, 2000). 
The most pronounced effects of serine phosphorylation have been 
observed in relation to transcriptional activation. Overexpression of 
S T A T 3 ~ ~ (lacking the serine 727 phosphorylation site) severely impairs 
• IL-6-induced STAT3 transactivation (Caldenhoven et at., 1996). Also 
STATI and STAT3 Ser-Ala mutations display a reduced transcriptional 
activity in response to IFNy or IL-6 type cytokines (Wen et at. , 1995), 
indicating a positive regulatory effect on transcription. However 
repressive effects on transcription have also been reported with STA T3 
serine phosphorylation. A STAT3 (Ser-Ala) mutant increased 
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transactivation in response to EGF in vitro and in vivo, suggesting 
serine phosphorylation either prevents tyrosine phosphorylation or 
increases tyrosine dephosphorylation (Chung et aI., 1997b). 
Serine phosphorylation of STAT proteins is mediated by a number of 
different kinases including; Mitogen-activated protein kinases (MAPK) 
and Protein kinase C isoforms ( P K C ~ ~ and PKCE) (Lim and Cao, 1999). 
The MAPKs are a group of protein serine/threonine kinases that are 
activated in response to a variety of extracellular stimuli and mediate 
signal transduction from the cell surface to the nucleus. Each MAPK 
pathway contains a three-tiered kinase cascade comprising of MAPK 
kinase kinase, MAPK Kinase and the activated MAP kinase '(reviewed 
in (Chang and Karin, 2001)). MAPK phosphorylates substrates with the 
PSMP consensus sequence and indeed the C-terminal region of STAT 1, 
STAT3 and STAT4 all resemble the MAPK consensus sequence 
PxpS/pTP (Gonzalez et aI., 1991). Studies have shown that the MAPKs 
~ x t r a c e l l u l a r r signal-regulated kinases (ERKs), ~ - J u n n N-terminal kinases 
(JNKs) and p38MAPK (p38) are involved in serine phosphorylation of 
STAT proteins (Chung et aI., 1997b, Lim and Cao, 1999, Ceresa et aI., 
1997, Turkson et aI., 1999). 
Jain and colleagues were in search of an H7-sensitive, IL-6 activated 
ST AT3 serine kinase when they identified P K C ~ ~ - a PKC family 
member of serine-threonine kinases. (Jain et aI., 1999). In mammals the 
PKC family members can be divided into four structurally and 
functionally distinct subgroups according to their regulatory domains. 
These are the classical isoforms (a,p,y), novel isoforms ( ~ , E , l l , e ) , ,
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atypical isoforms (s,t/A) and the PKC-related kinases (PKN1, PKN2 
and PKN3) (Rosse et at, 2010). Activated G-protein coupled seven 
transmembrane receptors bind and activate phospholipase C (PLC) at 
the plasma membrane where it hydrolyses phosphatidylinositol 4,5 
bisphosphate (PtdIns(4,5)P2) into diacylglycerol (DAG) and inositol 
1,4,5-triphosphate (IP3). PKC8 belongs to the novel subfamily and 
requires diacylglycerol (DAG) for activation (Mellor and Parker, 1998). 
In addition to DAG, PKC8 is also regulated by phosphorylation (Li et 
at, 1997b). While most PKC isoforms are phosphorylated at conserved 
Ser/Thr sites, PKC8 is also phosphorylated at several tyrosine residues 
by various stimuli including oxidative stress and DNA damaging agents 
(Steinberg, 2008, Yoshida, 2007). 
PKC8 is associated with cardiomyocyte cell death. Murriel and 
colleagues have shown that PKC8 increases ischaemia and reperfusion-
induced apoptosis by affecting the balance between pro- and anti-
apoptotic signals (Murrie I et at, 2004). By using 8VI-l to specifically 
inhibit PKC8 translocation at the onset of reperfusion, they observed 
inhibition of cytochrome c release, caspase-3 activation and P ARP 
cleavage (Murriel et at, 2004). Prolonged exposure to hypoxia has also 
been associated with the proteolytic and feed-forward activation of 
PKC8 and caspase-3, resulting in the irreversible commitment to 
apoptosis (Clavijo et at, 2007). 
Studies regarding ST A T3 serine phosphorylation by PKC8 are 
somewhat contradictory. For example, studies by Jain and colleagues 
revealed that serine phosphorylation by PKC8 has a negative influence 
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on DNA binding and transcriptional activity (Jain et aI., 1999) whereas, 
activated fonns of PKC() and ST A T3 were essential for the insulin-
induced PKC()-ST A T3 activation in kerationcyte proliferation 
(Gartsbein et aI., 2006). 
Another member of the novel PKC subfamily, PKCE has also been 
associated with the ST A T3 serine phosphorylation. Studies show that 
PKCE interacts with and serine phosphorylates ST A T3, which increases 
DNA binding and transcriptional activity. PKCE-mediated ST A T3 
serine phosphorylation seems to be essential for the constitutive 
activation of STAT3 and prostate cancer invasion (Aziz et aI., 2007). 
1.2.5.2 Acetylation 
The idea that STAT proteins could be acetylated was due to the 
discovery that various ST A Ts associate with histone acetyltransferase 
CREB-binding (CBP/p300) and show enhanced transcriptional activity 
(Zhang et aI., 1996, Korzus et aI., 1998). The first report described that 
acetylation of ST AT6 by CBP /p300 was required for the transcriptional 
activation of 15-lipoxygenase (15-lox-I) by IL-4 (McDonald and 
Reich, 1999, Shankaranarayanan et aI., 2001). Treatment of cells with 
histone deacetylase inhibitors (HDACi) was reported to reveal the 
acetylation sites in STATI at Lys410 and Lys413 (Kramer et aI., 2006) 
and was proposed to regulate apoptosis by facilitating binding of NF-
KB and control immune responses by suppressing STATI tyrosine 
phosphorylation (Kramer et aI., 2009). However, recently Antunes and 
colleagues have questioned this work as they demonstrate that 
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inhibition of deacetylase had no effect on STATI acetylation and did 
not suppress tyrosine phosphorylation. They propose that the defective 
DNA binding activity and transcriptional activity may be due to 
inactivation of the DNA binding domain of STAT! or nuclear import 
signal rather than due to its acetylation status (Antunes et aI., 2011). 
It was also reported that ST AT3 could be acetylated in the N-terrninal 
region, at positions Lys49 and Lys87 by CBP/p300. Mutational analysis 
(STAT3 K49R1K87R) had no effect on inducible DNA binding, but 
blocked CBP/p300-mediated ST A T3 acetylation and abrogated IL-6-
induced human angiotensinogen (hAGT) gene activation in hepatocytes 
(Ray et aI., 2005). 
1.2.5.3 Methylation 
Methylation of STAT proteins was first described for STAT 1 at residue 
Arg31 in the N-terrninal domain in response to IFN-y by protein 
arginine methyl-transferase (PRMT 1). Interestingly, methylation led to 
a weaker interaction between STAT! and the protein inhibitor of 
activated STATs (PIAS), resulting in increased DNA binding by 
STATI (Mowen et aI., 2001). Recently, it has been reported that 
STAT3 IS methylated at residue Lys140 by the H3K4 
methyltransferase, SET9 in response to IL-6. Prevention of methylation 
by mutation of K140 allowed greater phosphorylation of STAT3 Y705 
in response to IL-6, which was associated with enhanced expression of 
the negative regulator of STAT3 activation (SOCS3) (Yang et aI., 
2010). 
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1.2.5.4 Glutathionylation 
Glutathione plays a role in reversible post-translational modification 
called S-glutathionylation, which is a physiological, reversible protein 
modification of cysteines residues with glutathione that occurs in 
response to mild oxidative stress (Klatt and Lamas, 2000). Recently a 
study has shown that ST A T3 is novel target for protein S-
glutathionylation (Xie et aI., 2009). Increased levels of S-
glutathionylated STAT3 were observed in cells treated with diamide - a 
thiol oxidising agent. S-glutathionylation of ST AT3 was accompanied 
with a reduction in IL-6 induced tyrosine phosphorylation of ST AT3, 
subsequent nuclear retention and transcriptional activities of ST AT3 
target genes (Xie et aI., 2009). 
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1.2.5.5 Ubiquitination 
Ubiquitination, the conjugation of proteins with a protein called 
ubiquitin (Ub) is essential for the degradation of proteins. 
o 
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Figure 1.9.The ubiquitylation system. The ubiquitination pathway consists 
of three sequential steps: 1) An ATP dependent step of loading E1 activating 
enzyme with ubiquitin (Ub), 2) Transfer of the E1's ubiquitin to an E2 
conjugating enzyme and 3) the E3 ligase mediated transfer of ubiquitin from 
an E2 to the substrate. Taken from (Dodd, 2005) 
Free Ub is activated in an ATP-dependent manner, by the activity of an 
ubiquitin-activation enzyme EI, leading to the formation of a thiol-ester 
linkage between EI and the carboxyl terminus of ubi quit in (figure 1.9). 
The ubiquitin is subsequently transferred to one of many ubiquitin-
conjugating enzymes E2. The last step in the process utilises a ubiquitin 
protein ligase E3 to catalyse the transfer of Ub from the E2 enzyme to 
the target proteins (Nandi et aI., 2006). Degradation of ubiquitinated 
proteins is performed by the 26S proteasome system, which is 
composed ot the two terminal 19S regulatory subunits bound to the 
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proteolytic core. The ubiquitin-proteasome degradation has shown to be 
important for the regulation of the JAKISTAT pathway. Studies show 
that with the use of proteasome inhibitors, JAK1, JAK2 and JAK3 are 
all targets for degradation (Ungureanu et aI., 2002, Yu and Burakoff, 
1997). In addition, tyrosine phosphorylated STAT1, STAT4, STAT5 
and STAT6 were also targets for degradation (Kim and Maniatis, 1996, 
Wang et aI., 2000), hence regulating their activities. 
1.2.5.6 SUMOlyation 
The SUMO (small ubiquitin-like modifier) family of proteins belong to 
the ubiquitin-related protein modifiers. SUMOlyation requires the 
covalent attachment of SUMO to its target protein, which is facilitated 
by a set of enzymes; El activating enzyme (Aosl and Uba2), 
conjugating E2 enzyme (Ubc9) and ligating E3 enzyme (PIAS, RAN-
binding protein 3 (RanBP2) or polycomb protein (pe2)). SUMOlyation 
was first described for STATI at residue Lys703 in the presence of 
PIASxa - an E3 ligase. A negative regulatory function for 
SUMOlyation of STAT 1 was suggested due to the fact that mutation of 
Lys703 in STATI resulted in increased mediated IFN-y mediated 
transcriptional activation (Ungureanu et aI., 2003). STAT3 activity is 
inhibited by SUMO-conjugation. Inhibition occurs directly by 
decreasing STAT 1 tyrosine phosphorylation and indirectly by 
facilitating STATI dephosphorylation, consequential to increase 
STATI solubility due to suppressed paracrystals assembly (Droescher 
et aI., 2010). 
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1.2.6 Negative regulation of STATs 
The rapid and transient nature of STAT activation suggests there are 
mechanisms in place to switch off this signaling pathway. Studies have 
show that STAT signaling is negatively regulated at different points 
within the signaling cascade. Factors involved in negative regulation 
are members of the sacs (suppressors of cytokine signaling) family, 
the PIAS (protein inhibitor of activated STATs) family and PTPs 
(protein tyrosine phosphatases). 
1.2.6.1 Suppressors of cytokine signaling 
The suppressors of cytokine signaling (SaCS) family comprise a 
family of 8 members that includes CIS-l (cytokine-inducible SH2 
containing protein) and sacs 1-7. All family members share a similar 
structure with a central SH2 domain, a region of homology called the 
sacs box at the C-terminus and a kinase inhibitory region located at 
the N-terminus (Naka et aI., 1997, Krebs and Hilton, 2000). sacs 
proteins are generally expressed at low levels in unstimulated cells and 
expression is greatly enhanced upon cytokine, insulin and EGF 
stimulation (Alexander, 2002). The mechanism of inhibition varies 
between different sacs proteins. For example, SaCSI binds directly 
to tyrosine-phosphorylated JAKs via its SH2 domain and as a 
consequence JAK activity is directly inhibited. SaCS3 acts by binding 
directly to the activated receptors inhibiting IL-6 and LIF signal 
transduction (Nicholson et aI., 1999). sacs are also direct gene targets 
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of ST A Ts indicating that sacs act part of a classical feedback 
inhibition loop (Matsumoto et aI., 1997). 
1.2.6.2 Protein inhibitors of activated STATs 
Five members belong to the family of proteins that inhibit activated 
STATs (PIAS), which include: PIAS 1, PIAS3, PIASx<l, P I A S x ~ ~ and 
PIASy. Protein inhibitor of activated STAT3 (PIAS3) was the first 
family member to be identified by its PIAS3 association with tyrosine-
phosphorylated ST AT3 and thus prevention of STAT3 DNA binding 
(Chung et aI., 1997a). PIASI was later identified using a yeast two-
hybrid screen with S T A T 1 ~ ~ as the bait. It was also described,as a novel 
regulator of STAT 1 that blocks DNA binding and consequently inhibits 
STATI mediated IFN-induced transcriptional activity (Liu et aI., 1998). 
In addition to inhibiting ST A Ts, PIAS proteins have been shown to 
impact on the function of many different proteins, but a major process 
on which all these proteins act is in the controlling gene expression 
(Schmidt and Muller, 2003, Shuai and Liu, 2005). Thus, PIAS proteins 
can be thought of as transcriptional co regulators. 
1.2.6.3 Protein phosphatases 
Dephosphorylation is an important way of inhibiting the STAT-
signaling pathway. It can occur at the cell membrane, where the 
receptors, JAKs and ST A Ts are targets, as well as in the nucleus where 
dephosphorylation of ST ATs take place. The best-characterised protein 
tyrosine phosphatase is SHP-l. SHP-l contains two SH2 domains and 
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can bind to phosphorylated JAKs and receptors. Expression of SHP-l is 
restricted to haematopoietic cells (Neel et aI., 2003). SHP-l down-
regulates erythropoietin (EPO)-induced proliferation signals by binding 
to the EPO-receptor and dephosphorylating the associated JAK2 
(Klingmuller et aI., 1995). SHP-2 shares a similar overall structure and 
high homology with SHP-l but is ubiquitously expressed. SHP-l 
negatively regulates the IFN-induced JAKlISTATI pathway (Shuai 
and Liu, 2003) and has also been shown to negatively regulate the 
activity of STAT3 (Chan et aI., 2003a). Studies have identified that 
SHP/l//l mutated murine ES cells showed defective differentiation and 
more efficient renewal in the presence of leukemia inhibitory factor 
(LIF), which was due in part to increased STAT3 activity (Chan et aI., 
2003a). 
Protein tyrosine phosphatases also regulate ST ATs in the nucleus. 
STATI protein tyrosine phosphatase activity was identified in HeLa 
nuclear extracts, known as TC45. TC45 can dephosphorylate STATl 
both in vitro and in vivo and nuclear extracts lacking TC45 failed to 
dephosphorylate STAT 1 (ten Hoeve et aI., 2002). More recently 
receptor-type tyrosine phosphatase, PTPRT has been shown to 
dephosphorylate STAT3 at Y705. Overexpression of PTPRT leads to 
the reduction in ST AT3 target gene expression (Zhang et aI., 2007). 
Studies have shown that there in an inter-relationship between DNA-
binding and nuclear phosphatase activity. Meyer and colleagues 
demonstrated that inactivation of STATI is controlled by its exchange 
with DNA, whereby DNA binding protects STATI from 
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dephosphorylation in a sequence specific manner (Meyer et aI., 2003). 
This was also observed with a constitutively active form of STAT3 
known as STAT-C (Li and Shaw, 2006). This STAT3 mutant displayed 
a higher DNA binding affinity than STA T3 WI and its slower DNA off 
rates delayed dephosphorylation by nuclear phosphatases (Li and Shaw, 
2006). 
1.2.7 Biological roles of STATs 
Although STAT proteins are structurally very similar, studies with 
genetically manipulated mice suggest a high degree of specificity for 
each STAT protein. The biological functions of STAT proteins have 
been extensively investigated through the generation of gene-targeted 
mice. All STAT family members have been successfully knocked-out 
and their phenotypes described with the exception ofSTAT3 (discussed 
in more detail in section 1.2.7.1). 
1.2.7.1 Biological roles of STA T3 
STAT3 is ubiquitously expressed in many tissues including the kidney, 
liver, lungs and the heart (GeneCards ID: GCI7M040465). However, 
unlike other STAT family members, functional analysis of STAT3 in 
vivo has been more complex. Takeda and colleagues generated ST AT3-
deficient mice to examine the biological function of STAT3. 
Homozygous null (ST AT3 -1-) mice were not generated, indicating 
embryonic lethality. STAT3 null embryos were able to implant and 
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develop until E6.0, however rapidly degenerated with no obvious 
mesoderm formation between E6.5-E7.5 (Takeda et aI., 1997). 
Therefore, to investigate the biological roles of STAT3 in adult mice, 
the gene has been conditionally knocked out in a tissue- or cell-specific 
manner using the Cre-LoxP recombination system (Rajewsky et aI., 
1996). 
The role of STAT3 has been investigated in the skin. Using the Cre-
LoxP system, STAT3 was specifically disrupted in keratinocytes. 
Despite functional ablation of ST A T3 in kerationcytes, the 
development of the epidermis and hair follicles appeared normal. 
However these mice had sparse hair; wound-healing processes were 
severely compromised and they spontaneously developed ulcers of the 
skin with age (Sano et aI., 1999). This analysis provided the first in vivo 
data showing ST AT3 has a function in cell migration and that ST AT3 
is necessary for skin remodeling, including hair cycle and wound 
healing (Sano et aI., 1999). ST A T3 has also been implicated in the 
initiation and progression of skin cancer (Chan et aI., 2004). Epidermis 
STAT3-deficient mice showed a significant reduction in the 
proliferative response following treatment with the tumor-promoter 
agent 12-0-tetradecanoylphorbol-13-acetate (TPA) due to a defect in 
GI-S phase cell cycle progression (Chan et aI., 2004). 
STAT3 also appears to playa regulatory role in the immune system. 
Mice generated with ST A T3-deficient macrophages and neutrophils 
were highly susceptible to endotoxin shock with increased production 
of inflammatory cytokines such as TNF alpha (Takeda et aI., 1999). 
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ST A T3 has also been implicated in the immune system in an anti-
apoptotic role. Studies show that ST AT3-deficient T -cells exhibited 
loss of a proliferative response to IL-6 due to a defect in IL-6-mediated 
suppression ofapoptosis. (Takeda et al., 1998). More recently, STAT3 
has also been shown to play an essential role in the pathogenesis of the 
IgG immune complex in acute lung injury by mediating the acute 
inflammatory responses in lung and alveolar macrophages (Tang et al., 
2011). Specific siRNA knockdown of STAT3 in alveolar macrophages 
showed a significant reduction in the production of pro-inflammatory 
mediators ofIgG immune complex stimulation (Tang et al., 2011). 
ST AT3 is also expressed in mammary glands where it d i s p ~ a y s s a pro-
apoptotic role in post-lactational regression. STAT3 phosphorylation 
occurs at the onset of mammary gland involution. ST A T3-deficient 
mammary glands showed a decrease in apoptosis and exhibited a 
dramatic delay in mammary gland involution, a stage of mammary 
gland post-lactational regression that is characterised by extensive 
apoptosis of epithelial cells due to impaired epithelial cell apoptosis 
(Chapman et al., 1999). This study identified for the first time that 
STAT3 plays an important role in apoptosis in vivo. However recently, 
morphological analysis of mammary gland involution in mice revealed 
features that were atypical for classical apoptosis, such as 
hypercondensed nuclei, swelling of cells and a complete lack of 
membrane blebbing. Studies show that ST AT3 controls involution of 
the mammary gland by epithelial cells undergoing a lysosomal-
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dependent programmed cell death, which is independent of executioner 
caspases (Kreuzaler et aI., 2011). 
The role of ST A T3 in cardiomyocytes has also been extensively studied 
through the cardiomyocyte-specific disruption of ST AT3 and is 
discussed in more detail in section 1.2.7.2. 
Further information regarding the biological functions of ST A T3 has 
emerged from overexpression studies utilising dominant negative 
versions of STAT3. Nakajima and colleagues described a role of 
STAT3 in differentiation. They used STAT3 mutants lacking the 
tyrosine phosphorylation site (Y705F), which were shown to block IL-6 
and LIF-induced macrophage differentiation of myeloid -leukaemia 
(ML) cells (Nakajima et aI., 1996). 
The self-renewal of embryonic stem (ES) cells has also been associated 
with STAT3. Self-renewal allows the continuously propagation of cells 
in an undifferentiated, pluripotent state. The pluripotency of mouse 
stem cells depends on LIF-activated STAT3, since mutations of either 
gp 130 receptor or ST AT3 abrogated the self-renewal of ES cells and 
led to the onset of differentiation (Humphrey et aI., 2004). The 
importance of the LIF/STAT3 pathway in self-renewal has also been 
documented in chicken and rat ES cells (Horiuchi et aI., 2004, Buehr et 
aI., 2008). ChIP-on-chip and ChIP-seq analyses has revealed that 
ST AT3 binds to the regulatory regions of several self-renewal genes in 
ES cells suggesting that LIF signaling in ES cells promotes expression 
of self-renewal genes and simultaneously suppresses induction of 
differentiation-associated genes (Chen et aI., 2008, Kidder et aI., 2008). 
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1.2.7.2. 5T A T3 and the heart 
STAT3 elicits diverse functions in various cell types and has also been 
showed to play extensive roles in the heart. Cardiomyocyte-ST A T3 
activity is required for controlling cardiac growth, function, tissue 
architecture and protection against cardiovascular stress. 
It has been suggested that ST A T3 plays a role in the early phase of 
postnatal angiogenesis of the heart - a process involving the growth of 
new blood vessels from pre-existing vessels. During postnatal growth 
of the heart there is rapid vascular development, providing nutrient-
rich, oxygenated blood to the heart which is required for optimum 
function of cardiac tissue (Hudlicka and Brown, 1996). Vascular 
endothelial growth factor (VEGF) is one of the most important known 
inducers of angiogenesis. Funamoto and colleagues have demonstrated 
that VEGF induction in cardiomyocytes by glycoprotein (gp) 130, a 
subunit of the IL-6 receptor requires ST AT3 signaling (Funamoto et aI., 
2000). More recently the siRNA knockdown of ST AT3 lead to a down-
regulation of mRNA expression of VEGF, thus reducing angiogenesis 
in lung cancer cells (Zhao et aI., 2011) 
Studies have shown that mice containing the STAT3s727A gene 
mutation show a failure to thrive as well as increased lethality during 
the first week of birth (Shen et aI., 2004). The STAT3 serine deletion 
was associated with a reduction in the transcriptional activity of ST AT3 
alongside a reduction in the serum levels of insulin-like growth factor 
(IGF-l) - a known proangiogenic factor, which is involved the 
upregulation, of pro-angiogenic VEGF (Dunn, 2000). Cardiomyocyte-
46 
specific deletion of ST A T3 has also been implicated in mechanisms 
that control cardiac vasculature and extra-cellular matrix (ECM) 
composition. Cardiomyocyte specific overexpression of STAT3 
increased myocardial capillary density and enhanced expression of 
VEGF - a STAT3 target gene (Hilfiker-Kleiner et ai., 2004). 
Conversely, cardiomyocyte STAT3 knockout mice display a 
progressive decrease in capillary density together with alterations in the 
ECM composition, which led to subsequent heart failure in older age 
(Jacoby et ai., 2003). 
Earlier studies showed that ST AT3 plays a key role in cardiac-
hypertrophy (Yasukawa et ai., 200 I). Cardiomyocyte-specific over-
expression of ST AT3 in mice caused spontaneous cardiac hypertrophy 
(Kunisada et ai., 2000). Activation of gp130 receptor signaling via LIF, 
induced hypertrophic growth in cardiomyocytes, a feature that was 
abolished by over expression of the negative regulator of 
gp130/JAKISTAT signaling, SOCS3 (Yasukawa et ai., 2001). Recently 
it has been shown that he angiotensin II type 1 receptor induces 
unregulated expression of STAT3, leading to nuclear accumulation of 
ST AT3 that significantly correlated with the progression of cardiac 
hypertrophy (Yue et ai., 2010). Van and colleagues also suggests that 
the a)-Adrenergic receptor (a)-AR) induces the activation of STAT3, 
mainly through transactivation of EGFR, which plays an important role 
in a)-AR-induced cardiac hypertrophy (Li et ai., 2011). 
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Changes in the regulation of STAT3 have been observed in failing 
hearts. Powedski and colleagues analysed samples obtained from 
patients undergoing heart transplantation due to dilated cardiomyopathy 
(DCM), which represents a common end-stage disease state of the 
myocardium that leads to cardiac dilation and heart failure (Hunter and 
Chien, 1999). In these samples they observed that the expression and 
tyrosine phosphorylation of STAT3 was severely reduced (Podewski et 
aI., 2003). This raised the possibility that decreased activation of 
ST AT3 may contribute to the development of heart failure in patients. 
This hypothesis was later supported by the observation that mice with 
cardiomyocyte-specific disruption of ST AT3 developed DCM, heart 
failure and succumbs to early death (Jacoby et aI., 2003, Hilfiker-
Kleiner et aI., 2004). 
STAT3 also seems to modulate inflammation in the heart in response to 
environmental factors. Treatment of cardiomyocytes with bacterial 
endotoxin lipopolysacharide (LPS) induced the activation of ST AT3 
(Cowan et aI., 2000). In support of this, cardiomyocyte-restricted 
knockout of ST A T3 in mice led to enhanced apoptosis upon LPS 
treatment, indicating that STAT3 knock-out mice may have a 
hyperactive response to inflammatory stimuli induced by bacterial 
toxins (Jacoby et aI., 2003). 
Studies have also demonstrated that ST AT3 plays an integrated role in 
ischaemic preconditioning (IPC) (Smith et aI., 2004) (Boengler et aI., 
2008b). In 2004 Smith and colleagues demonstrated that ST A T3 is 
necessary for IPC; genetic depletion of cardiomyocyte-specific ST AT3 
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completely abolished the cardio-protective effects observed with 
classical IPe. These findings were confirmed III isolated 
cardiomyocytes from ST AT3 knockout mice, which did not display an 
increase in cell viability by IPe after 26h ischaemia (Smith et ai., 
2004). Consistent with this, later studies in mouse hearts identified an 
increase in the tyrosine phosphorylation of JAK proteins (JAKI and 
JAK2), STAT! and STAT3, as well as enhanced STAT3 DNA binding 
in response to IPC (Boengler et ai., 2008b). In addition to IPC, ST AT3 
has also been associated with the cardioprotective roles of ischaemic 
post conditioning (postC) - a process in which transient periods of 
ischaemia/reperfusion occur at the onset a reperfusion assault. Boengler 
and colleagues demonstrated that during postC there was an increase in 
phosphory lated ST A T3, which accompanied a reduction in infarct size. 
The cardioprotection observed with postC was also abolished in 
cardiomyocyte-specific ST A T3 deficient mice (Boengler et al., 2008a). 
Cardioprotective effects by ST A T3 have been linked to direct 
transcriptional up-regulation of antioxidant enzymes such as manganese 
dismutase (MnSOD) (discussed in section 1.3.3), as well as the 
induction of anti-apoptotic and cytoprotective proteins including BclxL 
and Hsp70 (Hilfiker-Kleiner et aI., 2004, Stephanou and Latchman, 
1999). In addition, studies on transgenic hearts expressing 
constitutively active ST AT3 have shown resistance to IIR injury 
through the upregulation of reactive oxygen species (ROS) scavengers 
Metallothioneinl (MTl) and metallothionein2 (MT2), which are 
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associated with reduction in ROS generation and apoptosis (Oshima et 
aI.,2005). 
STAT3 also offers protection against age-related cardiac dysfunction 
(Jacoby et aI., 2003). Cardiomyocyte-specific STAT3 knock-out mice 
develop normally into adulthood without any obvious cardiac 
abnormalities. However, slight morphological changes such as a 
marginal increase in interstitial fibrosis and decrease in myocardial 
capillary density became apparent in young adult STAT3-KO mice (3 
months). Beyond 8 months STAT3-KO mice developed dilated 
cardiomyopathy with severe heart failure and premature death (Jacoby 
et aI., 2003). 
1.3 Reactive Oxygen Species 
1.3.1 What are Reactive Oxygen Species? 
Reactive oxygen species (ROS) include free radicals, which typically 
have oxygen or nitrogen based unpaired electron. Examples of free 
radicals include O£ (superoxide anion), OHo (hydroxyl radical) and 
ONOO- (peroxynitrite). Other species such as hydrogen peroxide 
(H202) can also act as oxidants (reviewed in (D'Autreaux and 
Toledano, 2007)). 
The physiological generation of ROS can occur as a by-product of other 
biochemical processes including within mitochondria, peroxisomes, 
xanthine oxidase and other cellular elements (Balaban et aI., 2005, 
Schrader and Fahimi, 2004, Tsutsui, 2001). The phagocyte NADPH 
so 
Oxidase (NOX) was the first identified by Rossi and colleagues in 1964 
as example of a system that generates ROS not as a by-product, but 
rather as a primary function (Rossi and Zatti, 1964). NADPH oxidases 
generate superoxide by transferring electrons to NADPH inside the cell, 
across the membrane and coupling these to molecular oxygen to 
produce superoxide, thus providing host defense against bacterial and 
fungal pathogens (Geiszt and Leto, 2004). 
1.3.2 Consequences of ROS 
Accumulation of ROS promotes the onset of cell death, resulting in 
characteristic cellular changes including lipid peroxidati6n, protein 
oxidation and double-stranded DNA breaks (Kukreja and Hess, 1992). 
Oxygen radicals catalyse the oxidation of lipids (figure 1.10) (Gardner, 
1989). For example, cell membranes, which are structurally composed 
of polyunsaturated fatty acids, which are highly susceptible to oxidative 
attack leading to changes in membrane fluidity and permeability. 
Indeed a study has shown that cell membrane damage and lipid 
peroxidation occurs during hypoxia-reoxygenation (Yajima et aI., 
2009). 
Excess ROS can also cause damage to nuclear and mitochondrial DNA 
(figure 1.10) The nature of the damage includes base modifications, 
strand breakage and DNA-protein cross-links, which can lead to DNA 
mutations. For example, ROS have been shown to induce mutations in 
the p53 tumour-suppressor gene (Hussain et aI., 1994). 
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Proteins are major targets for ROS because of their abundance in 
biological systems. Oxidative damage to proteins is induced directly by 
ROS or indirectly by reactions of secondary by-products of oxidative 
stress, and can lead to peptide-backbone cleavage, cross-linking, and/or 
modifications to amino acid side chains (Dalle-Donne et al., 2003). The 
susceptibility to oxidation varies from one amino acid to another 
(Stadtman, 1995). The most sensitive amino acids are those containing 
sulfhydryl groups, which include methionine and cysteine. Sulphydryl 
groups interact with ROS producing sulphoxides, sulphenic acids and 
disulphide bridges (Sohal, 2002). 
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Figure 1.10. Reactive Oxygen Species production and cellular defense 
mechanisms. Antioxidant enzymes; Catalase, Superoxide Dismutase (SOD) 
and Glutathione (GSH) remove reactive oxygen species O2• (superoxide) and 
hydrogen peroxide (H20 2) from the cell. Modified from (Dennis V. Cokkinos, 
2006). 
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1.3.3 Defenses against ROS 
Cells have well adapted mechanisms that control the fonnation of 
excess free radicals, which utilise antioxidant enzymes and free radical 
scavengers. The antioxidant superoxide dismutase (SOD) (Fridovich, 
1983, Fridovich, 1986) catalyses the conversion of superoxide into 
hydrogen peroxide. The copper-zinc SOD metalloprotein is located in 
the cytosol, while the manganese SOD (mnSOD) is located in the 
mitochondria. The biosynthesis of SOD is mainly controlled by its 
substrate, superoxide anion O2-. Increased expression of SOD is 
observed with intracellular fluxes of 02- (Rister and Baehner, 1976). 
The physiological importance of SODs is illustrated by the severe 
pathologies demonstrated through studies on SOD knock-out mice. For 
example, mice lacking MnSOD die several days after birth, through 
substantial oxidative stress (Li et aI., 1995). 
Glutathione peroxidase catalyses the reaction of reduced glutathione 
(GSH) with reactive hydroperoxides to fonn glutathione disulphide 
(GSSG), which leads to the reduction of products of hydroperoxide 
(section 1.3.2.2). 
Glutathione peroxidase is a saleno-enzyme that is present in the cytosol 
and mitochondria (Freeman and Crapo, 1982). 
Catalase is present in all mammalian cells and is localised to the 
p e r o x i s o m e ~ . . Catalase aids in the rapid decomposition of hydrogen 
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peroxide into less reactive gaseous oxygen and water molecules 
(Deisseroth and Dounce, 1970) 
In addition to the primary defense against ROS by antioxidant enzymes, 
a secondary defense is offered by small molecules that can act as direct 
redox regulators to protein thiols. Thioredoxins are small thiol-
oxidoreducatases that act as antioxidants by facilitating the reduction of 
other proteins by cysteine-thiol-disulphide exchange. Thioredoxins 
contain two vicinal cysteines in a CxxC motif that participates in 
protein thiol reduction. Another antioxidant that can protect against 
ROS is a cysteine-containing tri-peptide called glutathione. Glutathione 
exists both in a reduced (GSH) and oxidised glutathione. disulphide 
(GSSG). The reduced glutathione acts as an antioxidant by serving as 
an electron donor. In the process, glutathione is converted to its 
oxidised form, GSSG. Glutathione is found almost exclusively in its 
reduced form, since the enzyme that reverts it from its oxidised form, 
glutathione reductase (GR) is constitutively active and inducible upon 
oxidative stress. In fact, the ratio of GSH:GSSG within cells is often 
used as a measure of cellular oxidative stress (Pastore et aI., 2001). 
1.3.4 ROS during cellular signaling 
High levels of ROS production can be detrimental leading to cell death, 
however ROS production at lower concentrations can modulate 
intracellular signaling pathways (Redox signaling). 
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The best understood pathway by which ROS achieves regulation 
through cell function occurs through regulating tyrosine phosphatases 
(PTPs). PTPs control the phosphorylation status of many signal-
transducing proteins and are therefore involved in many processes 
including proliferation, differentiation and survival (Hunter, 2000). The 
catalytic region of PTPs contains cysteines (Barford, 2004), which are 
susceptible to oxidation inactivation (Denu and Tanner, 1998). 
Consistent with this mechanism, NOX-derived ROS has shown to 
regulate protein tyrosine phosphorylation (Goldstein et aI., 2005). 
ROS is also a regulator in the SUMOlyationideSUMOlyation 
equilibrium. Studies have shown that low levels of ROS c a ~ s e e a rapid 
disappearance of most SUMO-conjugates. Inhibition was achieved 
through the formation of disulphide bonds involving the catalytic 
cysteines of the SUMO E I subunit Uba2 and the conjugating enzyme 
Ubc9 (Bossis and Melchior, 2006). 
Studies have shown that ROS can also offer cardioprotection - Vue and 
colleagues demonstrated that the mitochondrial ROS generator 
menadione can cause cardioprotection through a pathway involving 
p38-mitogen activated protein kinase (MAPK) activation (Yue et aI., 
2002). Antimycin has also been shown to generate mitochondrially-
derived ROS, which activates PKCE that has been shown to be crucial 
for cardioprotection (Kabir et aI., 2006). 
ROS had also been shown to stimulate cardiac hypertrophy - Kwon and 
colleagues demonstrated that hydrogen peroxide caused concentration 
dependant' effects on adult rat ventricular myocytes (ARVM) 
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phonotype. Hypertrophy was observed at low concentrations (10-
30IlM) whereas high concentration (100 IlM) leads to apoptosis (Kwon 
et aI., 2003). 
ROS has also been implicated in redox signaling in cardiomyocytes. A 
variety of cardiac proteins are susceptible to redox modification 
including PKG I a and the sacroplasmic reticulum calcium pump 
(SERCA) (Burgoyne et aI., 2007, Adachi et aI., 2004). In addition ROS 
can modulate signaling pathways including the activation of ERK1I2, 
p38 MAPK, Akt, PKCs and NF-K8 that are involved in cardiac 
hypertrophy (reviewed in (Sugden and Clerk, 2006). 
1.3.4.1 Regulation of JAKISTA T pathway by ROS 
Reactive oxygen species have also been implicated in the regulation of 
the JAKISTAT pathway. Studies have shown that tyrosine 
phosphorylation and DNA binding activities of STAT3 were activated 
in response to oxidative stress (Simon et aI., 1998, Carballo et aI., 
1999). Rat-l fibroblast cells exposed hydrogen peroxide (1 mM H202) 
showed an induction ST AT3 activity and this activity could be 
abolished by the addition of antioxidants (Simon et aI., 1998). 
Enhanced tyrosine phosphorylated of ST A T3 was later observed in 
human lymphocytes exposed to oxidative stress (Carballo et aI., 1999). 
ST AT3 has also been associated with protection against oxidative 
stress. Studies show that ST AT3 deficient mouse embryonic fibroblasts 
(MEFs) were more sensitive to death when treated with H20 2 in a dose 
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dependent manner, indicating that ST A T3-deficiency renders cells 
more susceptible to oxidative stress (Barry et aI., 2009). 
ST AT3 is also modified directly in response to oxidative stress. ST AT3 
becomes s-glutathionylated upon mild oxidative stress (section 1.2.5.4) 
leading to marked reduction in IL-6-dependent ST A T3 signaling (Xie 
et aI., 2009). More recently, Li and colleagues have demonstrated that 
ST A T3 is capable of forming high molecular weight ( ~ ~180kDa, 
~ 2 7 0 k D a a and ~ 3 6 0 k D a ) ) complexes in various cell types that are 
exposed to peroxide. As mass spectrometry analyses did not detect 
other proteins within these complexes it suggests the formation of 
ST AT3 redox multimers. The formation of these ST AT3 redox 
multimers also correlated with the loss of STAT3 DNA binding during 
peroxide treatment (Li et aI., 2010). 
1.3.5 ROS and cardiovascular disease 
ROS generated during I1R injury has been implicated as primary cause 
of oxidative stress and tissue damage in ischaemic heart disease 
(Turrens and Boveris, 1980, Blake et aI., 1987). 
The concept that oxidative stress is important in the pathogenesis of 
cardiovascular disease was conceived from studies that noted the 
cytotoxic and atherogenic properties of oxidized LDL (oxLDL). Free 
radicals oxidise LDL causing macrophages to devour them and become 
"foam cells" which clog up arterial walls and contribute to the 
development of atherosclerosis. Steinberg and colleagues revealed that 
macrophages engulf oxLDL at a faster rate than un-oxidised LDL, 
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accelerating the process of atherosclerosis (Steinberg et aI., 1989, 
Witztum and Steinberg, 1991). 
The superoxide anion O2.- is capable of reacting with nitric oxide (NO), 
a blood vessel dilator and anti-thrombotic agent generated in the lining 
of the blood vessel. This reaction inactivates nitric oxide and its 
diminished bioactivity causes constriction of coronary arteries, which 
contributes to myocardial ischaemia in patients with coronary artery 
disease (Cannon, 1998). The reaction between NO and O2.- also leads 
to the formation of peroxynitrite (ONOO-), which is implicated in DNA 
damage (Ballinger et aI., 2000), enzyme inactivation (MacMillan-Crow 
et aI., 1998) and lipid peroxidation. 
1.4 Mitochondrial dysfunction 
1.4.1 The role of mitochondria 
Mitochondria are membrane-enclosed organelles found in most 
eukaryotic cells (Henze and Martin, 2003). Mitochondria are generally 
considered "cellular power plants" due to the fact they generate the 
majority of the cell's supply of adenosine triphosphate (ATP) in a 
process called oxidative phosphorylation. In this process, electrons are 
transported between complexes I to IV of the mitochondrial electron 
transport chain (ETC) (figure 1.11) (McBride et aI., 2006). Electron 
transport is coupled with the movement of protons from complexes I, 
III and IV into the intermembrane space, creating an electrochemical 
gradient (Ll'V) across the inner mitochondrial membrane. Protons then 
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flow through complex V (ATP synthase), which utilises the energy to 
generate ATP. In addition to cellular energy, mitochondria are involved 
in various other cellular processes including signaling, cell death, 
control of the cell cycle and growth (McBride et aI., 2006). 
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Figure 1.11. Electron Transport Chain. The diagram shows the five 
complexes that are involved in the mitochondrial electron-transport chain. 
Complexes I-IV are the electron-transport complexes, whereas complex V 
synthesizes adenosine triphosphate (ATP). Electrons are passed down the 
four complexes (black arrows) to molecular oxygen and then complex V 
generates one ATP molecule from ADP and inorganic phosphate (Pi). The 
dotted arrows show where the protons are pumped into the- inter-membrane 
space to generate an electrochemical gradient ( ~ 4 J ) ) and where proton 
movement back across complex V (the ATP synthase) is used to drive ATP 
synthesis. Adapted from (8ayir and Kagan, 2008). 
1.4.2 Mitochondria and ROS production 
Mitochondria are considered the pnmary source of endogenous 
oxidants within the cell (figure 1.12). Chance and colleagues 
demonstrated that isolated mitochondria produce H20 2 (Loschen et aI. , 
1971 , Chance et aI. , 1979). It was later confirmed that this H20 2 in fact, 
arose from the dismutation of superoxide generated within 
mitochondria (Loschen et aI., 1974). The majority of oxygen is 
consumed · by the mitochondrion and converted into water in the 
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electron transport chain (ETC) at complex IV (cytochrome c oxidase). 
However oxygen is able to acquire electrons directly from the 
ubiquinone site at complex III and from flavin mononucleotide (FMN) 
group at complex I to generate 0 2·- (Zhang et aI. , 1990, Turrens, 2003). 
mitochondrion 
al'e< 
~ ~ ~
~ ~
IIIler· 
membtllne 
sp4Ce 
/ ~ ~ defective 
proteins 
oxidative 
damage 
Figure 1.12. Mitochondrial ROS production. Schematic diagram 
representing ROS production by mitochondria. ROS leads to oxidative 
damage of mitochondrial proteins, membrane and DNA, which impairs the 
ability of mitochondria to synthesize ATP. PTP; Permeability Transition Pore, 
cyt c; cytochrome c.Taken from (Murphy, 2009). 
Mitochondrial ROS production has also been observed to increase 
under conditions of low oxygen (hypoxia) (Semenza, 2004). Increased 
ROS production during hypoxia was revealed from investigations 
initially carried out on HIP-I, which plays a central role in the response 
of cells to hypoxia (Semenza, 2004). Hypoxia has been shown to 
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significantly increases the generation of ROS in adipose-derived stem 
cells (ASCs) and this increase is reversed by the treatment with the 
antioxidants N-acetyl-cysteine and diphenyleneiodonium (Kim et aI., 
2011). Evidence also suggests that ischaemialreperfusion injury causes 
a "burst" in mitochondrial ROS production. This burst was 
demonstrated clearly in cardiomyocytes in the first several minutes of 
reperfusion using a fluorescent probe sensitive to oxidants (Vanden 
Hoek et aI., 1997). 
There is a body of evidence linking mitochondrially generated ROS 
with the apoptosis of cardiomyocytes (von Harsdorf et aI., 1999, 
Kotamraju et aI., 2000, Childs et aI., 2002, Ghosh et aI., 2 0 ~ 4 ) . . A study 
shows that cytochrome c is released from mitochondria in H202 treated 
cardiomyocyte leadingto apoptosis (Whelan et aI., 2010). It has also 
been suggested that activation of the mitochondrial apoptotic pathway 
leads to executioner caspase activation in heart injury (Whelan et aI., 
2010). Doxorubicin-induced cardiomyopathy is partially caused by an 
increase in ROS production in the heart, resulting in apoptosis 
(Kotamraju et aI., 2000) and Childs and colleagues demonstrated that 
doxorubicin induced radical production and oxidative stress that 
triggers the release of cytochrome c from the mitochondria, resulting in 
the activation of caspase-3 and apoptosis (Childs et aI., 2002). In 
addition, a study has shown that rats treated with streptozotocin to 
simulate acute diabetes displayed depletion in the antioxidant 
glutathione, leading to increased ROS levels and cardiac apoptosis 
(Ghosh et al., 2004). Later work demonstrated that the ROS generated 
in this scenario was due to mitochondria (Ghosh et al., 2005). 
1.4.3. Cardiovascular disease and mitochondria 
The function of the heart is highly dependent on oxidative energy, 
which is generated in mitochondria. Defects in mitochondrial structure 
and function can be found in association with cardiovascular diseases. 
Abnormalities in mitochondrial structure and function have been 
associated with numerous myocardial injury and disease states (Marin-
Garcia and Goldenthal, 2002). Morphological studies usmg 
transmission electron microscopy revealed that the number, size and 
structural integrity of mitochondria were compromised in the 
myocardium of dogs suffering from chronic heart failure (CHF) 
(Sabbah et al., 1992). 
Mitochondrial function was also reduced in failing hearts.(Sharov et al., 
1998). The capacity of the mitochondria for oxygen consumption and 
oxidative phosphorylation was significantly reduced compared to 
normal hearts. The results indicate abnormal mitochondrial respiratory 
activity in myocardium of dogs with CHF (Sharov et al., 1998). In 
addition, patients suffering from DCM and heart failure with a history 
of ischeamic heart disease showed a reduction in the activity of 
complex III, a component of the ETC (Jarreta et al., 2000). A study hast 
also reported that prolonged ischaemia significantly impairs the 
mitochondrial respiratory chain at the level of complexes IIII and IPC 
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(cardioprotective mechanism) protected against such impairments 
(Thaveau et aI., 2007). 
1.4.4. Mitochondria and STAT3 
Recently it has emerged that ST A T3 plays a role in mitochondrial 
respiration. Wegrzyn and colleagues identified a population of ST A T3 
present in the mitochondria that regulated oxidative phosphorylation 
through association with complexes I and II of the ETC (Wegrzyn et 
aI., 2009). Later studies confirmed the mitochondrial localisation of 
STAT3 and its role in respiration (Boengler et aI., 2010). This group 
also demonstrated that STAT3 co-immunoprecipitated with cyc10philin 
D, a mitochondrial matrix protein that facilitates membrane 
permeability transition pore (MPTP) opening when bound to the 
mitochondrial membrane. Interaction of cyc10philin D with ST AT3 
caused a delay in MPTP opening and a reduction in infarct size in 
response to IIR injury (Boengler et aI., Boengler et aI., 2010). 
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1.5 Research aims and objectives 
Cardiovascular disease represents a significant threat to the health of an 
aging society and the development of effective treatments for this 
disease will require an understanding of the aging and ischaemic heart. 
ST AT3 is important for the phenotypic stability and survival of cardiac 
tissue; it plays a crucial role in hypoxic preconditioning (Smith et aI., 
2004) and is susceptible to regulation by oxidative stress (Barry et aI., 
2009, Xie et aI., 2009, Li et aI., 2010). These data indicate that STAT3 
may be subject to direct control by oxygen levels in cardiac cells, which 
warrants further investigation. This study aims to identify the effects of 
hypoxia and reoxygenation (oxidative stress) on ST AT3 activity in two 
cardiomyocyte-like cell lines (P19CL6 and H9c2) and primary rat 
cardiomyocytes (RCMs). This will be achieved by assessing the 
phosphorylation status of STAT3 and its ability to bind to DNA from 
cardiomyocyte cells exposed to hypoxic/oxidative stress. The 
contribution of ST A T3 towards cardiomyocyte survival following 
hypoxic/oxidative stress will also be addressed through the exogenous 
expression of STAT3 and various STAT3 mutants (STAT3C3s and 
STAT3s727A) and measuring levels of apoptosis. Understanding the 
mechanism and consequences of ST A T3 regulation by hypoxia and 
oxidative stress in cardiomyocytes will be important for developing 
new therapeutic approaches to progressive ischaemic heart disease. 
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Chapter 2. Materials and methods 
2.1 Materials 
2.1.1. Antibodies 
Table 1. Antibodies used throughout this study. 
~ ~ ~ ~ . . ~ ~udYL'. ' , ~ : : ';" : ~ ' ' •. ~ . . , _ . : : . " " - : ~ , , M a n ~ f a c ~ ~ r ~ c ~ " , ; ' ' ... : h . , 
a-Actin (A-2066) Sigma Aldrich 1:1000 
a-Bid (FL-195) Santa Cruz Biotechnology 1:500 
a-Flag (F3165) Sigma Aldrich 1:1000 
a-McI-1 (s-19) Santa Cruz B i o t e c h n o l o g ~ ~ 1:500 
a-PKC5 (2058) Cell signaling 1:1000 
a-phospho-PKC5/9 Cell Signaling 1:1000 
(Ser 643/676) (9376) 
a-TBP (N-12) Santa Cruz Biotechnology 1:1000 
a-Tubulin (H-3001 Santa Cruz Biotechnology 1:500 
a-STAT3 (S21320) Transduction Laboratories 1:1000 
a-phospho-STAT3 (Y705) Upstate 1:500 
a-phospho-STAT3 (S727) Cell Signaling 1:500 
a-VDAC (D73012) Cell Signaling 1:500 
a-mouse HRP-conjugated Sigma Aldrich 1:5,000 
(A6782) 
a-Rabbit HRP-conjugated Sigma Aldrich 1:10,000 
(A0545) 
2.1.2. Commercial chemicals and Kits 
• Annexin V-FITC apoptosis kit (Autogen Bioclear) 
• ATP monitoring reagent (BioTherma) 
• BioRad protein assay kit (BioRad) 
• Complete protease inhibitor cocktail tablets (Roche) 
• ECL detection reagent (Millipore) 
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• EeL advance detection reagent (Amersham UK) 
• JetSorb gel extraction kit (Genomed) 
• Leukemia Inhibitory Factor (L5158) (Sigma Aldrich) 
• Nucleobond AX maxi-prep kit (Machery NagaI Germany) 
• Phos-Stop phosphatase inhibitor tablets (Roche) 
• Protein-G-sepharose™ beads (GE Healthcare) 
• Qiagen QIAprep spin mini-prep kit (Qiagen) 
• Qiagen Nucleotide removal kit (Qiagen) 
• Trypan blue solution - 0.4% (Sigma Aldrich) 
• Strep-Tactin® sepharose (IBA BIOTAGnology) 
2.1.3. Bacterial strains 
All cloning was achieved using the bacterial strains NM522 and XL-2 
blue ultra-competent cells. Bacmid DNA for baculovirus expression 
was generated using max efficiency® DH 10 Bac ™ chemically 
competent cells. 
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2.1.4. Plasmid constructs 
Table 2. Plasmids used throughout this study 
P.lamld.", .... .i' .... '.'. Descriiit(c:ml ..... , . .., . . , . ~ : . . G Q ~ q y c t e d d by. 
pFastBac mSTAT3 Mouse wild-type ST AT3 Emma Evans 
wt cDNA expression 
cassette 
pFastBac mSTAT3 Mouse ST A T3"''''' cDNA Emma Evans 
C3S expression cassette. 
C418S, C426S and 
C468S. Residues 
changed to serine render 
the molecule as redox-
insenstive 
pRc/CMV Flag Mouse Wild-type ST A T3 (Horvath et aI., 
STAT3 wt cDNA expression vector 19951 
pRc/CMV Flag Mouse ST A T3"''''' cDNA (Li et al.) 
STAT3 C3S expression vector. 
C418S, C426S and 
C468S. Residues 
changed to serine render 
the molecule as redox-
insenstive 
pRc/CMV Flag Mouse ST A T3-C cDNA (Li and Shaw, 
STAT3C expression vector. A662C 2006) 
and N664C. Residues 
changed to Cys renders 
the molecule constitutively 
active 
pRc/CMV Flag Mouse STAT3"'f£fM cDNA (Wen and 
STAT3 S272A expression vector. Darnell, 1997) 
Residue changed to Ala 
prevents serine 
phosphorylation of this 
molecule 
pRc/CMV Flag Mouse STAT3"""LU cDNA Emma Evans 
STAT3 S7270 expression vector. 
Residue changed to Asp 
renders the molecule as 
serine J ) h o s ~ h o - m i m e t i c c
pRc/CMV Flag Mouse STAT3"'£fLt: cDNA Emma Evans 
STAT3 S727E expression vector. 
Residue changed to Glu 
renders the molecule as 
serine ~ h o s ~ h o - m i m e t i c c
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2.1.5. Oligonucleotides 
Table 3. Cloning oligonucleotides used to PCR clone Strep tagged STAT3 cDNA 
+Stre 
ForSTAT3 Emma Evans 
Table 4. Mutagenic oligonucleotides used to generate serine phospho-mimetic 
STAT3 cDNA 
~ _ ~ f f i ( ' ' ' T r ' ~ ' ~ f ~ ~
, . ~ ' ' ; ; _,", ~ " " -: _ ',;':',,'/' ~ ' . . < .. 'i ,,{!li ( i . \ b , : ~ " . : :
il..1UUU "j .... ' ,,', " ~ ~ '. ,'./ .. ', ~ . - " , , · ~ " " , d ! ) ' '.. ":,' - :'!tI::i. ;, .... ' .... '" ~ ~ .... r'" '.':'. " : J ' . ' " ~ « ' ~ T ' ' ' ' !; .... , ~ ~ .... ",. ... _ 1_,. ' ...... 
S727E 5'GACCTGCCGATGGAACCCCGC Emma Evans 
For ATTTAG3' 
S272E 5'CT AAAGTGCGGGGTTCCATCG Emma Evans 
Rev GCAGGTC3' 
S7270 GACCTGCCGATGGACCCCCGCA Emma Evans 
For CTTTAG3' 
S272 5'CT AAAGTGCGGGGGTCCATCG Emma Evans 
Rev GCAGGTC3' 
Table 5. Oligonucleotides used for synthesis OP2p labeled oligonucleotide probes 
used in electrophoretic mobility shift assays 
5'CTAGCA TTTCCCGT AAAA T3' 
5'CT AA TTT ACGGGAAA TG3' 
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2.2. Methods 
2.2.1. Nucleic Acid Techniques 
2.2.1.1. Amplification of DNA 
Small scale DNA Preparation 
Five mls of Luria-Bertani (LB) broth supplemented with appropriate 
antibiotics, were inoculated with a bacterial strain of interest (from a 
colony or glycerol stock) and incubated over night at 37°C on a rotating 
wheel (New Brunswick Scientific). Cells from I-2ml of the over night 
culture were collected by centrifugation at 8,000rpm for 3 minutes at 
room temperature. The supernatant was discarded and the bacterial cell 
pellet resuspended in 250 I.d Buffer P I and then lysed using 250 f.ll 
Buffer P2. The denatured lysate was neutralised by the addition of 350 
f.ll Buffer N3 causing the formation of a precipitate containing 
chromosomal DNA and other cellular compounds. The precipitate was 
cleared by centrifugation at 13,000rpm for 10 minutes. The cleared 
lysate was applied to the QIAprep column where plasmid DNA bound 
to the unique silica membrane, while RNA, cellular proteins, and 
metabolites were not retained on the membrane and removed by 
centrifugation at 13,OOOrpm for 30 seconds. Salts were efficiently 
removed by a brief wash step with 750f.l1 of buffer PE buffer followed 
by centrifugation at 13,OOOrpm for 30 seconds. High-quality plasmid 
DNA was then eluted from the QIAprep column with 50-100f.l1 of 
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buffer EB and collected by centrifugation at 13,OOOrpm for 30 seconds 
and purified DNA was stored at -20°C. Small scale DNA was prepared 
using the QIAprep Spin Miniprep Kit. 
Large Scale DNA preparation 
One hundred and fifty mls of LB broth supplemented with appropriate 
antibiotics, were inoculated with a bacterial strain of interest (from a 
colony or glycerol stock) and incubated over night at 37°C in a shaking 
incubator (New Brunswick Scientific). Cells from the overnight 
cultures were collected by centrifugation at 6,000rpm for 30 minutes at 
4°C and the supernatant discarded. The bacterial pellet was 
resuspended in l2ml of resuspension buffer (50 mM Tris-HCI, 10 mM 
EDTA, 100 /lg/mL RNase A, pH 8.0) and then lysed using 12mllysis 
buffer (200 mM NaOH, 1 % SDS). The denatured lysate was 
neutralised by the addition of 12ml of neutralisation buffer (2.8 M KAc, 
pH 5.1) causing the formation of a precipitate containing chromosomal 
DNA and other cellular compounds. The precipitate was cleared by 
centrifugation at 12,000g for 45 minutes at 4°C. The cleared lysate was 
applied to the equilibrated NucleoBond® AX column and plasmid 
DNA is bound to the anion-exchange resin. The column was washed 
with 32ml of wash buffer (100 mM Tris, 15 % ethanol, 1.15 M KCl, pH 
6.3) and DNA eluted from the column using 15ml of elution buffer 
(100 mM Tris, 15 % ethanol, 1 M KCl, pH 8.5). Eluted DNA was 
precipitated with 11 ml of isopropanol and collected by centrifugation at 
15,000g for 30 minutes at 4°C. The DNA pellet was subsequently 
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washed with 7ml ethanol (70%) and finally reconstituted in I ml TE 
buffer (lOmM TrisIHCI, ImM EDTA, pH8.0). 
Large scale DNA was extracted using the Nucleobond AX PC500 kit 
(Machery NagaI Germany). 
Small Scale bacmid DNA preparation 
Bacmid DNA was utilised in the generation of recombinant proteins 
using the baculovirus expression system (Section 3.7) 
Two mls of LB broth supplemented with with 50J.lVml kanamycin, 
7J.lglml gentamicin and lOJ.lg/ml tetracycline were inoculated with 
DHlOBac (Invitrogen) cells containing pPastBac p l a s m ~ d d of interest 
overnight at 37°C on a rotating wheel. Cells from the overnight cultures 
were collected by centrifugation at 14,000g for I minute at 4°C. Cells 
were resuspended in 300J.lI of solution I (15mM Tris, 10mM EDT A, 
100J.lg/ml RNase A pH 8.0) before lysing the cells in solution II 
(200mM NaOH, 1% SDS) at room temperature for 5 minutes. To 
precipitate proteins and chromosomal DNA, 300J.lI 3M potassium 
acetate pH 5.5 was added to the samples and incubated on ice for 10 
minutes. Lysates were cleared by centrifugation at 14,000g for 10 
minutes at 4°C and the supernatants were transferred to a fresh 
Eppendorf tube containing 800J.lI of isopropanol. Samples were mixed 
gently by inversion and incubated on ice for 10 minutes. Bacmid DNA 
was collected by centrifugation at 14,000g for 15 minutes at room 
temperature. DNA pellets were washed in 500J.lI 70% ethanol before 
drying in air for 10 minutes. Bacmid DNA was dissolved in 40J.lllxTE 
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(lOmM Tris, ImM EDTA) pH8.0 with gentle rocking at room 
temperature for 3 minutes before storing at 4°C. 
2.2.1.2. Restriction digestion of DNA 
Restriction digests of DNA were carried out in a standard 15Jll reaction 
volume. DNA was digested using 5U of appropriate restriction enzyme 
supplemented with restriction buffer supplied by the manufacturer. 
Digests were incubated for 1 hour 30 minutes at 37°C in a water bath. 
2.2.1.3. Alkaline phosphatase treatment of DNA 
Subsequent to restriction digest, 5' phosphate groups were removed 
from DNA vectors with calf intestinal alkaline phosphatase (ClAP) to 
prevent self-ligation. To the 15111 restriction digest, 1.5Jll of 1 M Tris-
HCl pH 9.5 and 1 U of ClAP (MBI Fermentas) were added to the 
reaction. After incubation for 20 minutes at 37°C, ClAP was by heat 
inactivated at 65°C for 5 minutes. 
2.2.1.4. Ligation of DNA 
The ligation of DNA fragments was performed in a 10Jll reaction 
volume using 1 U of DNA ligase (F ermentas Life Sciences) with a 1:2 
ratio of vector to insert. Ligations were incubated at 16°C in a water 
bath overnight. 
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2.2.1.5. Oligonucleotide 32p_ATP 5' end-labelling 
Routinely 400ng of 32p_A TP labeled oligonucleotide duplex was 
prepared using a modified protocol from Wagner and colleagues 
(Wagner et aI., 1990). Water was added to 200ng of "upper" 
oligonucleotide strand to give a final volume of 6/l1. To remove 
secondary structure (from the DNA) the sample was incubated at 95°C 
for 5 minutes and then immediately placed on ice for two minutes. 
After brief centrifugation, l,.d of lOX polynucleotide (PNK) buffer A 
(Prom ega UK), 2/l1 of 32pY_A TP (3000 Ci/mmol, Amersham Pharmacia 
Biotech) and l/ll T4 polynucleotide kinase (PNK, IOU) (Promega UK) 
was added. The reaction was incubated at 37°C for 30 minutes before 
enzyme inactivation at 65°C for 10 minutes. Water was added to 400ng 
of lower oligonucleotide strand to a final volume of 4/li. The sample 
was heated to 95°C for 5minutes, cooled on ice for 2 minutes and after 
brief centrifugation added to the 32p ATP- labeled lower 
oligonucleotide strand. The two oligonucleotide strands were denatured 
by immersing the tube in alL beaker of boiling water and allowed to 
cool slowly to room temperature (approx. 4 hours), creating an 
oligonucleotide duplex. 
Unincorporated 32p_ATP was removed from the oligonucleotide duplex 
using the Qiagen nucleotide removal kit following manufacturer's 
instructions. The 32P-Iabelled oligonucleotide duplex was eluted from 
the Qiagen column in 100JlI of Qiagen EB buffer and stored at -20°C 
until required. 
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2.2.1.6.DNA Cloning 
Polymerase chain reaction 
During this study the polymerase chain reaction PCR was used to 
modify and amplify target DNA sequences for subsequent cloning. A 
proof reading DNA polymerase pfu (New England Biolabs) was 
utilised to ensure that errors were not introduced into the sequence 
during amplification. The following thermal profile was used for PCR 
with extension times calculated based on amp Ii con length and 
polymerase synthesis rate. Annealing temperatures were dependent on 
the melting temperature (Tm) of the primers. 
Initiation :.95°(, for 2 minutcs 
t 
D c n ~ t u r i n g g :- 95° lor I minute ...-
t 
Anncaling :- X O(' for I minute 25-30 C) cles 
t 
Extension :- 72°(' lor X minutes -
t 
Final cxten ion :_72°(' for 5 minutes 
Site-directed mutagenesis 
Mutation of a single amino acid was achieved by PCR-based 
QuickChange® Site- Directed Mutagenesis (Stratagene). The reaction 
mixture consisted of :- 25ng template plasmid DNA, 5 ~ 1 1 lOx reaction 
buffer (Stratagene), 125ng forward and reverse primer, 2 0 0 ~ ~ dNTPs, 
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0.51l1 pfu (1.24 units) in a final volume of 50Ill. The thermal profile 
below was used. 
Initiation :- 95°(.' lor 2 minutes 
t 
Denaturing :- 95°(' for 30 sl'conds ~ ~
t 
nm:aling :- 55°(' for I minute 16 C) Ie;. 
t 
Extcn ion :- 68°(' lor 16 minutes -
I' innl cxtcn ion :_72°(' fur 5 minutes 
The PCR product was then incubated with 0.51l1 of restriction 
endonuclease DpnI (lOU/ill) (Promega) at 37°C for 1.5 hours. This 
allowed digestion of the non-mutated methylated template plasmid thus 
increasing the mutation frequency (Section 3.2.). 
2.2.1.7. Sequencing of DNA 
The 3130 ABI PRISM Genetic Analyser (PE Applised Biosystems) 
was used for sequencing reactions. Approximately 100ng purified 
plasmid DNA was used for each reaction. Analyses were performed in 
the Biopolymer Synthesis and Analysis Unit of the School of 
Biomedical Sciences, University of Nottingham. 
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2.2.2. Bacterial Techniques 
2.2.2.1. Production of chemically competent cells 
The ability of E.coli to be transformed with DNA (by heat shocking) 
required the cells to be made chemically competent. A 5ml LB culture 
was inoculated from a NM522 glycerol stock and grown overnight in a 
rotating wheel (New Brunswick Scientific) at 3rC. A 100m I culture 
was seeded with Iml of overnight culture and grown at 37°C in a 
shaking incubator (New Brunswick Scientific) until an optical density 
of 0.4 (wavelength of 600nm) was achieved, indicating mid-log phase 
The bacterial cells were collected by centrifugation at 4300rpm for 10 
minutes at 4°C and the LB discarded. Cells were resuspended in 30ml 
of sterile (ice cold) transformation buffer I (TFBI) (10mM MOPS 
pH7.0, lOmM RbCl) before incubating them on ice for 10 min. Cells 
were collected by centrifugation at 4300rpm for 10 minutes at 4°C and 
the TFBI discarded. The bacterial cell pellet was resuspended in 4ml of 
sterile (ice cold) transformation buffer III (TFBIII) (100mM MOPS 
pH6.5, 50mM CaCh, lOmM KCI, 15% glycerol) before aliquoting into 
200f,.t1 aliquots and snap freezing in liquid nitrogen. The competent cells 
were stored at -80°C until use. 
2.2.2.2. Transformation of competent NM522 cells 
Plasmid DNA or ligation reactions were gently added to 50f,.t1 of thawed 
NM522 competent cells and incubated on ice for 20 minutes. Cells 
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were heat shocked at 42°C m a waterbath for 2 minutes before 
immediately returning to ice for 2 minutes. Cells were allowed to 
recover by the addition of 1 ml LB for 1 hour at 37°C in a bench top 
shaker at 400rpm (Thermomixer compact, Eppendorf). Cells were 
collected by centrifugation at 5,500rpm for 2 minutes at room 
temperature and I ml of LB discarded. The bacterial cell pellet was 
resuspended in residual LB and spread evenly across pre-warmed 
LBI Agar plates containing appropriate antibiotics under sterile 
conditions. Plates were inverted and incubated at 37°C over night. 
2.2.2.3. Transformation of ultracompetent XL2·Blue cells 
Ultracompetent XL-2 blue cells (Stratagene) were thawed on ice before 
adding 2 ~ 1 1 ~ - m e r c a p t o e t h a n o l l to each aliquot of cells ( 1 0 0 ~ 1 ) ) and 
incubating on ice for 10 minutes. Plasmid DNA or ligation reactions 
were gently added to 5 0 ~ 1 1 of ultracompetent cells and allowed to 
incubate on ice for a further 30 minutes. After incubation, cells were 
heat shocked in a 42°C waterbath for 30 seconds before immediately 
returning to ice for 2 minutes. Cells were allowed to recover by the 
addition of 9 0 0 ~ 1 1 of preheated NZY + broth (GIBCO) and incubated at 
37°C with gentle shaking (225-250rpm) for 1 hour. Bacterial cells were 
collected by centrifugation at 8,000rpm for 3 minutes at room 
temperature and 9 0 0 ~ 1 1 of NZY+ broth discarded. The bacterial cell 
pellet was resuspended in residual NZY + broth and spread evenly over 
pre-warmed LB/agar plates containing appropriate antibiotics under 
sterile conditions and incubated at 37°C over night. 
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2.2.2.4. Transformation of Max efficiency@ DH10Bac™ 
chemically competent cells 
An aliquot (100111) of Max efficiency® DHlOBac™ chemically 
competent cells (Invitrogen) was thawed on ice before the addition of 
lng of pFastBac plasmid DNA and allowed to incubate on ice for 30 
minutes. After incubation, cells were heat shocked in a 42°C waterbath 
for 45 seconds before immediately being returned to ice for 2 minutes. 
Cells were allowed to recover by the addition of 900111 of s.o.c 
medium (2% tryptone, 0.5% yeast extract, 10 mM sodium chloride, 2.5 
mM potassium chloride, 10 mM magnesium chloride, 10 mM 
magnesium sulfate and 20 mM glucose) (Invitrogen) and incubated at 
37°C with gentle shaking (225rpm) for 4 hours. The bacterial 
suspension was diluted lO-fold in pre-warmed S.O.C medium and 
100111 spread evenly over pre-warmed LB/agar plates supplemented 
with appropriate antibiotics (50Ill/ml kanamycin, 71lg/ml gentamicin 
and lOllg/ml tetracycline, lOOl1g/ml X-gal and 40llg IPTG) under 
sterile conditions and incubated at 37°C for 48 hours. 
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2.2.3. Gel Electrophoresis 
2.2.3.1. Agarose gel electrophoresis 
DNA agarose electrophoresis 
DNA was separated by electrophoresis in 0.8-3% (w/v) agarose (Biorad 
Laboratories) depending on DNA fragment size. Agarose was 
suspended in lxTAE (40mM Tris-acetate pH8.0, ImM EDTA) and 
solubilised by heating in a microwave oven. The agarose mixture was 
cooled to approximately 60°C and then poured into a casting tray. Once 
the agarose had set, the electrophoresis tank (Biorad Laboratories) was 
filled with cold lxT AE until the gel was completely immersed. DNA 
mixed with lxDNA loading dye (0.25% (w/v) bromophenol blue, 
0.25% (w/v) xylene cyanol FF, and 15% (v/v) ficoll) was then loaded 
into the wells. Gels were run at 70-90V for 40-60 minutes (dependent 
on DNA fragment size and gel percentage). DNA was visualised by 
staining the agarose gel in ethidium bromide (0.5Ilg/ml in lxTAE) for 
20 minutes. The gel was briefly washed with water to remove excess 
ethidium bromide before the stained DNA was visualised using a UV 
gel documentation system (Syngene). 
Extraction of DNA from agarose gels 
The desired DNA band was excised from the agarose gel with a scalpel. 
DNA was extracted from the agarose gel slice using the Jetsorb gel 
extraction kit (Genomed) according to the manufacturer's protocol. The 
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gel slice was melted in A I buffer (1 OOfll per 100mg gel slice) 
containing IOfll of Jetsorb resin at 50°C for 15 minutes with brief 
mixing every 3 minutes. Jetsorb resin was collected by centrifugation at 
14,000rpm for 1 minute at room temperature and the supernatant 
discarded. The Jetsorb resin was subsequently washed twice with 300fll 
of A2 buffer. The A2 buffer was removed and the Jetsorb resin dried by 
incubating at 50°C for 10 minutes with the eppendorf tube lid left open. 
DNA was eluted from the Jetsorb resin by incubation in 20fll of TE 
buffer (lOmM Tris/HCI, ImM EDTA, pH8.0) and incubated at 50°C 
for 5 minutes. The DNA eluate was cleared by centrifugation at 
14,000rpm for 1 minute. 
2.2.3.2. Polyacrylamide gels 
Non-denaturing polyacrylamide gel electrophoresis 
DNNprotein complexes were resolved on non-denaturing 5% 
polyacrylamide gels (9.4ml 40% acrylamide:bis-acrylamide 37.5: 1 
ratio) (Sigma Aldrich), 7.5ml 5xTBE (445mM Tris, 445mM boric acid, 
IOmM EDTA), 1.8ml (2.4% v/v) glycerol, 65fll TEMED, 700fll 
ammonium persulphate (10% w/v) made to 75ml with water). The gels 
were pre-electrophoresed in 0.5xTBE at 18rnA for 30 minutes. After 
loading DNNprotein complexes into the wells, gels were 
electrophoresed at 18-20rnA until the lower dye band had migrated % 
the total length of the gel, taking approximately 4-5 hours. Gels were 
fixed in 10% glacial acetic acid, 40% methanol for 2 minutes before 
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being placed on filter paper and dried at 85°C for 60 minutes using a 
vacuum gel drier. 
50S polyacrylamide gel electrophoresis 
Proteins were separated according to size using SDS polyacrylamide 
gel electrophoresis (SDS-PAGE) using the Biorad mini protean II 
system. 
Resolving gels (7.5-10% acrylamide (29: 1 acrylamide:bis-acrylamide), 
500mM Tris-HCI pH6.8, O.4%SDS, 0.25% TEMED, 0.038% APS) 
were poured first and 1 ml of water saturated iso-butanol was layered on 
top during gel polymerization to ensure the top edge of the gel was 
level. A stacking gel (4% acrylamide (29:1 acrylamide:bis-acrylamide), 
1.5mM Tris-HCI pH 8.8, O.4%SDS, 0.2% TEMED, 0.025% APS) was 
poured onto the set resolving gel to allow concentration of proteins 
before entering the resolving gel. 
SDS loading buffer (50mM Tris-HCI pH 8.0. 2% SDS, 10% glycerol, 
I44mM 2-mercaptoethanol, 0.05% bromophenol blue, 2mM EDTA) 
was added to protein samples before heating to 100°C for 5 minutes. 
After brief centrifugation, samples were loaded into the gel and 
subjected to electrophoresis (80-I60V) using the Biorad mini protean II 
system in IX SDS running buffer (25mM Tris-HCI, I92mM glycine, 
1% SDS) until the dye front reached the end of the gel. 
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2.2.4. Protein Techniques 
2.2.4.1 Protein Extraction 
Production of whole cell protein extracts 
Medium was removed and adherent cells were detached from plates in 
1ml of cold phosphate-buffered saline (PBS) with a rubber cell scraper. 
Cells were collected by centrifugation at 14,000rpm for I minute at 
4°C. Supernatants were discarded and cell pellets resuspended in 1ml 
cold PBS. Cells were collected by centrifugation at 14,000rpm for I 
minute at 4°C. Cells were lysed in 100-200/l1 of RIPA buffer (I50mM 
NaCI, 50mM Tris-HCI pH8.0, 0.1 % SDS, 0.1 % NP-40, ImM DTT and 
complete protease inhibitor cocktail tablets (Roche)). Lysates were 
sonicated with two 5-second pulses (Jencons Vibracell, amplitude 50), 
before incubation on ice for 30 minutes. Cellular debris was removed 
by centrifugation at 14,000rpm for I minute at 4°C and the cleared 
whole cell lysates were transferred to fresh l.5ml eppendorf tubes, snap 
frozen in liquid N2 and stored at -80°C. 
Production of nuclear protein extracts 
Medium was removed and adherent cells were washed once with 1ml 
cold PBS+V+F (IX PBS, ImM Na3V04, 5mM NaF) and once with 1ml 
of hypotonic buffer (20mM HEPES pH 7.9, 20mM NaF, 1mM 
Na3V04, 1mM N ~ P 2 0 7 , , 1mM EDTA, 1mM DTT, complete protease 
inhibitor cocktail tablets (Roche)). Cells were lysed by the addition of 
0.5ml cold hypotonic buffer + 0.1 % NP-40. Nuclei were collected by 
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centrifugation at 14,000rpm for 30 seconds at 4°C. Supernatants were 
transferred to fresh eppendorf tubes, supplemented with NaCI to 
120mM and 10% (v/v) glycerol to generate the cytoplasmic fractions. 
Nuclear pellets were resuspended in 100JlI of high salt buffer 
(Hypotonic buffer supplemented with 420mM NaCl, 0.2% (v/v) NP-40, 
20% (v/v) glycerol, ImM DTT, complete protease inhibitor cocktail 
tablets (Roche». The nuclei were lysed by incubation at 4°C for 60 
minutes with gentle rocking. Nuclear lysates were cleared by 
centrifugation at 14,000rpm for 20 minutes at 4°C, cleared nuclear 
extracts were transferred to fresh Eppendorf tubes, snap frozen in liquid 
N2 and stored at -80°C. 
Production of mitochondrial protein extracts 
Medium was removed and adherent cells were detached from plates in 
Iml of cold IX PBS using a rubber scraper. Cells were collected by 
centrifugation at 300g for 3 minutes at 4°C, supernatants were 
discarded and the cell pellets washed in Iml of cold IX PBS. Cells 
were collected by centrifugation at 300g for 3 minutes at 4°C. Cell 
pellets were resuspended in 0.5ml of extraction buffer (10mM HEPES 
pH 7.5, 200mM mannitol, ImM EGTA, 700M sucrose, protease 
inhibitor cocktail tablets (Roche), Phos-Stop phosphatase inhibitor 
cocktail tablets (Roche) before lysing with 20 gentle strokes using a 
2ml teflon/glass homogeniser. Nuclei were collected by centrifugation 
at 1,000g for 5 minutes at 4°C and supernatants transferred to fresh 
1.5ml Eppendorf tubes (labeled mitochondrial fraction). Nuclei were 
washed in 200JlI extraction buffer followed by centrifugation at I,OOOg 
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for 10 minutes at 4°C and supernatants pooled together (mitochondrial 
fraction). Mitochondria were collected from pooled cytoplasmic 
supernatants by centrifugation at 1O,000g for 15 minutes at 4°C. 
Supernatants were transferred to fresh l.5ml Eppendorf tubes (labeled 
cytoplasmic fraction). The brownish mitochondrial pellets were washed 
with 200/l1 of extraction buffer before being subjected to centrifugation 
at 10,000g for 10 minutes at 4°C. The supernatants were again pooled 
together with the cytoplasmic extracts and the nuclear and 
mitochondrial pellets were resuspended in 200/l1 and 100/l1 of 
extraction buffer respectively. All samples were snap frozen in liquid 
N2 and stored at -80°C. 
2.2.4.2. Immunoprecipitation of proteins 
This procedure was utilised to concentrate ST A T3 from protein 
extracts. Approximately 90% of the protein extract was made up to a 
final volume of 500/l1 using an appropriate buffer (RIP A and extraction 
buffer for whole cell and mitochondrial extracts respectively) before the 
addition of 2/lg flag antibody (Sigma) and incubated on a wheel (Stuart 
Scientific) at 4°C over night. In parallel 25/l1 of protein-G-sepharose ™ 
bead slurry (GE Healthcare) was added to Iml of cold lXPBS and 
centrifuged at 4000g for 2 minutes at room temperature. This step was 
repeated before pre-blocking the beads in Iml of 1% BSA (Sigma) in 
PBS on a wheel at 4°C over night. The next day, beads were collected 
by centrifugation at 4000g for 2 minutes at room temperature and 
washed in the appropriate buffer (RIPA or extraction buffer). The 
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centrifugation step was repeated before resuspending the beads in the 
protein extract (+ flag antibody) and incubating on the wheel at 4°C for 
a further 2 hours. Beads were collected by centrifugation at 4000g at 
room temperature for 2 minutes. The beads were subsequently washed 
3 times in an appropriate buffer (same buffer as protein extract) before 
the addition of 30111 lxSDS loading buffer. Samples were boiled for 5 
minutes before centrifugation at 13,000g for 1 minute at room 
temperature. Supernatants were loaded onto polyacrylamide gels 
(Section 3.3.2.2.) and immunoprecipitated STAT3 detected by western 
blot analysis (Section 3.4.4.). 
2.2.4.3. Protein quantification 
Nanodrop spectrophotometer 
To ensure equal loading of proteins between lanes on a polyacrylamide 
gel the Nanodrop OD280 program was used to determine relative 
protein concentrations. Protein concentrations were measured in 
duplicate and mean value calculated. 
Bradford protein assay 
Protein concentration was also determined using the Biorad protein 
assay kit. The assay was performed according to the manufacturer's 
protocol and a standard curve prepared using BSA. Samples under 
investigation were diluted 1 :500 and 1: 1000; however these dilutions 
were adjusted accordingly if the protein concentrations were outside the 
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range of the standard curve. Diluted sample or BSA standard (800111) 
was added to a 1 ml path length spectrophotometer cuvette, followed by 
200111 of diluted dye reagent. The solutions were mixed by inversion 
and incubated at room temperature for 10 minutes before reading the 
optical density at 595nm using a spectrophotometer (Pharmacia 
Biotech). Standards and samples were analysed in duplicate and mean 
values calculated. 
2.2.4.4. Western Blot analysis 
Transfer of protein to polyvinylidene fluoride 
membrane 
Proteins resolved by SDS-PAGE (Section 3.3.2.2.) were transferred to a 
polyvinylidene fluoride (PVDF) 0.211M membrane (Schleicher and 
Schuell) using a semi-dry transfer system (Biorad). Prior to transfer the 
membrane was immersed in methanol for 10 seconds before 
equilibrating in transfer buffer (24mM Tris, 192mM glycine, 20% (v/v) 
methanol). Filter paper and the polyacrylamide gel were soaked in 
transfer buffer for 5 minutes. Three layers of wet filter paper were laid 
on the bottom of the transfer apparatus followed by the PVDF 
membrane, polyacrylamide gel and finally three more wet filter papers. 
Proteins were transferred to the PVDF membrane at 12V, 100mA per 
gel for 1 hour 45 minutes. 
86 
Immuno-detection of desired protein 
After transfer, PVDF membranes were blocked for 1 hour at room 
temperature in 5% milk in lxTBST (50mM Tris, 150mM NaCI, 0.05% 
(v/v) tween) with gentle shaking. Primary antibodies (section 2.1.1, 
table I) were added at dilutions indicated by manufacturers protocol 
and incubated at 4°C over night on the roller. Membranes were washed 
3 times in 1 xTBST for 10 minutes. HRPO-coupled secondary 
antibodies were applied at a dilution between 1: 10,000 and 1 :5,000 in 
5% milk in lxTBST and incubated at room temperature for 1 hour. 
Membranes were then washed a further 3 times in lxTBST before ECL 
reagent (Millipore) was added and an image captured using a LAS-
3000 mini chemiluminescence camera (Fuji-film). Images were 
analysed using the AIDA v4.20 software package. 
2.2.4.5. Electrophoretic mobility shift assay 
This assay was utilised to identify DNA-bound protein complexes using 
a 32P-Iabeled oligonucleotide duplex (Fried and Crothers, 1981, Gamer 
and Revzin, 1981). 
A complex formation reaction containing 100J.lg nuclear protein and 
15J.lI 2xDNA binding buffer (26mM HEPES pH7.9, 130mM NaCI, 
2mM DTT, 0.3mM EDTA, 100ng/ml poly dUdC, 8% (v/v) glycerol) 
made up to a final volume of 30J.lI was left to incubate on ice for 20 
minutes. For supershift analysis of SIE/ST AT3 complexes, nuclear 
extracts were pre-incubated with 1 J.lI a-ST A T3 antibody in 2xbinding 
buffer supplemented with 0.05% (v/v) NP-40 at room temperature for 
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30 minutes. DNA/protein complexes were formed by the addition of 
32P-Iabeled oligonucleotide duplex (Section 3.1.5.) and incubated at 
room temperature for 15 minutes. After the addition of 2f.l1 DNA 
loading buffer (0.25% bromophenol blue, 0.25% xylene cyanol FF and 
15% ficoll) complexes were loaded onto a 5% non-denaturing 
polyacrylamide gel. Complexes were resolved by electrophoresis 
(section 3.3.2.2.). Dried gels were placed into a Fuji film 
phosphoimager cassette and exposed for between 16 hours and 14 days 
before reading the plate using an FLA-2000 phospho imager (Fuji-film). 
Images were analysed using the AIDA v4.20 software package. 
2.2.5. Eukaryotic cell techniques 
2.2.5.1. Determination of cell number 
A haemocytometer (Hawksley) was used to determine the density of 
cells in suspension using a light microscope. 
2.2.5.2. Trypan blue exclusion assay 
Cell viability was assessed using a Trypan blue exclusion assay. To a 
cell suspension, a 1: 1 ratio of 0.4% trypan blue solution (Sigma) was 
added and incubated at room temperature for 5 minutes. The density of 
stained and unstained cells was determined using a haemocytometer 
(Section 3.5.1.) and the percentage viability was determined using the 
following equation: -
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(Total Cells - Stained Cells) 
x I 00 =:: % Cell Viability 
Total Cell 
2.2.5.3. Isolation of neonatal rat cardiomyocytes 
Neonatal rat cardiomyocytes (RCMs) were obtained from 20-60 Wistar 
rat pups between 2-5 days old. The rats were culled through cervical 
dislocation and the torso sterilised with 70% ethanol. Hearts were 
extracted using sterile fine forceps and any visible connective tissue 
removed using a pair of sterile micro dissection scissors. The hearts 
were then washed three times in ice cold saline A solution (13 7mM 
NaCl, 5.4mM KCI, 4.2mM NaHC03, 5.5mM D-glucose) to remove any 
excess blood and then diced into pieces approximately' 0.5cm3• Diced 
hearts were subjected to two initial digests in 10ml of pre-warmed 0.1 % 
trypsin (0.1 % Trypsin/EDT A in saline A solution) for 10 minutes at 
37°C with gentle stirring at 60 rpm with a magnetic flea. The trypsin 
solution from the first two digests was discarded. Subsequently, 9-15 
cycles of 10 minute, 0.1 % trypsin digests were carried out with the 
trypsin solution collected each time. The trypsin solution containing 
released cells was added to 10ml of ice cold plating medium (22mM 
glucose DMEM (D5796 Sigma Aldrich), 10% foetal calf serum 
(Autogen Bioclear UK), lOOU/ml penicillin and lOOflg/ml 
streptomycin) per digest to inactivate the trypsin. The cells were 
collected from the suspension by centrifugation at 1,200rpm for 5 
minutes at room temperature and resuspended in 5ml of ice cold plating 
medium and stored on ice. After all digest steps, resuspended cells were 
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pooled together. Cells were plated onto 10cm cell culture dishes (BD 
Bioscience) and incubated at 37°C, 5% C02 for 1-1.5 hours. This step 
reduced fibroblast contamination as fibroblasts adhere to plates faster 
than cardiomyocytes. The enriched cardiomyocyte suspension was 
removed from the cell culture dishes and subjected to a trypan blue 
exclusion assay (Section 3.5.2.). Cells were replated at a density of 
lx107 viable cells per lOcm cell culture dish and incubated at 37°C, 5% 
C02. After 4-6 hours post-plating, the culture medium was replenished 
with lOml of exchanging medium (5.5mM glucose DMEM, 10% foetal 
calf serum, 100U/ml penicillin and 100J.lg/ml streptomycin) and 
returned to a humidified 5% CO2 incubator at 37°C (Shelton, 2009). 
2.2.5.4. Maintenance of eukaryotic cells 
Maintenance of isolated rat cardiomyocytes 
Isolated RCMs (Section 3.5.3) began to beat 24 hours after initial 
plating. Cells were analysed within 3 days of isolation to ensure limited 
fibroblast contamination. 
Maintenance of HEK293 cells 
The human embryonic kidney cell line (HEK293) was used in this 
study to confirm whether ST A T3 expression plasmids expressed 
ST AT3 protein. HEK293 cells were cultured on lOcm Falcon tissue 
culture dishes (BD Biosciences) using Full DMEM culture medium 
(5.5mM glucose, DMEM (Sigma D6046), 10% foetal calf serum, 
100U/ml penicillin and 100J.lg/ml streptomycin). Cells were cultured at 
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37°C in a humidified 7.5% C02 incubator. Cells were passaged 
between 1:8 and I: 10 every 3-4 days. 
Maintenance of H9c2 cells 
H9c2 is a cell line derived from rat ventricular tissue and was obtained 
from American Type Culture Collection (ATCC number: CRL 1446). 
Cells were cultured in 75cm2 easy flask (Nunc) in maintenance medium 
(22mM glucose DMEM, 10% foetal calf serum, 100U/mi penicillin and 
100Jlg/mi streptomycin) at 37°C in a humidified 5% C02 incubator. 
Cells were passaged between 1:3 and 1:5 every 2-3 days. 
Maintance of P19CL6 cells 
PI9Cl6 is a subclone (Clone 6) of the PI9 cell line that was initially 
derived from mouse embryonic carcinoma cells. The cells were 
obtained from Dr Alison Brewer, Kings College London. 
Cells were cultured on 10cm falcon tissue culture dishes (BD 
Biosciences) in full a-MEM medium (Alpha MEM (12-169F) (Lonza), 
10% foetal calf serum (Lonza), 2mM L-glutamine, 100U/mi penicillin 
and 100Jlg/ml streptomycin) at 37°C in a humidified 5% C02 incubator 
(Revco). Cells were passaged I: 15 every two days. 
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Maintance of sf9 cells 
Spodoptera frugiperda (sf9) cells are insect cells that grow in 
suspension and are used for recombinant protein expreSSIon usmg 
insect-specific viruses called baculoviruses. 
Sf9 cells were cultured at a density of 1-2x106 cells/ml in serum free 
medium (Insect-xpress medium (Lonza), 100U/ml penicillin, 10% 
pluronic F-68 (Sigma) and 10% partricin (Biochrom AG) in 50ml 
round bottom shaker flask and incubated at 27°C, 120rpm 
(Kuhnershaker). Cells were passaged every 2-3 days. 
2.2.5.5. Cell recovery from liquid nitrogen stock 
For consistency between experiments a fresh vial of cells under 
investigation (from the same master batch) were thawed for each 
experiment. This ensured each experiment used cells with a similar 
passage number and reduced the possibility of the cells changing over 
time. 
Recovery of H9c2 cells 
A cell vial was removed from liquid N2 tank and immediately thawed 
in a water bath at 37°C. Cells were diluted into 10ml of pre-warmed 
full (22mM glucose) DMEM medium to remove dimethyl sulfoxide 
(DMSO) and collected by centrifugation at 1,OOOrpm for 5 minutes at 
room temperature. The supernatant was discarded and the cell pellet 
resuspended in 1ml of pre-warmed full DMEM medium before adding 
to a pre-incubated tissue culture dish containing lOml full (22mM 
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glucose) DMEM medium. Cells were left to recover overnight at 37°C 
in a humidified 5% CO2 incubator before replenishing with 10ml of 
fresh full (22mM glucose) DMEM medium. 
Recovery of P19CL6 cells 
A cell vial was removed from liquid N2 tank and immediately thawed 
in a water bath at 37°C. Cells were diluted into 10ml of pre-warmed 
full a-MEM medium to remove DMSO and collected by centrifugation 
at I,OOOrpm for 5 minutes at room temperature. As P 19CL6 cells 
differentiate in the presence of DMSO it was important to ensure that 
all residual DMSO was removed, therefore the cells were resuspended 
in a further lOml pre-warmed a-MEM medium and the centrifugation 
step repeated. The supernatant was discarded and the cell pellet 
resuspended in 4ml of pre-warmed a-MEM media before adding to a 
pre-incubated tissue culture dish containing 16ml full a-MEM. Cells 
were left to recover overnight at 37°C in a humidified 5% CO2 
incubator before replenishing with IOml of fresh full a-MEM media. 
2.2.5.6. Cardiac differentiation of eukaryotic cells 
Throughout this study a number of cell lines required differentiation 
towards a cardiac phenotype. The differentiation procedure varied 
between cell lines, but involved regulation of growth and differentiation 
signals by varying the foetal calf serum level and culturing cells in the 
presence of compounds such as DMSO. 
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Cardiac differentiation of H9c2 cells 
When cultured in low-serum containing medium, H9c2 cells exit the 
cell cycle and differentiate into myocytes (Kimes and Brandt, 1976). 
The cell density was adjusted to 5xl05 cells per lOcm plate in full 
(22mM glucose) DMEM medium and cultured overnight at 37°C in a 
humidified 5% CO2 incubator. The following day the medium was 
exchanged for low glucose starvation DMEM medium (DMEM 5.5mM 
glucose, 100U/ml penicillin and 1001lg/ml streptomycin) and cultured 
for 24 hours at 37°C in a humidified 5% CO2 incubator. The cells were 
allowed to recover for 5 days in full low glucose DMEM media 
(DMEM 5.5mM glucose, 10% foetal calf serum, 100U/ml penicillin 
and 1001lg/ml streptomycin). As H9c2 cells fail to beat, cardiac 
differentiation was characterized by an increase in the expression of 
cardiac markers Nkx2.5 and Gata-4 (Shelton, 2009). 
Cardiac differentiation of P19CL6 cells 
P 19CL6 cells have been partially differentiated towards a cardiac 
phenotype. This was achieved by culturing the P 19 cell line in the 
presence of InM retinoic acid for 6 months and selecting a single clone 
(clone 6). The resulting P 19CL6 cell line shows a greatly enhanced 
ability to form beating cardiomyocytes when cultured in the presence of 
DMSO (Habara-Ohkubo, 1996). 
The cell density was adjusted to 1.75x105 cells per 6cm plate (Corning). 
Cells were cultured in differentiation medium (a-MEM, 10 % foetal 
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calf serum, 2mM L-glutamine, 100U/ml penicillin and IOOllg/ml 
streptomycin supplemented with 0.5% (v/v) DMSO) for 16 days at 
37°C in a humidified 5% CO2 incubator. Differentiation medium was 
replenished every two days. 
2.2.5.7. Transfection of eukaryotic cells 
Calcium phosphate 
During this study HEK293 cells were transfected using DNA calcium 
phosphate coprecipitation (to confirm whether newly generated STAT3 
expression plasmids express ST AT3 protein). Cells were passaged 1:5 
to 1:7 depending on cell density the day before transfection. Four hours 
prior transfection, the culture medium was exchanged for fresh full 
DMEM medium. A total of IOllg of plasmid DNA was diluted to a final 
volume of 50111 in sterile water. To the DNA mixture, 500lli of ice cold 
300mM CaCh was mixed under vortex before incubation on ice for 10 
minutes. After incubation, 550111 of 2xHEPES buffered saline (HBS) 
(280mM NaCl, 50mM HEPES pH 7.1) was added dropwise to the 
DNAICaCl2 while mixing slowly using a vortex mixer. The mixture 
was incubated for a further 20 minutes on ice before adding to the cells 
dropwise. The medium was gently mixed to ensure equal distribution of 
the calcium phosphate-DNA precipitate. The cells were returned to a 
37°C humidified 7.5% CO2 incubator. 
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Lipofectamine plus 
In this study differentiated P 19CL6 cells were transfected usmg 
Lipofectamine (Invitrogen) and Plus™ reagent (Invitrogen). Day 12 
differentiated P 19CL6 cells were passaged 1 :4 the day before 
transfection. A total of 1 O ~ g g of plasmid DNA was diluted to a final 
volume of 1 2 5 ~ 1 1 in opti-MEM (GIBCO) before the addition of 1 5 ~ 1 1
plus™ reagent and the DNA mixture incubated at room temperature for 
20 minutes. During this time, 21 ~ l l lipofectamine was diluted to a final 
volume of 1 4 6 ~ 1 1 in opti-MEM. After incubation the lipofectamine was 
added to the DNA mixture dropwise and incubated for a further 30 
minutes at room temperature. During this time, medium was removed 
from the differentiated P 19CL6 cells and exchanged for 2ml of pre-
warmed opti-MEM. After 30 minutes incubation the DNA-
lipofectamine mixture was added dropwise to the medium and mixed 
gently to ensure equal distribution. The cells were returned to a 37°C 
humidified 5% C02 incubator for 4-6 hours before exchanging the 
medium to (l-MEM differentiating medium. 
Monitoring transfection efficiency 
To monitor the transfection efficiency, l ~ g g of plasmid expressing green 
fluorescence protein (GFP) was transfected to cells under the same 
condition. Transfected cells were allowed to recover overnight under 
normal growth conditions and monitored under Leica DMIRE inverted 
fluorescence microscope 16 hours post-transfection. Three areas of the 
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plate were assessed first by counting the total number of cells followed 
by counting the OFP-positive cells by turning on the green emission. 
Transfection efficiency was calculated based on the number of OFP-
positive cells among the total cell population. 
2.2.5.8. Cytokine stimulation of eukaryotic cells 
LlF treatment of eukaryotic cells 
Cells were treated with lOng/ml of LIF (Sigma) for 20 minutes or 
immediately prior to exposure to hypoxia (Section 3.5.9.1.). 
2.2.5.9. Exposure of eukaryotic cells to hypoxia and 
oxidative stress. 
Hypoxia treatment of eukaryotic cells 
Cells were exposed to hypoxia (defined by an atmospheric oxygen level 
of 1%) using a Biospherix ProOx chamber. Cells were cultured under 
hypoxia in the chamber at 37°C in a humidified incubator. After 
hypoxia treatment for the indicated times, cells were removed from the 
chamber and placed on ice prior to analysis. 
Reoxygenation treatment of eukaryotic cells 
Following exposure to hypoxia (Section 3.5.9.1.), cells were 
reoxygenated for I hour by returning to a 37°C humidified 5% C02. 
Cells were then removed from the incubator and placed on ice prior to 
analysis. 
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2.2.5.10. Annexin V staining assay 
Following exposure to hypoxia (section 3.5.9.1.) an annex in V staining 
assay was performed to determine the level of apoptosis induced. This 
assay takes advantage of the redistribution of phosphatidylserine (PS) 
in the cell membrane during apoptosis. In non-apoptotic cells, the 
majority of PS molecules are localised to the inner layer of the plasma 
membrane, however soon after inducing apoptosis PS redistributes to 
the outer layer of the plasma membrane and becomes exposed to the 
extracellular environment. Annexin V FITC has a very strong affinity 
for PS therefore apoptotic cells can be easily distinguished. 
For Annexin V binding the Annexin V-FITC apoptosis'kit (ABE 2227) 
(Autogen Bioc1ear) was used according to the manufacturer's 
instructions. Treated cells were washed in 5ml ice-cold PBS, adherent 
cells were removed from the plate with 0.25% trypsin (Sigma-Aldrich) 
and the cell density determined (Section 3.5.1.). 5x105 cells were 
collected by centrifugation at 1000g for 5 minutes at room temperature 
before being resuspended in 500J.lI of I xbinding buffer (provided by the 
kit). A volume of 5J.lI of both annexin V-FITC and propidium iodide 
(PI) solution (provided by the kit) were added to the cellular suspension 
and allowed to incubate at room temperature for 5 minutes in the dark. 
Unstained, Annexin V-FITC only and PI only stained cells were used 
as controls for background staining. The stained cells were analysed 
immediately using a Coulter Altra Flow Sorter and the data 
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subsequently analysed using WinMDI v2.9 software. Three biological 
repeats were perfonned for each experiment. 
2.2.5.11. DNA Laddering assay 
Following exposure to hypoxia (section 3.5.9.1.), cells were washed in 
5ml ice-cold PBS, adherent cells were removed from the plate with 
0.25% trypsin (Sigma-Aldrich) and the cell density was detennined. 
2x 1 06 cells were collected by centrifugation at 200g for 5 minutes at 
room temperature. Cells were resuspended in 1ml of ice cold Hank's 
Buffered Salt Solution (HBS) (Sigma) and added dropwise to lOmlof 
ice cold 70% ethanol before storing at -20°C for at least 24 hours. Fixed 
cells were collected by centrifugation at 800g for 5 minutes at 4°C. 
Cells were resuspended in 4 0 ~ 1 1 of phosphate-citrate buffer (192 parts 
O.2M Na2HP04 and 8 parts O.lM citric acid pH 7.8) and incubated at 
room temperature for 30 minutes. Lysates were cleared by 
centrifugation at 1000g for 5 minutes at room temperature and the 
supernatant transferred to a fresh eppendorf tube and concentrated in a 
vacuum concentrator (BACHOFER) for 10 minutes. Next, 3 ~ 1 1 of 
0.25% (v/v) NP-40 AND 3 ~ 1 1 of RNase A (Sigma) were added to the 
concentrated samples before incubating at 37°C for 30 minutes. After 
RNA digestion, 3 ~ 1 1 of proteinase K (lmglml) (Sigma) was added to the 
samples and allowed to incubate for a further 30 minutes at 37°C. 
Before loading the samples onto a 1.5% agarose gel, 1 2 ~ 1 1 of loading 
buffer (0.25% bromophenol blue, 30% glycerol) was added. The gel 
99 
was run at 28V for 4 hours at 4°C before ethidium bromide staining and 
DNA detection using the UV documentation system (Syngene). 
2.2.5.12. Functional mitochondrial ATP assay 
Isolation of functional mitochondria 
Medium was removed and adherent cells were detached from the plate 
in I ml of cold PBS with a rubber scraper. Cells were collected by 
centrifugation at 300g for 3 minutes at 4°C, supernatants were 
discarded and cell pellets resuspended in Iml of cold PBS. Cells were 
collected by centrifugation at 300g for 3 minutes at 4°C. Cell pellets 
were resuspended in 0.5ml of extraction buffer before lysing with 20 
gentle using a 2ml teflon/glass homogeniser. Lysates were cleared by 
centrifugation at 650g at 4°C for 3 minutes. Supernatants were 
transferred to a fresh Eppendorf tube and mitochondria collected by 
centrifugation at 15,000g at 4°C for 3 minutes. Supernatants were 
removed and the small brownish mitochondrial pellets washed in 200lli 
of extraction buffer and collected by centrifugation at 15,000g at 4°C 
for 3 minutes. Mitochondrial pellets were resuspended gently in lOOlll 
of resuspension butTer (human serum albumin (0.5mg/ml) pH 7.2, 
240mM sucrose, 15mM KH2P04, 2mM magnesmm acetate 
tetrahydrate, 0.5mM EDT A) and used immediately in the mitochondrial 
ATP production rate assay (Section 3.5.12.2). 
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Mitochondrial AlP production rate (MAPR) analysis 
This procedure allows the analysis of mitochondrial ability to utilise 
different substrates for the production of ATP. 
Having isolated mitochondria from treated cells the following 1 cm 
cuvette compositions were made up. To each cuvette; 800111 ATP 
monitoring reagent (BioTherma) (Lyophilized ATP monitoring reagent 
(containing firefly luciferase, D-Iuciferine 0.1 giL, L-Iuciferine 4mg/L, 
bovine serum albumin 1 giL, and 111M Na2P207) dissolved in reagent 
buffer (0.19M sucrose, 19mM KH2P04, 2.SmM magnesium acetate 
tetrahydrate, 0.7mM EDT A, pH 7), 140111 of chosen substrate (16.4mM 
glutamate/ lSmM succinate, SIlM palmitoyl-L-carnitine/l.SmM malate, 
SOmM pyruvate/ 22mM malate, 2.SmM succinate and 32.7SmM 
glutamate/ 22mM malate.) and SOIlI of SOmM ADP. The mitochondrial 
suspension (Section 3.S.12.1.) was diluted 300x in resuspension buffer 
before adding 10111 of this to each cuvette. The cuvettes were read 
immediately using the BioOrbit luminometer. After a 10 minute 
monitoring period 10111 SOIlM A TP was added to each cuvette as an 
internal calibrator. All samples were measured in duplicate (technical 
repeats) and normalised to total mitochondrial protein concentration 
(Section 3.4.3.2.). Three biological repeats were performed for each 
experiment. 
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2.2.6. Viral techniques 
2.2.6.1. Production of recombinant baculovirus 
Transfection of 8f9 cells 
In this study sf9 cells were transfected using lipofectamine and Plus™ 
reagent in order to generate baculovirus containing the gene of interest. 
Sf9 cells were plated at a cell density of 9x 105 cells per 35mm well (of 
a 6-well plate) and allowed to adhere for at least 1 hour. A total of 
1.5flg ofbacmid DNA (prepared as in section 3.1.1.3.) was diluted to a 
final volume of 90fll in serum free medium (SFM) (Insect-xpress, no 
antibiotics) before the addition of lOfll of Plus™ reagent. The DNA 
mixture was incubated at room temperature for 30 minutes. During this 
time, 5fll of lipofectamine was diluted to a final volume of 100fli in 
SFM (no antibiotics). After incubation, the two mixtures were 
combined and allowed to incubate for a further 30 minutes at room 
temperature. During this time, medium was removed from the sf9 cells 
and exchanged with 800fll of SFM (no antibiotics). After the 30 minute 
incubation the DNA-lipofectamine mixture was added dropwise to the 
cells and mixed gently to ensure equal distribution. Cells were 
incubated at 27°C for 4-6 hours before exchanging the medium for 
SFM supplemented with antibiotics (IOOU/mi penicillin, 10% pluronic 
F-68 and 10% partricin). 
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Isolation of P1 viral stock 
Once transfected s9f cells (Section 3.6.1.1) demonstrated signs of 
infection (e.g. 72 hours post infection) the medium containing 
baculovirus was cleared by centrifugation at 500xg for 5 minutes at 
room temperature. To concentrate the viral stock, the supernatant was 
filtered through a 0.2I1M, low protein binding filter followed by the 
addition of 2% foetal calf serum to act as substrates for proteases. The 
viral PI stock was protected from light and stored at 4°C. 
Amplification of viral stock 
To amplify the PI viral stock sf9 cells were infected at a multiplicity of 
infection (MOl) of 0.1 with the assumption that the PI viral stock had a 
titer of 5x I 06 pfu/ml. To calculate the inoculum required, the equation 
below was utilised. 
Inoculum required (ml) = MOl (pfuiceU) X number of cells 
Titer of viral stock (pfu/ml) 
On the day of infection 2x I 06 cells were cultured in 10mi of SFM in a 
50ml round bottom shaker flask and incubated at room temperature, 
120rpm for 1 hour. After incubation, O.4ml of PI viral stock was added 
to the cells and allowed to incubate at 120rpm for 48 hours in a 27°C 
humidified incubator. Post-infection (48 hours) medium was removed 
from the cells and cleared by centrifugation at 500xg at room 
temperature for 5 minutes. The supernatant was filtered through a 
0.2JlM, low protein binding filter followed by the addition of 2% foetal 
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bovine serum. The viral stock was protected from light and stored at 
4°C. 
Expression and extraction of recombinant protein 
Sf9 cells were seeded at the cell density of 4xlO5cells/ml and incubated 
at 120rpm in a 27°C humidified incubator until they reached mid-
logarithmic phase of growth at a density of ~ 2 x 1 0 6 6 cells/ml. At this 
time 10% (total final volume) of amplified viral stock was added to the 
cells and incubated at 120rpm in a 27°C humidified incubator. Sf9 cells 
were infected with baculovirus for 72 hours and collected by 
centrifugation at 4,000rpm for 15 minutes at 4°C. Cell pellets were 
resuspended in (lOml per gram of pellet) extraction buffer (IOmM 
HEPES, 150mM NaCl. 0.5% (v/v) Triton x-IOO, 10% (v/v) glycerol, 
ImM Na3V04, complete protease inhibitor cocktail tablets (Roche)) 
and lysed using a dounce homogeniser, 5 gentle strokes. Lysates were 
cleared by centrifugation at 14,000prm for 45 minutes at 4°C. To 
precipitate DNA, 0.1 % (v/v) polyethylenimine (Sigma Aldrich) was 
added to the supernatant before centrifugation at 14,000rpm at 4°C for 
30 minutes. Proteins were precipitated by the addition of 50% (v/v) 
saturated ammonium sulphate (Sigma) drop-wise before incubating 
overnight at 4°C on the roller. The next day the protein precipitate was 
collected by centrifugation at 4,000rpm for 30 minutes at 4°C. The 
protein pellet was then resuspended in 10mi of buffer W (I OOmM Tris-
HCI, 150mM NaCl, ImM EDTA pH 8.0) ready for purification using 
the Strep-Tactin® purification system (Section 3.6.1.5). 
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Purification of recombinant protein using a Strep-
Tactin® column 
Three column bed volumes (CV) of a SO% suspension of Strep-Tactin 
sepharose (IBA BIOTAGnology) were added gently to a column 
(Brand) before equilibrating with 2CV of buffer W under gravity flow. 
Protein extracts (Section 3.6.1.4.) were loaded onto the column and the 
flow-through collected for SDS-PAGE analysis. The column was 
subsequently washed S times with 1 CV of buffer Wand the first wash 
step collected for SDS-PAGE analysis. The recombinant protein was 
eluted from the column using 6 times O.SCV of buffer E (lOOmM Tris-
HC1, ISOmM NaCI, I mM EDT A, 2.SmM desthiobiotin pH 8.0). A 20111 
sample was taken from each fraction for SDS-PAGE analysis (Section 
3.3.2.2) and the rest of the sample aliquoted, snap frozen in liquid N2 
and stored at -80°C. For regeneration, the column was washed with 
three times SCV of buffer R (lOOmM Tris-HC1, ISOmM NaCl, ImM 
EDTA, ImM hydroxy-azophenyl-benzoic acid (HABA), pH 8.0) in 
which a colour change from yellow to red is observed. The column was 
stored at 4°C overlaid with 2ml of buffer R. 
2.2.7. Data presentation and statistics 
Data are expressed as means with error bars representing standard error 
of the mean. The Student t-test was employed to evaluate if differences 
between two data points were statistically significant. Generally p-
values smaller than O.OS were considered significant. The t-test was 
performed using Prism 4 for Macintosh version 4.0. 
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Chapter 3. Results 
3.1. 8T AT3 regulation in an ischaemic heart 
disease model. 
This study set out to develop a model system relevant to ischaemic 
heart disease whereby the regulation of ST A T3 in response to 
hypoxiaireoxygenation could be studied. The model system employed 
cardiomyocytes (primary and cell lines) exposed to hypoxia (1 % 02) 
with or without reoxygenation for Ih to mimic the conditions 
experienced by cardiomyocytes in hypoxia heart (Jiang et aI., 1996). 
4.1.1 STAT3 activity remains constant during with 
long exposures to hypoxia 
To establish the overall picture of the effects of hypoxia on ST AT3 
activity on cardiomyocytes, isolated primary rat cardiomyocytes 
(RCMs) were subjected to hypoxia (1 % O2, 5% CO2) over increasing 
time periods in a Biospherix ProOx chamber. Reoxygenation following 
hypoxia has been shown to increase levels of cardiomyocyte apoptosis 
over hypoxia treatment alone (Yang et aI., 1999a), therefore cells were 
harvested immediately or returned to aerobic conditions for 1 hour 
(reoxygenation) prior to harvest. To determine the phosphorylation 
status of STA T3 during hypoxiaireoxygenation, nuclear extracts were 
analysed by western blotting using phospho-specific antibodies. 
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Figure 3.1. (a) Tyrosine phosphorylation status of STAT3 in isolated 
RCMs cells following hypoxia/reoxygenation. RCMs were exposed to 
normoxia (N) or hypoxia for indicated times (+) or (-) reoxygenation for 1 hour 
and nuclear extracts prepared. 50IJg of protein for each sample was resolved 
by denaturing polyacrylamide gel electrophoresis. The resolved proteins were 
transferred to a PVDF membrane and subjected to western blotting with the 
antibodies indicated. (b) Tyrosine phosphorylation status of STAT3 in 
RCM cells following hypoxia/reoxygenation. Densitometry was performed 
using AIDA and expressed as a ratio of pSTAT3 (Y705) against total STAT3. 
n=3. 
STAT3 protein levels were stable under hypoxiaireoxygenation (figure 
3.1 a, middle panel), however ST AT3 tyrosine phosphorylation levels 
decreased approximately 4 fold after 1 hour of hypoxia (figure 3 .1 b) 
but recovered by 8h and remained stable thereafter (figure 3.1 a, top 
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panel). TAT A-Binding Protein (TBP) was used as a nuclear loading 
control (figure 3.1a, lower panel). 
The DNA binding activity of ST A T3 in nuclear extracts prepared from 
hypoxia/reoxygenated treated ReM cells was demonstrated by EMSA 
using the vSis-inducible element (SIE) (Wagner et aI. , 1990) . 
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Figure 3.2. In vitro DNA binding of endogenous STAT3 from isolated 
ReM cells exposed to hypoxia/reoxygenation. Nuclear extracts prepared 
from ReM celis exposed to normoxia (N) or hypoxia for indicated times (+) or 
(-) reoxygenation for 1 hour and subjected to EMSA on the M67 SIE probe. 
Black arrow indicates ST A T3 homodimerlDNA complex. White Arrow 
indicates free probe. * Indicates unidentified complex n=1. 
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STAT3 binding to the SIE also decreased temporarily after Ih hypoxia 
(figure 3.2, lane 2) showing a correlation between STAT3 tyrosine 
phosphorylation (figure 3.1a) and its DNA activity. Reoxygenation 
following hypoxia had little effect of STAT3 tyrosine phosphorylation 
and ultimately DNA binding in RCM cells. 
4.1.2 Isolated neonatal rat cardiomyocytes are 
resistant to hypoxia-induced apoptosis. 
Determination of apoptosis levels was necessary in order to investigate 
cardiomyocyte survival during hypoxia. There are characteristic 
morphological changes observed during apoptosis, including cellular 
shrinkage, blebbing, DNA fragmentation, and condensation of nuclear 
chromatin. Gross cell morphology of RCM cells remained unchanged 
with hypoxia (figure 3.3.) indicating a level of resistance to hypoxia, 
consistent with work by Lu and colleagues (Lu et aI. , 2008). 
Normoxia 
Figure 3.3. Phase images of isolated RCMs exposed to hypoxia. Phase 
images of RCMs exposed to hypoxia for times indicated. 
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Apoptosis involves the activation of executioner caspases, including 
caspase-3. Cleavage of the caspase-3 substrate Poly-ADP Ribose 
Polymerase (P ARP) was assessed by western blot analysis to give an 
indication of apoptosis induced by hypoxia. 
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Figure 3.4. Caspase- cleavage of poly ADP-Ribose polymerase (PARP) 
in isolated RCM cells exposed to hypoxia. ReM cells were exposed to 
normoxia (N) or hypoxia for indicated times and nuclear extracts prepared. 
50l-lg of protein for each sample was resolved by denaturhlg polyacrylamide 
gel electrophoresis. The resolved proteins were transferred to a PVDF 
membrane and subjected to western blotting with antibodies indicated. Black 
arrow 1 indicates full-length 116KDa PARP and the white arrow 2 indicates 
the 89KDa caspase generated fragment. n=1. 
Nuclear extracts prepared from RMCs treated with hypoxia were 
subjected to western blot analysis using an antibody capable of 
detecting full-length and cleaved fragments of PARP. There was a 
slight increase in the levels of cleaved P ARP with 1 h hypoxia when 
RCMs were treated with hypoxia (figure 3.4, lane 2) and this signal 
increased with exposure to hypoxia for 24h (figure 3.4, lane 4). 
However this experiment was only carried out once, thus needs to be 
repeated in order to obtain significant results. 
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3.2. Validation of STAT3 regulation using 
alternative cell models. 
3.2.1 Hypoxia differentially affects 51 A13 activity in 
H9c2 and P19CL6 cells 
To broaden the picture of ST AT3 regulation, cardiac cell lines H9c2 
and P19CL6 were utilised. The H9c2 cell line is derived from 
embryonic rat ventricular cells and is reported to differentiate into 
cardiomyocytes in the absence of serum (Kimes and Brandt, 1976). 
H9c2 cells were chosen for this study as they are easily cultured and 
have been used as a cardiomyocyte model previously (Hescheler et aI., 
1991, Hescheler et aI., 1999). H9c2 cells were i n c u b ~ t e d d in starvation 
medium for 24 hours before recovery in full medium for 5 days. This 5-
day recovery allowed expression of cardiac markers including Nkx2.5 
and Gata-4, indicating a cardiac phenotype (Shelton, 2009). 
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Figure 3.5. (a) Tyrosine phosphorylation status of STAT3 in H9c2 cells 
following hypox ia/reoxygenation. H9c2 cells were exposed to normoxia (N) 
or hypoxia for indicated times (+) or (-) reoxygenation for 1 hour and nuclear 
extracts prepared. 100l-lg of protein for each sample was resolved by 
denaturing polyacrylamide gel electrophoresis. The resolved proteins were 
transferred to PVDF membrane and subjected to western blotting with the 
antibodies indicated. (b) Tyrosine phosphorylation status of STAT3 in 
H9c2 cells follow ing hypoxia/reoxygenation. Densitometry was performed 
using AIDA and expressed as a ratio of pSTAT3 (Y705) against total STAT3. 
Results are means ± SEM. n=3 *P<0.05.vs normoxia. 
In H9c2 cells there is a slight but significant time-dependant decrease in 
the levels of tyrosine phosphorylated STAT3 under 
hypoxiaireoxygenation (figure 3.5a, top panel), whereas total STAT3 
levels remained unchanged (figure 3.5a, bottom panel). A maximum 
reduction (0.70±0.13 relative intensity) in tyrosine phosphorylated 
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ST AT3 was observed at 24h hypoxia, demonstrating an approximate 
reduction of 50% when compared to norrnoxia sample (figure 3 .5b). 
The DNA binding activity of STAT3 in H9c2 cells was assessed by 
EMSA. STAT3 DNA binding was observed throughout treatment with 
hypoxia/reoxygenation (figure 3.6, lanes 1-5), with a slight reduction in 
DNA binding at 24h hypoxia (figure 3.6, lane 6), displaying a positive 
correlation with STAT3 tyrosine phosphorylation in which a reduction 
was also observed (figure 3.5a). 
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Figure 3.6. In Vitro DNA binding of endogenous ST AT3 from H9c2 cells 
exposed to hypoxia/reoxygenation. Nuclear extracts prepared from H9c2 
cells exposed to normoxia (N) or hypoxia for indicated times (+) or (-) 
reoxyge..nation for 1 hour and subjected to EMSA on the M67 SIE probe. Black 
arrow indicates STAT3 homodimer/DNA complex. White Arrow indicates free 
probe. n=2. 
P 19C16 is a subc10ne of the P 19 cell line that was initially derived from 
mouse embryonic carcinoma cells. P19CL6 cells have been reported to 
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differentiate efficiently into beating cardiomyocytes in the presence of 
0.5-1 % DMSO (Habara-Ohkubo, 1996). Differentiated P 19CL6 cells 
have been reported to retain the ability to spontaneously contract and 
express cardiac transcripts, suggestive of a cardiac phenotype 
(Skerjanc, 1999, Wobus et aI., 1994). P19CL6 cells have also been 
extensively used to study cardiac cell physiology (van der Heyden and 
Defize, 2003, Anisimov et aI., 2002, Rudnicki et aI., 1990). 
114 
(a) 
1% O/h):-
ReOx: - r--N __ ----''--_----''--__ "''''--1 
1 8 24 
II II +1 + + 
1 
1 IB:a-pSTAT3 (Y705) 
'": =-; IIB:a-STAT3 
1----- ... IIB:a-TBP 
1 2 3 4 5 6 7 
(b) 
~ ~
C") 
~ ~
1ZJ 
'3 1.5 
~ ~
---
1.2 C") 
~ ~~ ~ 0.9 1ZJ 
-8 
C 0.6 
.;;; 
0 (1) 
.... 0.3 
..s 
(1) 
;> 0 . ~ ~
ell N v 
~ ~
+ + ReOx 
'-----', 
1% 02(h) 24 
+ 
8 
Figure 3.7. (a) Tyrosine phosphorylation status of STAT3 in P19CL6 cells 
following hypoxia/reoxygenation. P19CL6 cells were exposed to normoxia 
(N) or hypoxia for indicated times (+) or (-) reoxygenation for 1 hour and 
nuclear extracts prepared. 100j..lg of protein for each sample was resolved by 
denaturing polyacrylamide gel electrophoresis. The resolved proteins were 
transferred to a PVDF membrane and subjected to western blotting with 
antibodies indicated. (b) Tyrosine phosphorylation status of STAT3 in 
P19CL6 cells following hypoxia/reoxygenation. Densitometry was 
performed using AIDA and expressed as a ratio of pSTAT3 (Y705) against 
total STAT3. Results are means ± SEM, n=3 **P<O.005. 
Similar to RCMs and H9c2 cells, STAT3 protein levels remained 
unchanged in P 19CL6 exposed to hypoxiaireoxygenation (figure 3.7 a, 
middle panel). In contrast, reoxygenation of P19CL6 cells after 8h 
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hypoxia caused a substantial 3.5 fold reduction (figure 3.7b) in tyrosine 
phosphorylated STAT3 (figure 3.9, top panel, lane 5) and after 24 h 
hypoxia tyrosine phosphorylation was completely abolished (figure 
3.7a, lanes 6 and 7). 
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Figure 3.8. In vitro DNA binding of endogenous ST A T3 from P19CL6 
cells exposed to hypoxia/reoxygenation. Nuclear extracts prepared from 
P19CL6 cells exposed to normoxia (N) or hypoxia for indicated times (+) or (-) 
reoxygenation for 1 hour and subjected to EMSA on the M67 SIE probe. Black 
arrow indicates STAT3 homodimer/DNA complex. White Arrow indicates free 
probe. * Indicates an unidentified complex. n=2. 
STAT} was detected binding to the SIE in P 19CL6 cells under 
normoxic conditions and when exposed to Ih hypoxia (+1-
reoxygenation) (figure 3.8, lanes 1-3). Interestingly, a complete loss of 
STAT3 DNA binding was observed in P19CL6 cells after 8h hypoxia 
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(figure 3.8, lane 4) even though tyrosine phosphorylation was still 
detectable at the time point (figure 3.7a, top panel, lane 4). 
3.2.2 P19L6 but not H9c2 cells are sensitive to hypoxia-
induced apoptosis 
Apoptosis was determined in H9c2 cells with reference to P ARP 
cleavage. There was no accumulation of the cleaved fragment of P ARP 
(figure 3.9, upper panel, white arrow) indicating resistance against 
hypoxia-induced apoptosis. 
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Figure 3.9. Caspase-cleavage of poly ADP-Ribose polymerase (PARP) in 
H9c2 cells exposed to hypoxia/reoxygenation. H9c2 cells were exposed to 
normoxia (N) or hypoxia for indicated times (+) or (-) reoxygenation for 1 hour 
and nuclear extracts prepared. 100l-lg of protein for each sample was resolved 
by denaturing polyacrylamide gel electrophoresis. The resolved proteins were 
transferred to a PVDF membrane and subjected to western blotting with 
antibodies indicated . Black arrow 1 indicates full-length 116KDa PARP and 
the white arrow 2 indicates the 89KDa caspase generated fragment. n=2. 
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Apoptosis was also determined experimentally by annexin V binding 
followed by fluorescence activated cell sorting (F ACS). Levels of 
apoptosis were very low III H9c2 cells exposed to 
hypoxia/reoxygenation with approximately a 1.3-fold increase with 
reoxygenation after 24h hypoxia (figure 3.10). This indicates that H9c2 
cells are resistant to hypoxia-induced apoptosis for long periods of 
time, which is consistent with studies carried out by Bonavita and 
colleagues (Bonavita et aI., 2003). 
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Figure 3.10. Annexin V binding in H9c2 cells exposed to hypoxia. H9c2 
were exposed to normoxia (N) or hypoxia for indicated times (+) or (-) 
reoxygenation for 1 hour and then subjected to Annexin V binding assay. The 
stained cells were then sorted using a Coulter Altra Flow Cytometer, set to 
count 20000 events. Results are means ± SEM, n=3, *P < 0.05. 
Hypoxia-induced apoptosis was also determined using the P19CL6 cell line 
model. In contrast to RCMs and H9c2 cells, P 19CL6 cells were extremely 
sensitive to hypoxia-induced apoptosis. 
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Figure 3.11. Caspase- cleavage of poly ADP-Ribose polymerase (PARP) 
in P19CL6 cells exposed to hypoxia/reoxygenation. (a) P19CL6 cells were 
exposed to normoxia (N) or hypoxia for indicated times (+) or (-) 
reoxygenation for 1 hour and nuclear extracts prepared. 100IJg of protein for 
each sample was resolved by denaturing polyacrylamide gel electrophoresis. 
The resolved proteins were transferred to a PVDF membrane and subjected 
to western blotting with antibodies indicated Black arrow 1 indicates full-length 
116KDa PARP and the white arrow 2 indicates the 89KDa caspase generated 
fragment. (b) Densitometry was performed using AIDA and expressed as a 
ratio of pSTAT3 (Y705) against total STAT3. Results are means ± SEM, n=3, 
*P < 0.05, **P<0.005, ***P<0.001 . 
P19CL6 cells displayed an increase III cleaved PARP following 
exposure to hypoxia for 8 or longer (+/ - reoxygenation) (figure 3.11, 
upper panel, white arrow, lanes 4-7), Cleaved P ARP increased by 
119 
approximately 3-fold (figure 3.11b), indicative of apoptosis. Levels of 
apoptosis was also measured in P19CL6 cells however hypoxic time 
points 1,4 and 8 hours were used instead of 1,8 and 24 hours. This was 
because the P19CL6 were extremely sensitive to hypoxia for 24h, with 
'sheets' of cells detaching from the tissue culture plate. Instead the 4 
hour hypoxic time point was introduced as significant apoptosis had 
already been observed in P 19CL6 cells with 8h hypoxia (Figure 3.11). 
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Figure 3.12. Annexin V binding in P19CL6 cells exposed to hypoxia. 
P19CL6 were exposed to normoxia (N) or hypoxia for indicated times (+) or (-) 
reoxygenation for 1 hour and then subjected to Annexin V binding assay. The 
stained cells were then sorted using a Coulter Altra Flow Cytometer, set to 
count 20000 events. Results are means ± SEM, n=3, *P < 0.05, **P<0.001 
P 19CL6 cells displayed a high basal level of apoptosis with around 
40% of cells staining positive for annex in V under normoxic conditions 
(figure- 3.12) when compared to 4.5% annex in V-stained H9c2 cells 
(figure 3.10). Exposure to hypoxia for 4 and 8 hours caused a 
significant 1.5-fold and 1.75-fold lllcrease in apoptosis respectively 
(figure 3.12). 
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In addition to P ARP-cleavage and annexin V staining, hypoxia-induced 
apoptosis was also assessed in P 19CL6 cells by apoptotic marker 
expression. Whole cell extracts were subjected to western blotting with 
antibodies raised against the anti-apoptotic factor Mcl-l and the pro-
apoptotic factor Bid. 
Figure 3.13. Apoptotic marker protein levels in P19CL6 cells following 
hypoxia. P19CL6 cells exposed to normoxia (N) or hypoxia for indicated 
times (+) or (-) reoxygenation and whole cell extracts prepared. 100l-ig of total 
protein was resolved by SOS PAGE and subjected to western blot analysis 
using antibodies indicated. Black arrow indicates full length Bid (22kOa) and 
the white arrow indicates caspase-c1eaved Bid (1SkOa). n=1. 
Mcl-l protein was detected in P19CL6 cells under normOXla but 
detection was abolished with reoxygenation after Ih hypoxia and 
remained undetectable thereafter (figure 3.13, upper panel, lanes 3-7). 
Conversely, accumulation of the caspase-cleaved pro-apoptotic factor 
Bid was detected in P19CL6 cells treated with 4 and 8h 
hypoxialreoxygenation (figure 3.13, lower panel, lanes 4-7, white 
arrow). The cleavage of Bid is a process, indicative of apoptosis as this 
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cleaved product trans locates to mitochondria triggers the permeability 
transition and release of pro-apoptotic factors (Li et ai. , 1998). 
Finally hypoxia-induced apoptosis was also identified in P19CL6 cells 
using a DNA fragmentation assay. DNA fragmentation IS a 
morphological characteristic of apoptotic cells. The protocol used 
allowed partially degraded oligonucleosomal DNA to be extracted quite 
selectively from cells whereas, higher molecular weight (intact) DNA 
stayed associated with the nuclei (Gong et ai., 1994). 
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Figure 3.14. DNA fragmentation in P19CL6 cells following hypoxia. 
P19CL6 cells exposed to normoxia (N) or hypoxia for indicated times (+) or (-) 
and DNA extracts prepared. Samples were resolved on a 1.5% Agarose gel ; 
stained with ethidium bromide and DNA detected using an UV documentation 
system. n=1 
Partially degraded DNA was observed from P 19CL6 cells exposed to 
hypoxia for 4 hours or more (+I-reoxygenation) (figure 3.14, lanes 4-7), 
correlating with data collected from the annex in V binding assay and 
western blot analysis. These results show that differentiated P 19CL6 
cells exhibit a higher sensitivity to hypoxia compared to RCMs and 
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H9c2 cells. The increased sensitivity observed in P 19CL6 cells makes 
them a more responsive model to study changes induced by hypoxia. 
3.3. The role of PKC6 in cardiomyocytes during 
hypoxia. 
3.3.1 Hypoxia differentially affects STAT3 serine 
phosphorylation in H9c2 and P19CL6 cells 
In addition to tyrosine phosphorylation, STAT3 is also phosphorylated 
on a serine residue (S727) in its carboxyl-terminal domain. Studies 
regarding the function of this serine phosphorylation site are somewhat 
controversial. Initially it was thought to be i m p o r t ~ n t t for enhanced 
transcriptional activation (Wen et aI., 1995, Zhang et aI., 1995), but 
other studies have associated the serine phosphorylation of ST AT3 with 
transcriptional repression (Jain et aI., 1999, Gartsbein et aI., 2006). In 
this study the serine phosphorylated status of ST A T3 was also assessed 
in response to hypoxia/reoxygenation. In H9c2 cells, ST AT3 S727 
phosphorylation was observed under normoxia and levels decreased 
approximately 3-fold with 8 and 24h hypoxia (figure 3.l5b) and 
recovered upon reoxygenation (figure 3.l5a, upper panel, lanes 5 and 
7). 
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Figure 3.15. (a) Serine phosphorylation status of STAT3 in H9c2 cells 
following hypoxia/reoxygenation. H9C2 cells were exposed to normoxia (n) 
or hypoxia for indicated times (+) or (-) reoxygenation for 1 hour and nuclear 
extracts prepared. 100j.Jg of protein for each sample was resolved by 
denaturing polyacrylamide gel electrophoresis. The resolved proteins were 
transferred to a PVDF membrane and subjected to western blotting with 
antibodies indicated . (b) Serine phosphorylation status of STAT3 in H9c2 
cells following hypoxia/reoxygenation. Densitometry was performed using 
AIDA and expressed as a ratio of pSTAT3 (S727) against total STAT3. 
Results are means ± SEM, n=3, *P<O.05. 
In contrast, P19CL6 cells displayed lower levels of STAT3 S727 
phosphorylation under normoxic conditions, with no change after 1-
hour hypoxiaireoxygenation (figure, 3.17a, upper panel. lanes 1-3). 
However, after 8 hours hypoxia STAT3 S727 phosphorylation was 
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(a) 
significantly elevated approximately 2.5-fold (figure 3.16b) and 
decreased only marginally (2-fold) upon reoxygenation (figure 3.16a, 
lane 5). With exposure to hypoxia (+1- reoxygenation) for 24 hours in 
P19CL6 cells, STAT3 S727 phosphorylation was undetectable (figure 
3 .16a, lanes 6-7). 
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Figure 3.16. (a) Serine phosphorylation status of STAT3 in P19CL6 
cells following hypoxia/reoxygenation. P19CL6 cells were exposed to 
normoxia (N) or hypoxia for indicated times (+) or (-) reoxygenation for 1 
hour and nuclear extracts prepared. 1 O O ~ g g of protein for each sample was 
resolved by denaturing polyacrylamide gel electrophoresis. The resolved 
proteins were transferred to a PVDF membrane and subjected to western 
blotting with antibodies indicated. (b) Serine phosphorylation status of 
ST AT3 in P19CL6 cells following hypoxia/reoxygenation. Densitometry 
was performed using AIDA and expressed as a ratio of pSTAT3 (S727) 
against total STAT3. Results are means ± SEM, n=3 ***P<O.001, **P<O.005, 
*P<O.05. 
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3.3.2 PKCl) activity differs in H9c2 and P19CL6 cells during 
hypoxia 
Novel PKC isoforms have been implicated in the phosphorylation of 
STAT3 on serine 727 and in the context of PKCcS linked to ST A T3 
inhibition. For example, IL-6 inducible association of PKCcS with 
STAT3 caused an increase in the S727 phosphorylation and the down-
regulation of STAT3 DNA binding and transcriptional activity (Jain et 
aI., 1999). 
The levels of total and phospho-PKCcS were assessed in H9c2 and 
P 19CL6 cells exposed to hypoxiaireoxygenation. The phosphorylation 
of serine 643 confers an autophosphorylation site on PKCcS, which is 
required for optimal activity (Li et aI., 1997b), In H9c2 cells 
phosphorylation of PKCcS increased with hypoxia, with peak 
phosphorylation at 8h and a gradual decline observed at 16 and 24 
hours hypoxia (figure 3.17, upper panel, lane 4). The peak in PKCcS 
phosphorylation does not correlate with STAT3 S727 phosphorylation -
with reduced levels observed at 8-hour hypoxia (figure 3.15a, upper 
panel, lane 4). This indicates PKCcS may not be the dominant kinase for 
the phosphorylation of STAT3 exposed to hypoxia in these cells. 
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Figure 3.17.Levels of PKC6 in H9c2 cells exposed to hypoxia. H9c2 
cells were exposed to normoxia (N) hypoxia for indicated times and whole 
cell extracts prepared. 100l-lg of protein for each sample was resolved by 
denaturing polyacrylamide gel electrophoresis. The resolved proteins were 
transferred to a PVDF membrane and subjected to western blotting with 
antibodies indicated. n=1 . 
The peak in PKC8 autophosphorylation was observed earlier in 
Pl9CL6 cells, with maximal PCK8 phosphorylation observed at 4h 
hypoxia and then a subsequent reduction at 8h hypoxia (figure 3.18, 
upper panel lanes 3-4). 
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Figure 3.18. Levels of PKC6 in P19CL6 cells exposed to hypoxia. 
P19CL6 cells were exposed to normoxia (N) or hypoxia for indicated times 
and whole cell extracts prepared. 100l-lg of protein for each sample was 
resolved by denaturing polyacrylamide gel electrophoresis . The resolved 
proteins were transferred to a PVDF membrane and subjected to western 
blotting with antibodies indicated. n=1 
These data shows that in P 19CL6 cells, phosphorylation and activation 
of PKC8 in response to hypoxia is present before (4 hours earlier) the 
phosphorylation ofSTAT3 on serine 727 (figure 3.16a). PKC8 may still 
be the kinase that phosphorylates S727 on STAT3, however the 4h time 
difference between the activation of PKC8 (4h hypoxia) and the serine 
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(b) 
phosphorylation of STAT3 (8h hypoxia) warrants further investigation. 
It may be plausible that STAT3 is phosphorylated by PKC8 between 
the 4 and 8h time point i.e. when PKC8 is most active. Unfortunately 
the serine phosphorylation status at 4h hypoxia was not measured 
therefore further investigation is required before interpretations can be 
made. 
The overall basal levels PKC8 also varied between H9c2 and Pl9CL6 
cell lines. A titration (120f..lg-15 f..lg) of nuclear extracts from normoxic 
H9c2 and P19CL6 cells was subjected to western blot analysis. The 
level of phospho-PKC8 in H9c2 was significantly lower when 
compared to equal total protein amounts from P 19CL6 cells (figure 
3.19, upper panel). 
(a) 
Nuclear H9c2 
Extract ( ~ g ) : : 1120 151 
r::=::-----.-.. 
11...--____ -=:=.....-_---1·1 IB:a-TBP 
1234 5678 
S643 
I 
,"ouse 601 FKTINWSLLEKRKVEPPFKPKVKSPSDYSNFDPEFLNEKPQLSFSDKNLIDSMDQEAFHG 660 
~ t t 601 FKTINWNLLEKRKVEPPFKPKVKSPSDYSNFDPEFLNEKPQLSFSDKNLIDSMDQTAFKG 660 
Figure 3.19. (a) Comparison of PKCl) activity in H9c2 and P19CL6 cells. 
Normoxic nuclear extracts from H9C2 and P19CL6 cells were prepared. 
Total protein concentration was determined by Bradford assay and a 2-fold 
dilution series from 120IJ9 to 15IJg prepared. Sample were resolved by 
denaturing polyacrylamide gel electrophoresis, transferred to a PVDF 
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membrane and subjected to western blotting with antibodies indicated. (b) 
Mouse and rat PKC5 protein sequence alignment. 
However, H9c2 and P19CL6 cells are from different species (rat and 
mouse respectively). Therefore it could be possible that the antibody 
has different specificities for different species of PKC8. However this is 
unlikely due to high level of protein sequence homology between the 
two species (figure 3.19b). 
3.3.3 Rottlerin enhances apoptosis in P19CL6 cells 
In this study the data shows that in P 19CL6 cells, there is a correlation 
between the activation of PKC8 at 4h hypoxia (figure .3.18) followed by 
the serine phosphorylation of STAT3 at 8h hypoxia (figure 3.16). 
Enhancement of serine phosphorylation accompanies loss of ST A T3 
DNA binding and increased levels of apoptosis. To identify whether 
PKC8 directly affects the serine phosphorylation status of ST AT3 and 
ultimately cell survival, the PKC8 inhibitor, rottlerin was used. 
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Figure 3.20. Effect of rottlerin on P19CL6 cells exposed to hypoxia. 
P19CL6 cells were pre-treated with (+) or (-) PCKo inhibitor rottlerin (31JM) 
before exposure to hypoxia and nuclear extracts prepared . 100IJg of protein 
for each sample was resolved by denaturing polyacrylamide gel 
electrophoresis . The resolved proteins were transferred to a PVDF 
membrane and subjected to western blotting with antibodies indicated . N=2. 
P 19CL6 cells were pre-treated with rottlerin immediately before 
exposure to 8h hypoxia. Maximal PKC8 phosphorylation was observed 
with 8h hypoxia and this was completely abolished with rottlerin 
treatment (figure 3.20, upper panel, lanes 3-4). 
The increase in ST AT3 S727 phosphorylation previously observed with 
8h hypoxia (figure 3.20, lane 4) was also abolished upon treatment with 
rottlerin (figure 3.20, lanes 3-4, panel 4). However unexpectedly 
STAT3 Y705 phosphorylation was also lost with rottlerin treatment, 
even under normoxic conditions (figure 3.20, 3rd panel lanes 1-2.). 
There were also lots of accompanying changes associated with rottlerin 
treatment, including reductions in total STAT3 (figure 3.20, 5th panel) 
and PKC8 (figure 3.20 2nd panel) protein levels and even levels of the 
loading control TBP (figure 3.2 6th panel). Therefore it was very 
diffic;.ult to interpret these results. 
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P19CL6 cells pre-treated with rottlerin were also subjected to Annexin 
V staining to give an indication of the levels of apoptosis. 
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Figure 3.21 Annexin V binding in P19CL6 cells. pre-treated with 
Rottlerin before exposure to hypoxia. P19CL6 were pre-treated with (+) 
or (-) Rottlerin (3IJM) before exposure to normoxia or hypoxia for 8 hours 
and then subjected to Annexin V binding assay. The stained cells were then 
sorted using a Coulter Altra Flow Cytometer, set to count 20000 events. n=2. 
P 19CL6 cells were highly sensitive to rottlerin. There is an approximate 
1. 7 5-fold increase in the number of annexin V-stained cells treated with 
rottlerin under nonnoxic conditions (figure 3.21). Although it continues 
to be used, rottlerin has been discredited as a selective and specific 
inhibitor of PKCcS due to its potent mitochondrial uncoupling and K+ 
channel activating properties (Soltoff, 2007). 
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3.4. Elevated STAT3 activity protects P19CL6 from 
hypoxia-induced apoptosis. 
To investigate whether STAT3 activity in P19CL6 cells contributes to 
cell survival during hypoxia, apoptosis was measured after the cells 
were pre-treated with LIF - a potent activator of STAT3 in these cells 
(van Puijenbroek et al., 1999). 
3.4.1 L1F stimulates STAT3 tyrosine phosphorylation 
in P19CL6 cells 
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Figure 3.22. STAT3 tyrosine phosphorylation in P19CL6 cells upon LlF 
treatment. P19CL6 cells were treated with 10ng/ml LlF or 10ng/ml IL-6 for 
20 minutes and whole cell extracts prepared. 100l-lg of protein for each 
sample was resolved by denaturing polyacrylamide gel electrophoresis. The 
resolved proteins were transferred to a PVDF membrane and subjected to 
wester!l blotting with antibodies indicated. 
Pre-treating P 19CL6 cells with 10ng/ml of LIF for 20 minutes caused 
tyrosine phosphorylation of STAT3 (figure 3.22, upper panel, lane 3), 
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whereas another type I cytokine IL-6, had no effect (figure 3.22, upper 
panel, lane 2). 
3.4.2 LlF maintains STAT3 phosphorylation but not 
DNA binding activity in P19CL6 cells during 
hypoxia 
3.4.2 
Stimulation of STA T3 with LIF increased STAT3 tyrosine 
phosphorylation levels by approximately 2-fold in both normoxic and 
Ih hypoxia treated cell s (figure 3.23, 2nd panel and figure 3.31). 
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Figure 3.23. (a) Phosphorylation status of STAT3 in P19CL6 pre-treated 
with LIF prior to exposure to hypoxia. P19CL6 were pre-treated with (+) 
or (-) LlF (10ng/ml) before exposure to normoxia (N) or hypoxia for indicated 
times and nuclear extracts prepared. 100l-lg of protein for each sample was 
resolved by denaturing polyacrylamide gel electrophoresis. The resolved 
proteins were transferred to a PVDF membrane and subjected to western 
blotting with antibodies indicated. (b) Tyrosine phosphorylation status of 
STAT3 in P19CL6 cells pre-treated with LIF following hypoxia. 
Densitometry was performed using AIDA and expressed as a ratio of 
pSTAT3 (Y705) against total STAT3. Results are means ± SEM, n=3 
***P<0.001. 
There was also a significant level of ST AT3 tyrosine phosphorylation 
still remaining after 8h hypoxia (figure 3.23a, 2nd panel, lane 6) with 
only ~ ~1.3 fold reduction after 8h hypoxia (normoxia vs. 8h hypoxia) in 
LIF treated cells compared to ~ ~12 fold reduction after 8h hypoxia 
(normoxia vs. 8h hypoxia) in untreated cells (figure 3)3b). 
Interestingly ST A T3 serine phosphorylation was also enhanced upon 
LIF treatment, especially in normoxic and Ih hypoxic samples (figure 
3.23a, upper panel, lane 4-6). 
In P19CL6 cells pre-treated with LIF, levels of STAT3 DNA binding 
substantially increased under normoxia and after 1 h hypoxia (figure 
3.24, lanes 4-5). However, after 8h hypoxia STAT3 DNA binding was 
greatly reduced (figure 3.24, lane 6), similar STAT3 DNA binding 
observed in untreated cells at 8h hypoxia (figure 3.24, lane 3). 
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Figure 3.24. In Vitro DNA binding of endogenous STAT3 from P19CL6 
cells pre-treated with LlF prior to exposure to hypoxia. P ~ 9 C L 6 6 were pre-
treated with (+) or (-) LlF (10ng/ml) before exposure to normoxia (N) or 
hypoxia for indicated times. Nuclear extracts were prepared and subjected to 
EMSA on the M67 SIE probe using OTT concentrations indicated. Black arrow 
indicates STAT3 homodimerlDNA complex and the white Arrow indicates free 
probe. * Indicates unidentified complex. n=2. 
During hypoxia excessive levels of ROS are generated, which could 
lead to oxidative modification of proteins, including STAT3. Such 
modifications may impair STAT3 ability to bind to DNA. Studies have 
shown that STAT3 DNA binding is sensitive to peroxide treatment (Li 
et al. , 2010). The DNA binding assay was also carried out under high 
levels (SmM) of DTT (a reducing agent) in order to reverse any such 
oxidative modifications that lead to the inhibition of DNA binding. The 
addition of DTT had no effect, with loss of ST AT3 DNA binding still 
apparent with 8h hypoxia (figure 3.24, lane 12). Studies have shown 
that the addition of DTT is required for in vitro DNA binding under 
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normoxia conditions (Li et ai. , 2010). Therefore it may be feasible in 
this case, that insufficient DTT was added to allow oxidative 
modifications to be reversed as well as ensuring optimal DNA binding 
of STAT3. To further validate whether STAT3 is redox modified 
during hypoxia-induced stress, higher concentration of DTT could be 
used as well as the addition of other reducing agents. 
3.4.3 LlF offers protection against hypoxia-induced 
apoptosis 
Flow cytometry revealed that pre-treating P19CL6 cells with LIF 
offered a degree of protection against hypoxia-induced apoptosis. 
P19CL6 cells displayed approximately 65% positive staining for 
annexin V at 8h hypoxia in untreated cells which, significantly reduced 
to 55% positively stained annexin V cells when pre-treated with LIF 
(figure 3.25). 
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Figure 3.25. Annexin V binding in P19CL6 cells pre-treated with LlF 
before exposure to hypoxia. P19CL6 were pre-treated with (+) or (-) LlF 
(10ng/ml) before exposure to hypoxia for indicated times and then subjected 
to an annexin V binding assay. The stained cells were then sorted using a 
Coulter Altra Flow Cytometer, set to count 20000 events. n=3, *P < 0.05. 
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The effects of LIF on hypoxia-induced apoptosis were also assessed by 
apoptotic marker expression. Whole cell extracts were subjected to 
western blotting with antibodies raised against the anti-apoptotic factor 
Mel-l and the pro-apoptotic factor Bid. 
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Figure 3.26. Apoptotic marker protein levels in P19CL6 cells pre-treated 
with LlF prior to exposure to hypoxia. P19CL6 cells were treated with (+) 
or (-) LlF (10ng/ml) prior to exposure to normoxia (N) or hypoxia for indicated 
times and whole cell extracts prepared. 100l-lg of total protein was resolved 
by SDS PAGE and subjected to western blot analysis using antibodies 
indicated . Black arrow indicates full length Bid and the white arrow indicates 
caspase-cleaved Bid. n=1 . 
In the presence of LIF, levels of the anti-apoptotic factor Mel-! were 
enhanced (figure 3.26, upper panel, lanes 4-6) when compared to 
untreated cells (figure 3.26, upper panel, lanes 1-3). However the pro-
apoptotic factor Bid, remained constant with no significant changes in 
the levels of eleaved Bid in treated or untreated cells (figure 3.26, 
middle panel, lanes 1-6). 
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3.5. Exogenous expression of STAT3 offers protection 
against hypoxia-induced apoptosis in P19CL6 Cells 
3.5.1 Passaging differentiated P19CL6 prior to 
transfection enhances transfection efficiency 
Snyder and colleagues demonstrated that differentiated P 19CL6 cells 
could be successfully transfected with STAT3 constructs using 
lipofectamine (Snyder et aI., 2010). 
At differentiation day 12 the Pl9CL6 cells were highly confluent with 
many multilayer cluster regions, which made transfection difficult 
yielding low transfection efficiencies. The protocol used by Snyder and 
colleagues (Snyder et aI., 2010) was modified slightly to give improved 
transfection efficiencies. Modifications included passaging the cells (1-
4 dilution) the day before transfection (figure 3.27, bottom panels) and 
also using the lipofectamine enhancer, Plus™ reagent. These 
modifications greatly enhanced the transfection efficiency. 
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Figure 3.27. GFP expression in P19CL6 cells. GFP and phase images of 
P19CL6 cells transfected (Iipofectamine in the presence of Plus TM reagent) 
with a vector containing GFP and cultured for 48h. 
Preliminary experiments were carried out to ensure that the additional 
passage to P 19CL6 cells did not affect the phosphorylation status of 
STAT3 that was observed previously (figures 3.7a and 3.16a). 
Differentiated P19CL6 cells were passaged (1-4 dilution) and the next 
day exposed to hypoxia for varying time lengths before the generation 
of nuclear extracts. Tyrosine phosphorylation began to reduce at 8h 
hypoxia with only very low levels visible with reoxygenation (figure 
3.28, 2nd panel, lanes 6-7). Serine phosphorylation remained low until 
4h hypoxia with reoxygenation and remained stable with 8h hypoxia 
(+1- reoxygenation) (figure 3.28, upper panel, lanes 5-7). 
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Figure 3.28. Phosphorylation status of STAT3 in P19CL6 passaged 1-4 
dilution prior to exposure to hypoxia. P19CL6 were passaged 1-4 one 
day before exposed to normoxia (N) or hypoxia for indicated times (+) or (-) 
reoxygenation for 1 hour and nuclear extracts prepared. 100l-'g of protein for 
each sample was resolved by denaturing polyacrylamide gel 
electrophoresis. The resolved proteins were transferred to a PVDF 
membrane and subjected to western blotting with antibodies indicated. n=1. 
The phosphorylation status of STAT3 at Y705 and S727 remained 
unchanged by the additional passage step. 
3.5.2 Exogenous expression of STAT3 protects P19CL6 
cells from hypoxia-induced apoptosis 
Differentiated P19CL6 cells were transfected with equal amounts 
(figure 3.29) of STAT3Wt and several STAT3 mutants including 
STAT3C (hyperactive mutant) (Li and Shaw, 2006), STAT3c3S (a 
redox-insensitive mutant) (Li et aI., 2010) and STAT3s727A (a mutant 
lacking the serine phosphorylation site) (Wen and Darnell, 1997). 
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Figure 3.29. Schematic representation of STAT proteins used 
throughout this study. Mutational changes represented above the 
appropriate function domains . 
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Figure 3.30. Expression of exogenous STAT3 and various mutants. 
Anti-Flag immuno-precipitates were collected from whole cell extracts 
prepared from P19CI6 cells transfected with the indicated STAT3 expression 
plasmids. 
STAT3 expression in P19CL6 cells (figure 3.30) significantly reduced 
apoptosis induced by hypoxia by approximately by half (figure 3.31), 
whereas STA T3C a hyperactive mutant of STAT3 had no effect on cell 
survival during hypoxia. In contrast, expression of STAT3c3s or 
STAT3S727A increased levels of apoptosis by approximately 20% when 
compared to mock (figure 3.31). These data indicate that serine 
phosphorylation and the redox status of STAT3 may be important for 
cell ~ u r r i v a l l during hypoxia. 
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Figure 3.31. Annexin V binding in P19CL6 cells over expressing STAT3 
forms before exposure to hypoxia. P19CL6 were transfected with 
indicated STAT3 expression plasm ids before exposure to normoxia or 
hypoxia for 8h and then subjected to Annexin V binding assay. The stained 
cells were then sorted using a Coulter Altra Flow Cytometer, set to count 
20000 events. n=3, *P < 0.05, **P<0.005. The dotted line indicates general 
level of apoptosis in P19CL6 cells exposed to hypoxia. 
3.6. STAT3 protects mitochondrial respiration during 
hypoxia 
There has been extensive work recently indicating a functional role for 
STAT3 in the mitochondria. A population of STAT3 is found in the 
mitochondria and mitochondria from cells lacking ST AT3 display 
defects in oxidative phosphorylation, which can be rescued by 
exogenous expression of mitochondrial-targeted ST AT3 (Wegrzyn et 
aI.,2009). 
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3.6.1 Serine-phosphorylated ST AT3 is reduced in 
mitochondrial extracts during hypoxia 
Endogenous ST AT3 was detected in mitochondria isolated from 
differentiated P19CL6 cells and remained fairly constant with exposure 
to hypoxia (figure 3.32, 3rd panel). Levels of tyrosine phosphorylated 
STAT3 are very low under normoxic conditions and reduced further 
with hypoxia (figure 3.32, 2nd panel). Serine phosphorylated STAT3 is 
present in mitochondria under nonnoxic conditions and levels 
decreased gradually during hypoxia in a time-dependant manner (figure 
3.32, 1 sl panel). 
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Figure 1.32. Phosphorylation status of STAT3 in mitochondrial extracts 
following hypoxia. P19CL6 cells were exposed to normoxia (N) or hypoxia 
for indicated times and mitochondrial extracts prepared. 100l-lg of protein for 
each sample was resolved by denaturing polyacrylamide gel 
electrophoresis, transferred to a PVDF membrane and subjected to western 
blotting with antibodies indicated. n=2. 
3.6.2 Exogenous STAT3 and redox-insensitive mutant 
are present in mitochondria whereas S727 A mutant 
is not. 
STAT3W', STAT3C3s and STAT3s272A were also exogenously expressed 
in differentiated P 19CL6 cells and their association with mitochondria 
assessed. Immunoprecipitation assays from isolated mitochondrial 
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lysates revealed that ST A T3 WI associated with mitochondria and levels 
increased slightly when exposed to hypoxia for 8h (figure 3.33, upper 
panel, lanes 3 and 4). The redox insensitive STAT3c3S mutant was 
similarly associated with mitochondria from both normoxic and 
hypoxic cell lysates (figure 3.33, upper panel, lanes 5 and 6), whereas 
the serine phosphorylation mutant STAT3s272A was absent in both 
conditions (figure 3.33, upper panel, lanes 7 and 8). 
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Figure 3.33. Mitochondrial localisation of exogenous STAT3 and mutants 
during hypoxia. (a) Protein expression was analysed by anti-FLAG 
immunoprecipitation from mitochondrial e x t r ~ c t s s (Flag IP - top panels) from 
P19CL6 cells transfected with STAT3 and various mutants prior to exposure 
to normoxia (N) or hypoxia for Bh. Middle panels (Mito inputs) indicate 5% of 
mitochondrial extract. (b) Densitometry was performed using AIDA and 
percentage intensity ST AT3. n=3. 
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The lack of STA T3 S272A present in mitochondrial extracts indicates that 
serine phosphorylation of STA T3 may be required for STAT3 
mitochondrial localisation. In order to investigate this further serine 
phospho-mimetic mutants of STAT3 (STAT3s272D and STAT3s727E) 
were generated using site-directed mutagenesis and their presence in 
mitochondria assessed by immunoprecipitation assays. 
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Figure 3.34. Mitochondrial localisation of exogenous STAT3 and 
phosoho-mimetic during hypoxia. Protein expression was analysed by anti-
FLAG immunoprecipitation from mitochondrial extracts (Flag IP - top panels) 
from P19CL6 cells transfected with STAT3 and phospho-mimetic mutants) 
prior to exposure to normoxia (N) or hypoxia for Bh. Lower panels (Mito 
inputs) indicate 5% of mitochondrial extract. n=1. 
Immunoprecipitation assays from isolated mitochondrial lysates 
revealed that both STAT3 phospho-mimetic mutants (STAT3s272D and 
SRAT3S272E) were present in mitochondria and levels remained when 
exposed to hypoxia for 8h (figure 3.34, upper panel, lanes 1-4). 
STAT3s727D levels in the mitochondria were higher when compared to 
STAT3 WI (figure 3.42, upper panel, lanes 3-6). These results indicate 
that STA T3 serine phosphorylation is important for mitochondrial 
impOJj:. Wegrzyn and colleagues demonstrated that the phospho-
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mimetic mutant MLS Stat3 Y705F/S727D reconstituted of complex VII 
activities (Wegrzyn et aI., 2009). Further investigation is required to see 
if these serine phospho-mimetic STAT3 mutants offer any protection 
against hypoxia-induced apoptosis in P 19CL6 cells. 
3.6.3 Exogenous STAT3 protects mitochondrial 
complex IIII-dependent respiration during hypoxia 
ST AT3 is required for the optimal function of the electron transport 
chain (Wegrzyn et aI., 2009); therefore to determine whether STAT3 
expressIOn influences mitochondrial function during hypoxia, 
mitochondrial ATP production rates (MAPR) were measured. This was 
achieved by exploiting the high sensitivity of the luminometric method 
based on firefly luciferase. This method measures the rate of ATP 
production in isolated mitochondria with different respiratory substrate 
combinations (Wibom et aI., 2002). 
The activity of complex I (NADH dehydrogenase) was monitored by 
the addition of glutamate/malate substrate combination. Glutamate and 
malate are oxidised by mitochondrial enzymes, which in turn feeds 
NADH into the respiratory chain via complex I. 
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Figure 3.35. Expression of STAT3 may protect glutamate + malate-
dependent respiration during hypoxia in P19CL6 cell mitochondria. 
P19CL6 cells transfected with STAT3 and various mutants (C3S; 
STAT3C418/426/486S, S727A; STAT3S727A) were exposed to 
normoxia/hypoxia for 8h and mitochondrial extracts prepared. ATP 
production was measured for glutamate + malate-dependent respiration . 
Results normalised to total mitochondrial protein concentration. N=3. 
In mitochondria isolated from differentiated, mock-transfected 
P 19CL6 cells, complex I-dependant (glutamate/malate) A TP 
production was reduced by approximately 85% after 8h hypoxia (figure 
3.35). Exogenous expression of STAT3 proteins caused an increase in 
the overall rate of A TP production under normoxic conditions 
STAT3 WI and offered slight but insignificant protection against the loss 
of mitochondrial function from cells after 8h hypoxia (figure 3.35). 
Additional biological repeats need to be preformed in order to draw any 
statically significant results from this experiment. The serine 
phosphorylation mutant STAT3s727 and the redox insensitive mutant 
STAT3C3S failed to protect complex I - - ~ p e n d a n t t respiration against 
hypoxia (figure 3.35). 
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The activity of complex II (succinate dehydrogenase) was also 
monitored by the addition of the respiratory substrate succinate. 
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Figure 3.36. Expression of STAT3 may protect succinate-dependent 
respiration during hypoxia in P19CL6 cell mitochondria. P19CL6 cells 
transfected with ST A T3 and various mutants were exposed to hypoxia for 8h 
and mitochondrial extracts prepared. ATP production 'was measured for 
succinate-dependent respiration. Results normalised to total mitochondrial 
protein concentration. N=3. 
In mock-transfected P19CL6 cells, complex II-dependant (succinate) 
activity was reduced by approximately 87% after 8h hypoxia (figure 
3.36). Exogenous expression of STAT3Wt again offered marginal 
protection for respiration observed after 8h hypoxia (figure, 3.36). 
However STAT3s727 and STAT3c3S failed to protect respiration during 
hypoxia (figure 3.36). 
In addition, complex I/II activities were measured simultaneously by 
via the glutamate/succinate respiratory substrate combination. 
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Figure 3.37. Expression of STAT3 protects glutamate + succinate-
dependent respiration during hypoxia in P19CL6 cell mitochondria. 
P19CL6 cells transfected with STAT3 and various mutants were exposed to 
hypoxia for 8h and mitochondrial extracts prepared. ATP production was 
measured for glutamate + succinate-dependent respiration. Results 
normalised to total mitochondrial protein concentration . N.=3, **P<O.005. 
In mitochondria isolated from differentiated, mock-transfected P19CL6 
cells, complex IIII -dependent (glutamate/succinate) A TP production 
was reduced by approximately 70% after 8h hypoxia (figure 3.37). 
Exogenous expression of ST A T3 caused an increase in the overall rate 
of ATP production under normoxic conditions and STAT3 WI offered 
protection against the loss of mitochondrial function from cells after 8h 
hypoxia with a significant 4-fold increase in ATP production when 
compared to mock 8h hypoxia sample (figure, 4.37). The STAT3s727 
and ST AT3 C3S mutants also failed to rescue complex IIII -dependent 
ATP production. 
As a control the respiratory substrate palmitoyl-L-carnitine/malate 
combination was used that monitors ATP production VIa beta-
oxidation. 
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Figure 3.38. Expression of STAT3 does not protect palmitoyl-L-
carnitine + malate-dependent respiration during hypoxia in P19CL6 cell 
mitochondria. P19CL6 cells transfected with STAT3 and various mutants 
were exposed to hypoxia for 8h and mitochondrial extracts prepared. ATP 
production was measured for palmitoyl-L-carnitine + malate -dependent 
respiration . Results normalised to total mitochondrial protein concentration. 
N=3. 
No significant differences were observed mitochondrial ATP 
production fuelled by palmitoyl-L-camitine in cells exogenously 
expressing STAT3 and various mutants (figure 3.38). 
Parallel analysis of mitochondrial protein confirmed the presence of 
STAT3Wt and STAT3c3s in the MAPR assay samples (figure 3.39, 
upper panel, lane 3-6). 
150 
(a) 
P19 L6 Wt C3S S727A 
8 II N 8 II N 8 1%02 (Sh):- N 8 I I N 
• IIB:a-Flag 
Flag I P ~ ; ; ; ; ; ; ; : : : : ; : : : = = = : ; ; : : : = = : ; : ; : = = = = = = = = = = : :
IIt!G H 
~ = = = = ~ = = ~ ~ ~ = = ~ ~
Mito inputs ~ ~_____ " " ' ~ " " I I I : : - \ \ DA 
, - - ~ _ ~ _ ~ ~___ ~ _ ~ _ ~ _ ~ ~..... IIB:a-TUbUljn 
(b) 
1 2354678 
D Normoxia ~ ~ 30 ~ ~ D 8h hypoxia 
00 
t)l) 
20 ~ ~
~ ~
"'"' 0 
.c 10 ~ ~
fIJ 
= ~ ~.. 
~ ~
0 ~ ~ P19CL6 Wt C3S S727A 
Figure 3.39. Flag-immunoprecipitation of exogenous STAT3 and 
mutants during hypoxia from ATP assay mitochondrial samples. (a) 
Protein expression was analysed by anti-FLAG immunoprecipitation from 
mitochondrial extracts (Flag IP - top panels) generated in the ATP formation 
assay prior exposure to normoxia (N) or hypoxia for Bh. Lower panels (Mito 
inputs) indicate 5% of mitochondrial extracts. (b) Densitometry was 
performed using AIDA and percentage intensity of STAT3 determined. n=3. 
The serine phosphorylation mutant STAT3 s727 failed to accumulate in 
mitochondria (3.39, upper panel, lanes 7-8) under normoxic or hypoxic 
conditiol}s as anticipated, did not sustain complex llII-dependent ATP 
production (figure 3.37), indicating that ' serine phosphorylation IS 
required for localisation/import into mitochondria in addition to 
mitochondrial function as previously reported (Wegrzyn et aI., 2009). 
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Even though the redox insensitive mutant STAT3C3S accumulated in the 
mitochondria as effectively as STAT3 WI (3.39, upper panel, lanes 7-8), 
it failed to rescue complex lIII-dependent ATP production (figure 3.37), 
indicating a potential redox mechanism for the role of ST AT3 in 
mitochondrial respiration. 
4.7. Generation of recombinant Flag-tagged STAT3 using 
the baculovirus expression system 
To investigate the potential redox modifications that occur in STAT3, 
recombinant streptavidin-tagged STAT3wI and redox insensitive mutant 
STAT3C3S proteins were generated usmg the Bac-to-Bac® 
Recombinant Baculovirus Expression System. 
pFastBac STAT3 WI and STAT3C3S vectors were generated by 
amplifying a region of STAT3 cDNA sequence (765-2378) from the 
pRc/cmv STAT3Wt/STAT3 C3S vectors using the PCR. STAT3 amplified 
PCR fragments and pFastBac hST AT3 (kindly provided by Vinkemeier 
group) were digested with Sph 1 before ligating together to generate 
pFastBac STAT3Wt and pFastBac STAT3C3S vectors. Vectors were 
subsequently sequenced for verification (section 2.17). 
DhlOBac™ E.Coli competent cells were transformed with the 
expression cassette pFastBac ST A T3 Wt/ST AT3C3S, which allowed 
recombination with the parent bacmid in DHlOBac cells to form an 
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expression bacmid. The bacmid was then transfected into sf9 insect 
cells for the production of recombinant baculovirus particles. 
3.7.1 Sf9 phenotypic change and reduced cell number 
indicates viral infection 
72h Post-infection 
Uninfected 
STAn wt 
STAT3 C3S 
Figure 3.40. Sf9 cell images 72h post-baculovirus infection. Phase 
images of sf9 cells 72 hours after initial baculovirus infection. 
Positive signs of recombinant baculovirus expression are evident by a 
reduction in cell number and increased areas of cellular debris when 
compared to uninfected cells 27h post transfection (figure 3.40). 
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3.7.2 Expression and purification of recombinant 
STAT3 proteins 
In order to verify expression of recombinant STAT3 proteins, sf9 whole 
cell lysates were prepared after 24, 48 and 72h post infection and 
subjected to western blot analysis. 
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Figure 3.41 . STAT3 expression from infected sf9 cells. 1 0 ~ 1 1 of infected 
sf9 cells were lysed in 1XSDS loading buffer at indicated times. Samples 
were resolved by denaturing polyacrylamide gel electrophoresis. The 
resolved proteins were transferred to a PVDF membrane and subjected to 
western blotting with antibodies indicated. 
The expression of STAT3Wt and STAT3C3S increased with infection 
time, with maximal expression observed at 72h post-infection (figure 
3.41, lanes 4 and 7). 
Large scale expression and Strep-Tactin® sepharose purification was 
performed to yield large amounts ( ~ 1 m g / m l ) ) of recombinant STAT3wt 
and STATc3S proteins (figure 3.42). 
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Figure 3.42. Purification of recombinant STAT3 using a strep-Tactin® 
column. Infected sf9 cells were lysed using a dounce homogeniser. Lysates were 
loaded onto a Strep-Tactin® column and washed with buffer w before eluting the 
protein in buffer E (6x O.Sml fractions) . 20IJI of each sample was resolved by 
denaturing polyacrylamide gel electrophoresis and visualised using coomassie 
blue stain. Black arrow indicates purified STAT3 protein. * Indicates contaminating 
band present in SDS loading buffer. 
3.7.3 Oxidation of recombinant STAT3 proteins 
Previous studies relieved that STAT3 is capable of forming higher 
molecular weight complexes when treated with hydrogen peroxide (Li et 
aI., 2010). Cell extracts treated with hydrogen peroxide were resolved on 
a polyacrylamide gel under non-reducing conditions and subjected to 
western blot analysis using a STAT3 antibody. The experiment revealed 
. 
that ST AT3 dimers, trimers and tetramers were formed upon exposure to 
hydrogen peroxide (Li et aI., 2010). 
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As the experiment was carried out using nuclear extracts, there was the 
potential for ST A3 to form redox complexes with other nuclear proteins 
resulting in the higher molecular weight complexes observed (Li et ai., 
2010). Therefore recombinant STAT3 protein was utilised to see whether 
STAT3 is capable of being directly oxidised in response to hydrogen 
peroxide. Recombinant STAT3 Wt and redox-insensitive mutant 
STAT3C3s proteins were treated with hydrogen peroxide and visualised 
by denaturing SDS PAGE under non-reducing conditions. 
STAT3 Wt 
IB:a-Flag 
234 
STAT3C3S 
5 6 7 8 
~ 2 7 0 k D a a
~ 1 8 0 k D a a
~ 9 0 k D a a
Figure 3.43. Oxidation of recombinant STAT3. Recombinant STAT3Wt and 
STAT3c 3S proteins were exposed normoxia (N) or varying concentrations 
H20 2 for 2 minutes at 3rC. 20j.J1 of each sample was resolved by denaturing 
polyacrylamide gel electrophoresis under non-denaturing conditions (no 13-
mercaptoethanol or OTT) The resolved proteins were transferred to a PVOF 
membrane and subjected to western blotting with antibodies indicated. White 
arrow indicates ST A T3 monomer and the black arrows indicate possible 
dimers and trimers of STAT3. n=1 . 
. 
Western blotting analysis revealed that STA T3 is capable of forming 
higher molecular weight complexes. STAT3 containing species are 
visible at approximately 180KDa and 270KDa, levels increased with 
the a d ~ i t i o n n of hydrogen peroxide in a concentration dependent manner 
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(figure 3.43, black arrows). The recombinant proteins were resolved 
under denaturing, non-reducing conditions suggesting that these 
complexes are stablised through disulphide-bridge covalent 
interactions, consistent with previous findings (Li et ai., 2010). 
Increased complex formation was observed with ST A T3 Wt when 
compared to the redox insensitive STAT3 mutant ST AT3C3s exposed to 
peroxide, indicating the cysteine residues C418, C426 and C468 are 
sensitive to oxidation and required for the formation of the higher 
molecular weight ST AT3 complexes. However, the difference observed 
in complex formation between the two ST AT3 proteins may be due to 
differences in the levels of total protein (figure 3.43, white arrow). 
Although this result looked very promising, numerous attempts to try 
and repeat this experiment failed. The higher molecular weight ST A T3 
complexes varied between attempts as well STAT3 monomer (figure 
3.43, white arrow). To ensure equal amount of the recombinant STAT3 
proteins were used, protein concentration was determined using the 
Bradford protein assay. Equal protein loading still varied between the 
two STAT3 recombinant proteins suggesting potential 
aggregation/precipitation of the proteins. This in tum could affect the 
proportions of higher molecular complexes observed due to varying 
amounts of protein being exposed to hydrogen peroxide. Due to time 
restraints, the direct oxidation of recombinant ST AT3 and the redox 
insensitive mutant still warrants further investigation. 
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Chapter 4. Discussion 
ST A T3 participates in a wide variety of seemingly contradictory 
processes, such as proliferation and apoptosis. Accumulating evidence 
links STA T3 with normal heart development and numerous studies 
have shown that STAT3 activation promotes cardiomyocyte survival, 
suggesting STA T3 is beneficial for the heart. Loss of ST AT3 in cardiac 
tissue has been linked to fibrosis and heart failure in aging mice 
(Jacoby et aI., 2003) and down regulation of STAT3 was observed in 
myocardial tissue from patients suffering from dilated cardiomyopathy 
(Podewski et aI., 2003). The mechanism underlying the role of STAT3 
in cardiac protection has yet to be fully defined and this thesis aimed to 
investigate this role further. By exploring various cardiomyocyte 
models this thesis addressed clear differences between cell models for 
hypoxia-induced apoptosis thus, providing insight into which model is 
most representative of the diseased heart. 
The main aim of this study was to explore the protective role of ST AT3 
in cardiomyocytes during hypoxia/oxidative stress; this was achieved 
by stimulating ST AT3 activity with LIF and exogenously expressing wt 
and mutant versions of ST AT3 in cardiomyocytes and looking for 
differences in levels of apoptosis. 
There is also accumulating evidence pointing to a protective role for 
STAT3 in the mitochondria, including cellular respiration (Boengler et 
aI., 2010, Wegrzyn et aI., 2009). Therefore to shed further insight on 
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this work, this study investigated the mitochondrial role of ST A T3 
during hypoxia/oxidative stress. 
4.1 Characterisation of STAT3 activity during 
hypoxia/reoxygenation 
Altered regulation of ST A T3 has been reported in human failing hearts. 
Podewski and colleagues reported that ST AT3 expression and 
phosphorylation were severely reduced in failing hearts (Podewski et 
aI., 2003). This was later supported by the observation that mice with 
cardiomyocyte-specific disruption of STAT3 developed DCM, heart 
failure and early death (Jacoby et aI., 2003, Hilfiker-Kleiner et aI., 
2004). 
STAT3 is activated by phosphorylation at tyrosine 705. Phospho-
tyrosine ST ATs dimerise and translocate to the nucleus, where they 
bind to DNA and activate transcription of various genes (Akira et aI., 
1994, Zhong et aI., 1994). Thus, to monitor STAT3 activity during 
hypoxia/reoxygenation, STAT3 tyrosine phosphorylation and ST A T3 
DNA binding were measured throughout this study by immunoblotting 
and EMSA respectively. 
In RCMs and H9c2 cells, tyrosine phosphorylation of ST A T3 remained 
detectable when exposed to hypoxia. A. slight but reproducible 
reduction in STAT3 tyrosine phosphorylation was observed at lh and 
24h hypoxia for RCMs (figure 3.1) and 24h for H9c2 (figure 3.5a). 
Similarly, the DNA binding profile of STAT3 showed a direct 
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correlation with levels of phospho-tyrosine STAT3 for both RCMs 
(figure 3.2) and H9c2 cell lines (figure 3.6). 
In contrast, reoxygenation of P 19CL6 cells after 8h hypoxia displayed a 
substantial reduction in tyrosine phosphorylation of STAT3, which was 
completely abolished with exposure to hypoxia for 24h (figure 3.7a). 
The DNA binding activity of ST AT3 was also more sensitive to 
hypoxia when compared to RCM and H9c2 cell lines, with complete 
loss of ST A T3 DNA binding with 8h hypoxia, even though tyrosine 
phosphorylation was still detectable (figure 3.8). 
The ratio between activated kinases and inactivated phosphatases could 
explain why ST A T3 tyrosine phosphorylation and ultimately ST A T3 
DNA binding is maintained during long periods of hypoxia-induced 
oxidative stress in RCM and H9c2 cell lines. STAT3 activity is 
required by a variety of processes during of mild hypoxia including 
tumourigenesis and angiogenesis (Kang et aI., 2010). Studies have 
shown that hypoxia markedly augmented phosphorylation and 
activation of JAKS (JAK1, JAK2 and JAK3) and their substrates, 
ST ATs (ST AT3 and ST AT5) in lung microvascular endothelial cells 
(Wang et aI., 2008). In addition, ROS has been implicated in the 
activation of the JAKISTAT pathway, in which H202 treatment was 
shown to stimulate the activity of JAK2 and TYK2 (Simon et aI., 
1998). 
The inactivation of protein tyrosine phosphatases (PTPs) is also 
associated with oxidative stress. PTPs contain cysteine residues in their 
catalytic site and ROS-mediated oxidation of these cysteine residues 
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results in their inactivation. Meng and colleagues demonstrated that 
multiple PTPs were reversibly oxidised and inactivated in Rat-1 cells 
following treatment with H202 (Meng et aI., 2002). More recently, the 
catalytic pan-PTP and SHP-2 activities were dramatically reduced from 
samples taken from ex vivo langendorff-model of rat heart 
ischaemia/reperfusion (Sandin et aI., 2011). 
Therefore a balance between kinase activation and PTP inactivation 
would allow levels of tyrosine-phosphorylated ST A T3 and ultimately 
ST A T3 DNA binding activities to be effectively maintained during 
prolonged exposures to hypoxia in RCM and H9c2 cells. To validate 
this hypothesis further investigation is required. Kinase inhibitors such 
as AG490, (a potent inhibitor for JAK2 and JAK3) could be utilised to 
determine whether ST A T3 tyrosine phosphorylation and DNA binding 
would be disrupted during hypoxia-induced oxidative stress. However, 
the balance between active kinases and inactivation of phosphatases 
does not explain the loss of STAT3 DNA-binding 8h hypoxia in 
P 19CL6 cells, even though STAT3 tyrosine phosphorylation is still 
detectable - another mechanism must be in operation. 
In theory, one reason for the dissonance between tyrosine 
phosphorylation and DNA binding could be direct oxidation of ST A T3 
by ROS. It is important for proteins to maintain a proper structure to 
perform their biological functions. This 'proper' structure may be 
altered if proteins become oxidised during oxidative stress. Oxidation 
of redox elements (mainly cysteine residues) will generate sulphoxides, 
s u l p h e ~ i c c acids and disulphide bridges within the protein, this will 
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result in changes in secondary and tertiary structure, which may affect 
the stability of DNA binding. 
Redox sensitive cysteine residues have been reported in the DNA 
binding domain of many transcription factors. For example, cysteine 
residues are found in the basic region of c-myb (Guehmann et aI., 
1992), the leucine zipper of AP-l (Abate et aI., 1990) and the zinc-
finger motif of the glucocorticoid receptor (Hutchison et aI., 1991). 
Tolendano and colleagues demonstrated that in vitro DNA binding of 
NF-KB could be inhibited by oxidative stress (Toledano and Leonard, 
1991). The transcription factor GA-binding protein (GABP) has also 
been implicated in redox regulation. In vitro and in vivo studies have 
show that oxidative conditions result in inhibition of DNA binding 
through COOH-terminal cysteine residues in the GABPa subunit 
(Martin et aI., 1996). 
DNA binding of ST AT3 also appears to be regulated by oxidative 
stress. Studies have shown that in vivo DNA binding of ST AT3 to the 
hepcidin promoter is diminished by hypoxia-induced oxidative stress 
and such a DNA binding decrease can be rescued with the addition of 
antioxidants (Choi et aI., 2007). More recently, we have demonstrated 
that the DNA binding properties of ST A T3 are sensitive to treatment 
with hydrogen peroxide (Li et aI., 2010). Also in this study, mutational 
analysis revealed three redox-sensitive cysteine residues (Cys418, 
Cys426 and Cys468) present in the DNA binding domain of STAT3. 
Substituting these cysteines for serine residues protected DNA binding 
during. oxidative stress (Li et aI., 2010). 
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Studies have shown that DNA-binding STAT protects proteins from 
dephosphorylation by phosphatases. DNA-bound STATI has been 
shown to be protected from dephosphorylation by phosphatases (Meyer 
et at, 2003) and also the STAT3 constitutively active mutant STAT3C, 
displays higher affinities for DNA with delayed dephosphorylation 
rates by nuclear phosphatases (Li and Shaw, 2006). 
During hypoxia-induced oxidative stress, it is feasible that redox 
modifications occur to cysteine residues within the DNA binding 
domain of STAT3. Modifications may alter the tertiary structure of 
ST AT3 and in turn reduce its affinity for DNA, resulting in loss of 
STAT3 DNA binding. Once ST AT3 possesses a weaker affinity for 
DNA, it may become more susceptible to dephosphorylation VIa 
phosphatases - explaining the loss of DNA binding before the 
subsequent reduction in tyrosine phosphorylation. The protein 
phosphatase SHP-2 (Src-homolgy-2 domain-containing protein 2) has 
been shown to dephosphorylate STAT3. In rat astrocytes, SHP-2 has 
been shown to form a complex with ST AT3 and reduce the steady state 
ST AT3 tyrosine phosphorylation when exposed to oxidative stress 
(Park et at, 2009). However, a redox modification of STAT3 many be 
questioned as the reducing agent DTT (5mM) did not rescue STAT3 
DNA binding at 8h hypoxia (figure 3.24). The addition of DTT has 
. 
been shown to be required for optimal ST AT3 in vitro DNA binding 
(Li et at, 2010), therefore it may be possible that Pl9CL6 cells have 
different buffer capacities and higher concentrations of reducing agents 
are required. 
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In addition, this study also revealed that serine-phosphorylated STAT3 
is significantly increased in P 19C16 cells with 8h hypoxia (figure 3.16). 
Studies have shown that ST AT3 is serine-phosphorylated by ERK2. 
Serine phosphorylation is also associated with a reduction in DNA 
binding activity and lower tyrosine-phosphorylated STAT3 levels (Jain 
et aI., 1998). Therefore the loss of STAT3 DNA binding could be 
associated with the elevated levels of serine-phosphorylated ST A T3 
observed at 8h hypoxia in P 19CL6 cells (discussed later). 
4.2 Hypoxia-induced apoptosis of cardiomyocytes 
The severity of hypoxia determines whether cells become apoptotic or 
adapt to hypoxia and survive. RCM and H9c2 cells are resistant to 
hypoxia-induced oxidative stress and only a slight but significant 
increase in levels of apoptosis were observed in H9c2 cells exposed to 
reoxygenation after 24h hypoxia (figure 3.10). However, on the other 
hand, Pl9CL6 cells were extremely sensitive to hypoxia-induced 
oxidative stress, showing ~ 5 0 % % increase over normoxia level of 
apoptosis when exposed to hypoxia for only 8h (figure 3.12). This 
clearly demonstrated differences in apoptotic-sensitivity during hypoxia 
in the different cell models. 
A wealth of evidence documents that STAT3 is involved in cell 
survival. One mechanism is its ability to drive expression of anti-
apoptotic factors, including Mcl-l (Epling-Burnette et aI., 2001). The 
rapid l ~ s s s of ST AT3 activity in P 19CL6 cells following hypoxia could 
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be responsible for the observed reduction in Mcl-l protein levels 
(figure 3.13). Down regulation of Mcl-J is thought to be required for 
Bax translocation to mitochondria and cytochrome c release - events 
indicative of apoptosis (Nijhawan et aI., 2003). 
There are substantial differences in the sensitively to hypoxia-induced 
apoptosis between RCM and H9c2 cells compared to P 19CL6 cells. 
One possible reason for this could be due to species differences 
(Houweling et aI., 2005). RCM and H9c2 cells are both of rat origin, 
whereas P 19CL6 cells are mouse. Phenotypic variations between 
species may account for the differences observed in hypoxia sensitivity 
throughout this study. This is unlikely to be the sole reason as it has 
been reported that cardiac function is highly conserved between species 
and both rat and mouse models are highly comparable with human 
development and pathology (Houweling et aI., 2005). 
The differences in sensitivity to hypoxia between cell lines could be 
due to the relative age of the cells. Increased incidence of apoptosis had 
been reported in several tissues during aging. For example, the aging-
associated atrophy of muscle - sarcopenia. Studies on sarcopenia in 
rodents have identified an apoptotic-like mechanism characterised by 
mitochondrial changes and caspase-independence (Marzetti et aI., 
2009). More recent studies have shown that aging increases myocardial 
ischaemialreperfusion-induced apoptosis(Liu et aI., 2011). Young (2 
months) and old (24 months) rats were subjected to I1R injury followed 
by TUNEL staining and caspase activity measurements. The results 
revealed a higher myocardial apoptotic ratio in the older rat group. This 
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study was validated in humans as elderly patients manifested decreased 
cardiac function and increased plasma apoptotic markers (soluble form 
ofFas and TNF-a) when compared to adult patients (Liu et aI., 2011). 
Pl9CL6 cells were isolated from the P19 mouse embryonal carcinoma 
cell line through an extensive 6 months selection process (Habara-
Ohkubo, 1996), followed by a 16-day differentiation step. Therefore, 
P 19CL6 cells were cultured significantly longer than RCMs or H9c2 
cells. RCMs were isolated directly from neonatal rat hearts and not 
passaged while, H9c2 cells were obtained from A TCC at passage 12 
and were not passaged more than 10 times during this study. 
Throughout this study RCM and H9c2 cells have- been resistant to 
hypoxia-induced apoptosis. Consistent with this observation, studies 
have also shown that neonatal rat ventricular myocytes (NRVMs) 
possess an apoptotic-resistance that acts as a cytoprotective mechanism 
against stress-induced injury (Lu et aI., 2008). In addition, Bonavita and 
colleagues demonstrated that hypoxia alone did not induce apoptosis in 
H9c2 cells for at least 48h (Bonavita et aI., 2003). 
Expression profiles in aged hearts indicate decreased cellular adaptation 
and protection against stress-induced injury together with the 
development of contractile dysfunction (Bodyak et aI., 2002). Aging 
expression profiles for the cardiac cell lin!? models would reveal 
whether or not the age of the cells contributes to the differences 
observed in hypoxia-induced apoptosis. Recently, Ding and colleagues 
set out to identify novel biomarkers of normal aging in male mice from 
2-19 months of age (Ding and Kopchick, 2011). They identified several 
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proteins that were significantly increased (transthyretin and 
haptoglobin) and a number of proteins that were significantly decreased 
(peroxiredoxin-2 and serum amyloid protein A-I) during aging (Ding 
and Kopchick, 2011). 
Regulated ROS production can modulate intracellular signaling 
pathways, which have been associated with growth of cardiac myocytes 
(Siwik et al., 1999) and ischaemic preconditioning (Vanden Hoek et aI., 
1998), both of which increase the ability of cardiac myocytes to survive 
oxidative stress. It could be feasible that RCMs and H9c2 cells have 
different tolerations to ROS during times of oxidative stress when 
compared to P 19CL6 cells. Differences in the concentrations of ROS 
generated could be due to variations in levels of antioxidant enzymes 
and free radical scavengers between the different cell lines. Indeed, 
studies on other cell lines have shown that HepG2 cells are extremely 
resistant to hydrogen peroxide treatment when compared to BR293 and 
MCF-7 cells (Chua et aI., 2009, Sekiya et aI., 2008). The level of ROS 
production during hypoxia was not measured in this study however, 
warrants further investigation. Chemiluminescence-based techniques 
could be utilised to measure ROS production in the different cardiac 
cell lines exposed to hypoxia. On exposure to ROS a chemiluminescent 
probe releases a photon, which in turn can be detected and measured by 
a luminometer. 
Given that IHD is typically a disease of old age, as it takes many years 
for fat deposition to restrict the coronary arteries, it may have been 
more appropriate to use an adult rat cardiomyocytes model to study the 
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pathological stresses associated with IHD. However, adult RCMs are 
difficult to isolate and have sensitive culture conditions when compared 
to neonatal RCMs. In particular, studies have shown that adult RCMs 
are extremely sensitive to Ca2+ levels and an increase in Ca2+ is 
associated with a reduction in membrane permeability and myocardial 
damage (Zimmerman and Hulsmann, 1966). P 19CL6 may reflect a 
phenotype representative on an aging cardiomyocyte, which have a 
reduced ability to adapt to hypoxic stress and hence enhanced levels of 
ROS and ultimately apoptosis. This would agree with studies that 
demonstrate that aging cardiomyocytes have a reduced ability to adapt 
to pathological conditions such as myocardial ischaemia, which is 
displayed in an aging diseased heart (Takahashi et aI., 1992, Liu et aI., 
2011 ). 
P19CL6 cells are able to differentiate into a beating phenotype that is 
reminiscent of cardiomyocytes upon exposure to DMSO (Habara-
Ohkubo, 1996). Khodadadi and colleagues demonstrated that 
differentiated P 19CL6 cells exhibit some markers of a cardiac 
phenotype (a-MHC, b-MHC) and the beating phenotype is positively 
responsive to adrenaline (Khodadadi, 2010). However, closer 
examination revealed a mixed, cardiac/skeletal muscle phenotype 
questioning the role of P19CL6 cells as a cardiac cell model 
(Khodadadi, 2010). 
Embryonic and neonatal rat cardiomyocytes have been extensively used 
models to study cardiac biology (Hescheler et aI., 1999, van der 
H e y d e ~ ~ and Defize, 2003, Chlopcikova et aI., 2001), however their use 
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may be limited due to the lack of some adult cardiomyocyte 
characteristics (Khodadadi, 2010). In addition, isolated primary 
cardiomyocytes become overgrown by non-moyoctyes after a few days 
in culture, they cease to divide after the neonatal period and genetic 
manipulation is extremely difficult (Claycomb, 1985). Another 
potential cell line that could be considered in this study is the HL-I cell 
line, which is derived from atrial cardiomyocyte AT-I cells. HL-I cells 
can be serially passaged while maintaining a differentiated phenotype 
(Claycomb et aI., 1998). HL-I cardiomyocytes have been characterised 
and show highly organised sarcomeres (necessary for mediating 
contraction) and gene expression analysis reveals HL-I cells exhibit an 
adult cardiomyocyte-like phenotype expression profile (Claycomb et 
aI., 1998). In addition, the angiotensin/STAT3 pathway has been shown 
to be important the atrial myocardium (Tsai et aI., 2008) implicating 
further potential roles of ST A T3 in this cardiac cell line. 
Further investigation is required for determining the appropriate cardiac 
cell model for studying the role of STAT3 in cardiomyocytes during 
hypoxia-induced apoptosis. H9c2 and RCMs have been shown to be 
relatively resistant to hypoxia-induced apoptosis in this study and 
previous work (Lu et aI., 2008)((Bonavita et aI., 2003) therefore not 
effective cardiac cell models for investigation ST AT3 and its role 
during hypoxia-induced apoptosis. PI9CL6 are indeed extremely 
sensitive to hypoxia-induced apoptosis, therefore providing an excellent 
cell model for the investigation the mechanisms of apoptosis. However 
there are doubts to whether these cells represent a true adult-
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cardiomyocyte cell model (Khodadadi, 2010). Future studies looking at 
the role of ST A T3 during hypoxia-induced apoptosis should be 
considered in a more appropriate cardiac cell model, potentially the 
HL-l cell line. 
4.3 The role of PKC in cardiomyocytes during 
hypoxia 
In addition to tyrosine phosphorylation, several STA Ts are 
phosphorylated on a serine residue (S727 in STAT3) in their carboxyl-
terminal domain, which was initially reported to be important for 
transcriptional activation (Wen et aI., 1995, Zhang et aI., 1995). Unlike 
tyrosine phosphorylation, the functional significance of serine 
phosphorylation of ST AT3 remains controversial. Depending on the 
cell type and the extracellular stimulus, serine phosphorylation can 
either enhance or suppress the transcriptional activity of phosphorylated 
ST AT3 (Chung et aI., 1997b, Jain et aI., 1998, Y okogami et aI., 2000). 
This study shows that serine phosphorylation of ST A T3 increases in 
P19CL6 cells exposed to 8h hypoxia (figure 3.16a, lane 4). An increase 
in serine phosphorylation is due to a shift in balance between inactive 
protein phosphatases and active protein kinases: 
Protein phosphatase 2A (PP2A) has been shown to have a direct effect 
the regulation of STAT3. Woetmann and colleagues demonstrated that 
PP2A inhibitors cause the serine phosphorylation of STAT3, inhibition 
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of tyrosine phosphorylation, loss of DNA binding activity and 
translocation of STAT3 from the nucleus to the cytoplasm (Woetmann 
et aI., 1999). This supports observations in this thesis by which an 
increase in STAT3 serine phosphorylation (figure 3.16a, lane 4) is 
accompanied by a loss in STAT3 DNA binding (figure 3.8, lane 4) and 
subsequent reduction in tyrosine phosphorylation (figure 3.7a, lane 4). 
This suggests that PP2A inactivation may be responsible for the 
accumulation of serine-phosphorylated STAT3 observed. Indeed, 
studies have shown that PP2A is susceptible to reversible inhibitory 
modification by thiol-disu1phide exchange, indicating that PP2A is a 
redox-sensitive protein phosphatase (Foley and Kintner, 2005). Further 
investigation is required to determine whether PP2A is inactivated in 
P19CL6 cells during hypoxia-induced oxidative stress and is 
responsible for the increase in serine-phosphorylated STAT3. 
Another possible explanation for the increase in serine phosphorylation 
of ST A T3 observed in P 19CL6 cells exposed to hypoxia could be due 
to the activation of ST AT3 serine kinases. Serine phosphorylation of 
STAT3 is mediated by several kinases. However, this study focused on 
the serine/threonine kinase PKC(3 due to the accumulating evidence 
associating this protein with apoptosis (Hahn et aI., 2002, Inagaki et aI., 
2003, Clavijo et aI., 2007). PKC(3 activation has been documented to be 
crucial in cardiac pathology such as hypertrophy, heart failure and UR 
injury (Hahn et aI., 2002, Inagaki et aI., 2003). A study has shown that 
prolonged exposure to hypoxia causes the proteolytic and feed-forward 
activation of PKC(3 and caspase-3, resulting in the irreversible 
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commitment to apoptosis (Clavijo et aI., 2007). In addition, PKC8 is 
described as a proapoptotic kinase due to the fact it is activated by 
oxidative stress and promotes apoptosis (Kanthasamy et aI., 2003). 
There is a potential positive correlation between PKC8 activity and 
serine-phosphorylated STAT3 during hypoxia in P19CL6 cells. The 
phosphorylation of PKC8 peaked at 4h hypoxia (figure 3.18) with an 
elevation in STAT3 serine phosphorylation with 8h hypoxia (figure 
3.16), which, accompanied the loss of DNA binding (figure 3.8) and 
increased levels of apoptosis (4h hypoxia) (figure 3.12). However 
further experiments will need to be carried out to include the serine 
phosphorylation status of STAT3 and it's DNA binding abilities at 4h 
hypoxia in order to effectively correlate with PKC8 activation. A study 
in HepG2 cells and other cell lines stimulated with IL-6, where PKC8 
was shown to physically interact with ST AT3 resulting in elevated 
levels of serine-phosphorylated STAT3, which in turn suppressed 
STA T3 DNA binding to the SIE (Jain et aI., 1999). However the data 
presented in this study shows only circumstantial evidence linking 
increased PKC8 activity to the elevation of serine-phosphorylated 
STAT3 in P19CL6 cells during hypoxia. To try and establish whether 
PKC8 is the kinase responsible for phosphorylating STAT3 during 
hypoxia-induced oxidative stress, the PKC8 inhibitor, and rottlerin was 
utilised in this study. The addition of rottlerin did in fact abolish the 
levels of ST AT3 serine phosphorylation previously observed with 8h 
hypoxia (figure 3.20), but levels of apoptosis were significantly 
enhanced, even under normoxic conditions (figure 3.21). Studies have 
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shown that using rottlerin is not be suitable as a selective inhibitor of 
PKC5 due to its potent mitochondrial uncoupling and K+ channel 
activating properties (Soltoff, 2007). Due to these findings the data 
generated (figure 3.20 and figure 3.21) in this thesis that uses the 
inhibitor rottlerin cannot be interpreted efficiently due to its wide 
spread application with other cellular targets (Soltoff, 2007). However 
research articles using rottlerin as a specific PKC5 inhibitor are 
currently still being published (Wallerstedt et aI., 2010, Matta et aI., 
2011). 
The use of inhibitors to identify targets of specific PKC isoforms is 
fraught with difficulty. A number of PKC inhibitors exist however 
some have broad specificity and additional cellular targets. For 
example, Go 6983 (bisindolylmaleimide) is a fast acting, lipid soluble, 
broad-spectrum protein kinase C inhibitor (1, 13, y, f>, 1;). A study has 
shown that when the inhibitor is administered at the beginning of 
reperfusion, it can restore cardiac function within 5 min and attenuate 
the deleterious effects associated with acute ischemialreperfusion 
(Young et aI., 2005). Chelerythrine has also been used as a PKC 
inhibitor and a study demonstrated that chelerythrine suppressed the 
translocation of PKC5 and PKCs to the membrane and blocked the 
improvement of cardiac function and ATP generation (Xu et aI., 2004). 
However chelerythrine is known to inhibit an additional cellular target -
BclxL. Chan and colleagues suggested that chelerythrine triggers 
apoptosis through a mechanism that involves direct inhibition of Bcl-2 
family proteins (Chan et aI., 2003b). 
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Additional experiments will be required to validate the correlation 
observed between PKC& and STAT3. Investigating the biochemical 
interactions between ST AT3 and PKC& and generating PKC& 
knockdown experiments would give a clearer insight to whether PKC& 
is responsible for STA T3 serine phosphorylation and contributes to cell 
death during hypoxia. Preliminary immunoprecipitation experiments 
have revealed that STAT3 and PKC& do interact in Pl9CL6 cells and 
this interaction is marginally increased during hypoxia (unpublished 
data). These data so far implicates PKC& as a kinase that is capable of 
serine--phosphorylating STAT3 in P19CL6 cells during hypoxia 
however; phosphorylation by other kinases has not been ruled out. 
4.4 Elevated STAT3 activity protects P19CL6 against 
hypoxia-induced apoptosis 
Persistent activation of ST A T3 is frequently associated with malignant 
transformation and it is established that constitutively active ST A T3 is 
one of the molecular abnormalities in oncogenesis (Turkson, 2004). In 
contrast to its negative effects in malignant transformation, studies have 
shown that continual activation of STAT3 offers cardioprotection. For 
example, the over expression of ST AT3 in the heart protects from 
doxorubicin-induced cardiomyopathy - an adverse side effect of the 
chemotherapy drug doxorubicin (Kunisada et aI., 2000). 
To establish whether promoting STAT3 activity could contribute to 
P 19CL6 cell survival during prolonged hypoxia, apoptosis was 
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monitored after pre-treatment with L1F - a cytokine that stimulates 
STAT3 activity in these cells (van Puijenbroek et aI., 1999). 
Stimulation of P19CL6 cells with LIF increased tyrosine 
phosphorylation of STAT3 in both normoxic and hypoxic cells (figure 
3.23a). In addition, STAT3 DNA binding was substantially enhanced in 
L1F treated cells and residual binding was still detectable after 8h 
hypoxia (figure 3.24). Importantly, stimulation of STAT3 activity with 
LIF was associated with reduced levels of apoptosis in P 19CL6 cells 
after 8h hypoxia (figure 3.25). This data is consistent with studies 
suggesting that L1F may promote survival of cardiomyocytes and 
regeneration of the myocardium. Zou and colleagues demonstrated that 
L1F protected cardiomyocytes from death and enhanced 
neovascularisation after myocardial infarction (Zou et aI., 2003). 
The protective effects of LIF observed in P19CL6 cells during hypoxia 
could be due to enhanced expression of STAT3 target genes, as residual 
DNA binding was still detectable after 8h hypoxia (figure 3.24). 
Indeed, expression of Mcl-l was still apparent in P19CL6 pre-treated 
with LIF even after 8h hypoxia (figure 3.26). Equally, LIF stimulation 
may offer protection via a non-transcriptional route. It was noted in this 
study that not only did LIF treatment stimulate tyrosine 
phosphorylation of ST AT3 but also the phosphorylation of serine 727 
(figure 3.23a). In addition to accumulating evidence suggesting that 
serine phosphorylation of STAT3 is associated with transcriptional 
suppression (Jain et aI., 1998, Jain et aI., 1999) it is also required for 
functional mitochondrial respiration (Wegrzyn et aI., 2009). Therefore 
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under hypoxic conditions, LIF stimulation may in fact direct STAT3 
from the nucleus to the mitochondria where it is able to maintain 
mitochondrial function during hypoxia-induced oxidative stress. 
4.5 Exogenous expression of STAT3 in 
cardiomyocytes 
The role of ST A T3 in cardiomyocyte survival following hypoxia was 
addressed through exogenous expression of ST AT3 and several 
mutants. ST AT3 over-expressIOn significantly reduced apoptosis, 
whereas STAT3C a constitutively active mutant of ST AT3 had no 
significant effect on cell survival under hypoxia. As discussed earlier, 
ST AT3C possesses higher DNA binding affinity when compared to 
STAT3 WI (Li and Shaw, 2006). If the protective role of STAT3 during 
hypoxia is indeed associated with mitochondrial respiration, then 
increased DNA binding affinities would reduce the latent pool of 
ST AT3 available for the mitochondria, causing a reduction m 
mitochondrial function and in turn increased levels of apoptosis. In 
addition, exogenous expression of the serine phosphorylation mutant 
STAT3s727 and the redox-insensitive mutant STAT3C3S also increased 
levels of apoptosis in P19CL6 cells. This indicates that serine 
phosphorylation and redox modification of STA:r3 may both contribute 
to the protective roles of ST A T3 in cardiomyocytes during hypoxia 
through mechanisms involving mitochondrial function, which is 
discussed later. 
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4.6 STAT3 protects mitochondrial respiration during 
hypoxia 
Loss of mitochondrial integrity is central to the initiation of apoptosis. 
Although ST A T3 has not been directly implicated in this process, 
defects in mitochondrial respiration have been reported. Mitochondria 
isolated from ST AT3-deficient cells show impaired respiratory function 
of complexes 1111 of the ETC and exogenously expressing ST A T3 
targeted to the mitochondria was shown to rescue respiration (Wegrzyn 
et aI., 2009). In this thesis, the role of ST A T3 in mitochondrial A TP 
production during hypoxia was accessed by exogenously expressing 
ST A T3 and various mutants. Measuring mitochondrial A TP production 
would give an insight to the functional activities of the ETC during 
hypoxia and depending on the substrate used, focus on a particular 
complex of the ETC. In mock-transfected P 19CL6 cells, mitochondrial 
ATP production was abolished during hypoxia. However, expressing 
STAT3Wt maintained the mitochondria's ability to produce complex 1111 
dependant ATP post hypoxia (figure 3.37), which in tum accompanied 
reduced levels of apoptosis (figure 3.31). Interestingly the redox-
insensitive STAT3c3S mutant, although imported into the mitochondria, 
failed to rescue A TP production (figure 3.37) or offer protection to 
P 19CL6 cells under hypoxia (figure 3.31). This indicates that redox 
modulation of STAT3 is involved in this protective mechanism. This 
supports a previous publication that demonstrated that breast carcinoma 
cells expressing STAT3C3S were more sensitive to oxidative stress 
when c ~ m p a r e d d to ST A T3 Wt counterparts (Li et aI., 2010). The serine 
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phosphorylation mutant STAT3s727A also failed to rescue ATP 
production during hypoxia, consistent with previous findings (Wegrzyn 
et aI., 2009). However, unlike Wegrzyn and colleagues who used a 
mitochondrial-targeted STAT3s727 mutant, this study revealed that 
serine phosphorylation of ST AT3 may be required for mitochondrial 
import/retention in addition to an intra-mitochondrial function. 
Phospho-mimetic versions of STAT3 (STAT3s727D and STAT3s272E) 
have also been over expressed in Pl9CL6 cells. STAT3s727D and to a 
lesser extent STAT3s272E are detected in mitochondrial extracts under 
both normoxic and hypoxic conditions (figure 3.34), further validating 
that the serine phosphorylation of ST AT3 is required for import into the 
mitochondrial. Experiments investigating levels of apoptosis and 
mitochondrial A TP production in response to these phospho-mimetic 
mutants have yet to be completed. 
It still remains unclear how STAT3, which lacks a putative 
mitochondrial import signal, can be translocated into mitochondria. It 
may be possible that STAT3 is able to interact and bind to other 
mitochondrial proteins to aid its translocation. Recent studies have 
shown that serine phosphorylated ST AT3 highly co-localises with 
ORIM-19, a known STAT3 binding partner and component of the 
mitochondrial electron transport complex I (Zhou and Too, 2011). In 
addition, studies have also shown that the serine phosphorylation status 
of a protein may enhance its translocation to the mitochondria. Robin 
and colleagues demonstrated using in vivo and in vitro systems, that the 
mitochondrial targeting of OST A4-4, an isoform of glutathione S-
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transferase (GST) is highly dependent on the phosphorylation status of 
the protein. They suggest that phosphorylation increases the affinity of 
the protein for binding to cytoplasmic chaperone Hsp70 as a possible 
basis for its enhanced mitochondrial targeting (Robin et aI., 2003). 
Another chaperone, Hsp90 has also been implicated in cellular 
protection during oxidative stress. Hsp90 has a mitochondrially-
localised paralogue, TRAP 1 that offers protection against oxidative 
stress (Pridgeon et aI., 2007). Kang and colleagues reported that 
mitochondria isolated from a panel of tumour cell lines express 
markedly higher levels of TRAP 1 and Hsp90 when compared to normal 
tissues and that mitochondrial specific inhibitors o,f TRAP 1 (Hsp90 
ATPase antagonists) caused a sudden collapse in mitochondrial 
integrity and apoptosis in selective tumours (Kang et aI., 2007). Sano 
and colleagues have reported a direct interaction between ST A T3 and 
Hsp90. Immunoprecipitation assays demonstrated that Hsp90 directly 
binds to STAT3 via its N-terminal region (Sato et aI., 2003). 
Interestingly, recent studies have shown that STAT3 and Hsp90 interact 
upon stimulation with LIF in cultured mouse embryonic stem (mES) 
(Setati et aI., 2010), yielding a possible explanation to the 
cardioprotective effects observed in this study when P 19CL6 cells pre-
treated with LIF were exposed to hypoxia. The mitochondrial function 
of ST AT3 has also been linked to another heat shock protein, H 11 
kinase/Hsp22 (Hsp22). Qiu and colleagues demonstrated that 
mitochondrial ST AT3 translocation and respiration were significantly 
impaired in Hps22 knockout mice and these mice experienced 
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accelerated heart failure in response to pressure overload (Qiu et aI., 
2011). The potential interaction of ST A T3 with various chaperones and 
their roles in mitochondrial function during oxidative stress warrants 
further investigation. 
Results from this study and prevIOus publications have led to a 
proposed mechanism on how ST AT3 may regulate mitochondrial 
respiration to aid cardiac survival during hypoxia/oxidative stress. 
During cellular stress ST A T3 is an anti-apoptotic factor that works both 
as a signaling molecule involved in the regulation of genes (Levy and 
Lee, 2002, Negoro et aI., 2001, Oshima et aI., 2005) and by modulating 
function of the electron transport chain (Wegrzyn et aI., 2009). Over 
expression of STAT3 in P19CL6 cells during 8h hypoxia leads to the 
rescue of complex VII activities of the ETC. ST A T3 is unlikely to 
influence oxidative phosphorylation directly as it has been reported by 
proteomic analysis that mitochondrial STAT3 is not present in 
stoichiometric amounts when compared to complex VII of the ETC 
(Phillips et aI., 2010). Instead, STAT3 is more likely to act by 
modulating activities of the ETC through non-stoichiometric 
mechanisms. ST AT3 has been shown to influence opening of the 
mitochondrial permeability transition pore (mPTP) in response to 
calcium uptake through protein-protein interactions with cyc10philin D 
(Boengler et aI., 2010). Redox modification of STAT3 may playa part 
in modulating complex VII activity during hypoxia. During this study a 
redox-insensitive form of STAT3, STAT3C3s was able to translocate to 
mitochondria but failed to rescue respiration like exogenous STAT3wt• 
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Ischaemia-reperfusion injury induces oxidative stress via the production 
of reactive oxygen species (Zweier et al., 1987). Increased levels of 
ROS are capable of modulating intracellular redox pathways. In the 
context of STAT3, this can be achieved by the inactivation of protein 
phosphatases by oxidation (Meng et al., 2002, Woetmann et al., 1999) 
or the upregulation of ST A T3 protein kinases including PKC8 leading 
to increased levels of serine phosphorylated ST A T3. In addition 
ST A T3 can be directly modified by ROS to form redox dimers and 
trimers (figure 3.43) (Li et al., 2010), or through interactions with other 
proteins (Xie et al., 2009, Qiu et al., 2011, Setati et al., 2010). 
In a post-ischaemic heart oxygen delivery to the myocardium is not 
sufficient to meet the needs of mitochondrial respiration during the 
physiological conditions of hypoxia, leaving the mitochondrial ETC in 
a mono-reduced state. This results in leakage of electrons from the ETC 
that in turn reacts with molecular oxygen to give superoxide (Ambrosio 
et al., 1993). Over production of ROS in mitochondria also initiates 
inactivation of the ETC (Zhao et al., 2005). Dysfunction of 
mitochondrial respiration and increased ROS production will lead to 
impaired mitochondrial integrity and enhanced levels of apoptosis. 
Data from this study suggest that redox modified, senne 
phosphorylated ST A T3 is required for mitochondrial function and it 
rescues mitochondrial respiration by modulating the activities of 
complex IIII of the ETC during hypoxia. As oxidative phosphorylation 
is maintained through mechanisms involving STAT3, levels of electron 
l e a k a g ~ ~ from the ETC are reduced resulting in less mitochondrial ROS 
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being generated. Recently, Zhou and colleagues demonstrated that 
inactivation of STAT3 leads to suppressIOn of load driven 
mitochondrial activity and ultimately an elevated level of ROS in 
cultured primary osteoblasts (Zhou et al., 2011). This supports the idea 
that mitochondrial STAT3 maintains respiration to prevent the further 
production of ROS that would ultimately lead to apoptosis. 
Mitochondrion 
HYPo:lia/oxidative 
Stress 
Figure 4.1 Proposed model for the role of STAT3 ~ u r i n g g hypoxia-induced 
stress. Hypoxia induced stress causes accumulation of reactive oxygen 
species (ROS) within the cells. Signaling levels of ROS can active kinases 
and inactive phosphatases resulting in the accumulation of serine 
phosphorylated STAT3, which can translocate the mitochondria. Further ROS ' 
production in the mitochondria leads to the redox modification of STAT3 and 
restoration of the electron transport chain (ETC) via complex 1/11- dependant 
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respiration. This results in a reduction in cellular ROS production and 
apoptotic cell death. 
The results from this study have also suggested there may be a switch 
between nuclear and mitochondrial functions of STAT3. During brief 
hypoxia (lh) STAT3 tyrosine phosphorylation and DNA binding are 
apparent which could lead to the transcriptional upregulation of 
antiapoptotic proteins such as Bcl-2 and Mcl-l and antioxidant 
enzymes such as MnSOD to maintain low levels of ROS within the cell 
(figure 4.1) However, during prolonged hypoxia, STAT3 DNA binding 
is abolished (possibly through redox modification) and is accompanied 
by increased serine phosphorylation and a reduction in tyrosine ST A T3 
phosphorylation. This may release a pool of ST AT3 from the nucleus 
making it available to the mitochondria for participation in respiration 
thus, reducing potential devastating mitochondrial ROS production that 
leads to apoptosis (figure 4.1) 
4.7. Concluding remarks 
Thus study sheds light onto how ST AT3 may be regulated in 
cardiomyocytes during hypoxia. By exploring cardiac cell models this 
study indentified clear differences in the susceptibility to hypoxia-
induced apoptosis between the different cell models. RCMs and H9c2 
cells had a high resilience to hypoxic insult, whereas P 19CL6 cells 
were extremely sensitive to hypoxia-induced apoptosis. Due to the fact 
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that apoptotic loss of cardiomyocytes is associated with ischaemic heart 
disease, this study suggests that P 19CL6 cells may offer a useful model 
for investigating mechanisms involving apoptosis in the future. 
However the use of P 19CL6 cells as a cardiac cell model has been 
questioned and warrants further investigation. This study has also 
identified a redox-dependant contribution of mitochondrial STA T3 to 
the survival of cardiomyocytes during hypoxia with the use of the 
redox-insensitive STAT3 mutant STAT3C3s . In addition, preliminary 
data has shed light on one of the potential kinases (PKCo) responsible 
for serine phosphorylation STAT3 in response to hypoxia. Having 
shown is importance ST A T3 to the survival of cardiomyocytes during 
hypoxia; the next step will be to investigate its significance in the heart. 
References 
ABATE, c., PATEL, L., RAUSCHER, F. 1., 3RD & CURRAN, T. (1990) 
Redox regulation of fos and jun DNA-binding activity in vitro. Science, 
249, 1157-61. 
ADACHI, T., WEISBROD, R M., PIMENTEL, D. R, YING, J., SHAROV, 
V. S., SCHONEICH, C. & COHEN, R A. (2004) S-Glutathiolation by 
peroxynitrite activates SERCA during arterial relaxation by nitric 
oxide. Nat Med, 10, 1200-7. 
AKIRA, S., NISHIO, Y., INOUE, M., WANG, X. J., WEI, S., MATSUSAKA, 
T., YOSHIDA, K., SUDO, T., NARUTO, M: & KISHIMOTO, T. 
(1994) Molecular cloning of APRF, a novel IFN-stimulated gene factor 
3 p91-related transcription factor involved in the gp 130-mediated 
signaling pathway. Cell, 77, 63-71. 
ALEXANDER, W. S. (2002) Suppressors of cytokine signalling (SOCS) in the 
immune system. Nat Rev Immunol, 2, 410-6. 
184 
AMBROSIO, G., ZWEIER, J. L., DUILlO, c., KUPPUSAMY, P., 
SANTORO, G., ELlA, P. P., TRITTO, I., CIRILLO, P., 
CONDORELLI, M., CHIARIELLO, M. & ET AL. (1993) Evidence 
that mitochondrial respiration is a source of potentially toxic oxygen 
free radicals in intact rabbit hearts subjected to ischemia and reflow. J 
Bioi Chem, 268, 18532-41. 
ANISIMOV, S. V., TARASOV, K. V., RIORDON, D., WOBUS, A. M. & 
BOHELER, K. R (2002) SAGE identification of differentiation 
responsive genes in P 19 embryonic cells induced to form 
cardiomyocytes in vitro. Mech Dev, 117,25-74. 
ANTUNES, F., MARG, A. & VINKEMEIER, u. (2011) STATI signaling is 
not regulated by a phosphorylation-acetylation switch. Mol Cell Bioi, 
31,3029-37. 
ASHKENAZI, A. & DIXIT, V. M. (1998) Death receptors: signaling and 
modulation. Science, 281, 1305-8. 
AUERNHAMMER, C. J. & MELMED, S. (2001) The central role of SOCS-3 
in integrating the neuro-immunoendocrine interface. J Clin Invest, 108, 
1735-40. 
AZAM, M., ERDJUMENT -BROMAGE, H., KREIDER, B. L., XIA, M., 
QUELLE, F., BASU, R, SARIS, c., TEMPST, P., IHLE, J. N. & 
SCHINDLER, C. (1995) Interleukin-3 signals through mUltiple 
isoforms of Stat5. EMBO J, 14, 1402-11. 
AZIZ, M. H., MANOHARAN, H. T., CHURCH, D. R, DRECKSCHMIDT, 
N. E., ZHONG, W., OBERLEY, T. D., WILDING, G. & VERMA, A. 
K. (2007) Protein kinase Cepsilon interacts with signal transducers and 
activators of transcription 3 (Stat3), phosphorylates Stat3Ser727, and 
regulates its constitutive activation in prostate cancer. Cancer Res, 67, 
8828-38. 
BALABAN, R S., NEMOTO, S. & FINKEL, T. (2005) Mitochondria, 
oxidants, and aging. Cell, 120,483-95. 
BALLINGER, S. W., PATTERSON, C., YAN, C. N., DOAN, R, BUROW, 
D. L., YOUNG, C. G., YAKES, F. M., VAN HOUTEN, B., 
BALLINGER, C. A., FREEMAN, B. A. & RUNGE, M. S. (2000) 
Hydrogen peroxide- and peroxynitrite-induced mitochondrial DNA 
damage and dysfunction in vascular endothelial and smooth muscle 
cells. Circ Res, 86, 960-6. 
BANAl, S., SHWEIKI, D., PINSON, A., CHANDRA, M., LAZAROVICI, G. 
& KESHET, E. (1994) Upregulation of vascular endothelial growth 
factor expression induced by myocardial ischaemia: implications for 
coronary angiogenesis. Cardiovasc Res, 28, 1176-9. 
BARFORD, D. (2004) The role of cysteine residues as redox-sensitive 
regulatory switches. Curr Opin Struct Bioi, 14,679-86. 
185 
BARRY, S. P., TOWNSEND, P. A, MCCORMICK, J., KNIGHT, R. A, 
SCARABELLI, T. M., LATCHMAN, D. S. & STEPHANOU, A. 
(2009) ST AT3 deletion sensitizes cells to oxidative stress. Biochem 
Biophys Res Commun, 385,324-9. 
BA YIR, H. & KAGAN, V. E. (2008) Bench-to-bedside review: Mitochondrial 
injury, oxidative stress and apoptosis--there is nothing more practical 
than a good theory. Crit Care, 12,206. 
BELTRAMI, C. A, FINATO, N., ROCCO, M., FERUGLIO, G. A, 
PURICELLI, C., CIGOLA, E., QUAINI, F., SONNENBLICK, E. H., 
OLIVETTI, G. & ANVERSA, P. (1994) Structural basis of end-stage 
failure in ischemic cardiomyopathy in humans. Circulation, 89, 151-63. 
BLAKE, D. R., ALLEN, R. E. & LUNEC, J. (1987) Free radicals in biological 
systems--a review orientated to inflammatory processes. Br Med Bull, 
43,371-85. 
BOATRIGHT, K. M., RENATUS, M., SCOTT, F. L., SPERANDIO, S., 
SHIN, H., PEDERSEN, I. M., RICCI, 1. E., EDRIS, W. A, 
SUTHERLIN, D. P., GREEN, D. R. & SALVESEN, G. S. (2003) A 
unified model for apical caspase activation. Mol C e l l ~ ~ 11, 529-41. 
BODYAK, N., KANG, P. M., HIROMURA, M., SULIJOADIKUSUMO, I., 
HORIKOSHI, N., KHRAPKO, K. & USHEV A, A (2002) Gene 
expression profiling of the aging mouse cardiac myocytes. Nucleic 
Acids Res, 30,3788-94. 
BOENGLER, K., BUECHERT, A., HEINEN, Y., ROESKES, c., HILFIKER-
KLEINER, D., HEUSCH, G. & SCHULZ, R. (2008a) Cardioprotection 
by ischemic postconditioning is lost in aged and STAT3-deficient mice. 
Circ Res, 102, 131-5. 
BOENGLER, K., HILFIKER-KLEINER, D., DREXLER, H., HEUSCH, G. & 
SCHULZ, R. (2008b) The myocardial JAKIST A T pathway: from 
protection to failure. Pharmacol Ther, 120, 172-85. 
BOENGLER, K., HILFIKER-KLEINER, D., HEUSCH, G. & SCHULZ, R. 
Inhibition of permeability transition pore opening by mitochondrial 
ST A T3 and its role in myocardial ischemialreperfusion. Basic Res 
Cardiol, 105, 771-85. 
BOENGLER, K., HILFIKER-KLEINER, D., HEUSCIJ, G. & SCHULZ, R. 
(2010) Inhibition of permeability transition pore opening by 
mitochondrial ST A T3 and its role in myocardial ischemialreperfusion. 
Basic Res Cardiol, 105, 771-85. 
BONAVITA, F., STEFANELLI, c., GIORDANO, E., COLUMBARO, M., 
FACCHINI, A, BONAFE, F., CALDARERA, C. M. & GUARNIERI, 
c. (2003) H9c2 cardiac myoblasts undergo apoptosis in a model of 
ischemia consisting of serum deprivation and hypoxia: inhibition by 
PMA. FEBS Lett, 536,85-91. 
186 
BOSSIS, G. & MELCHIOR, F. (2006) Regulation of SUMOylation by 
reversible oxidation of SUMO conjugating enzymes. Mol Cell, 21, 349-
57. 
BRILL, A., TORCHINSKY, A., CARP, H. & TODER, V. (1999) The role of 
apoptosis in normal and abnormal embryonic development. J Assist 
Reprod Genet, 16,512-9. 
BROMBERG, J. & DARNELL, J. E., JR. (2000) The role of STATs in 
transcriptional control and their impact on cellular function. Oncogene, 
19,2468-73. 
BROMBERG, 1. F., WRZESZCZYNSKA, M. H., DEVGAN, G., ZHAO, Y., 
PESTELL, R. G., ALBANESE, C. & DARNELL, J. E., JR. (1999) 
Stat3 as an oncogene. Cell, 98,295-303. 
BUEHR, M., MEEK, S., BLAIR, K., YANG, J., URE, J., SILVA, J., MCLAY, 
R., HALL, J., YING, Q. L. & SMITH, A. (2008) Capture of authentic 
embryonic stem cells from rat blastocysts. Cell, 135, 1287-98. 
BURGOYNE, 1. R., MADHANI, M., CUELLO, F., CHARLES, R. L., 
BRENNAN,1. P., SCHRODER, E., BROWNING,.D. D. & EATON, 
P. (2007) Cysteine redox sensor in PKGIa enables oxidant-induced 
activation. Science, 317, 1393-7. 
CALDENHOVEN, E., VAN DIJK, T. B., SOLARI, R., ARMSTRONG, J., 
RAAIJMAKERS,1. A., LAMMERS, 1. W., KOENDERMAN, L. & 
DE GROOT, R. P. (1996) STAT3beta, a splice variant of transcription 
factor ST AT3, is a dominant negative regulator of transcription. J BioI 
Chern, 271, 13221-7. 
CANNON, R. 0., 3RD (1998) Role of nitric oxide in cardiovascular disease: 
focus on the endothelium. Clin Chern, 44, 1809-19. 
CAO, X., TAY, A., GUY, G. R. & TAN, Y. H. (1996) Activation and 
association of Stat3 with Src in v-Src-transformed cell lines. Mol Cell 
BioI, 16, 1595-603. 
CARBALLO, M., CONDE, M., EL BEKA Y, R., MARTIN-NIETO, 1., 
CAMACHO, M. J., MONTESEIRIN, 1., CONDE, 1., BEDOYA, F. J. 
& SOBRINO, F. (1999) Oxidative stress triggers STAT3 tyrosine 
phosphorylation and nuclear translocation in human lymphocytes. J 
BioI Chern, 274, 17580-6. 
CERESA, B. P., HORVATH, C. M. & PESSIN, J. E. (1997) Signal transducer 
and activator of transcription-3 serine phosphorylation by insulin is 
mediated by a Ras/RafIMEK-dependent pathway. Endocrinology, 138, 
4131-7. 
CHAN, K. S., SANO, S., KIGUCHI, K., ANDERS, 1., KOMAZA WA, N., 
TAKEDA,1. & DIGIOVANNI, J. (2004) Disruption of Stat3 reveals a 
187 
critical role in both the initiation and the promotion stages of epithelial 
carcinogenesis. J Clin Invest, 114, 720-8. 
CHAN, R. J., JOHNSON, S. A., LI, Y., YODER, M. C. & FENG, G. S. 
(2003a) A definitive role of Shp-2 tyrosine phosphatase in mediating 
embryonic stem cell differentiation and hematopoiesis. Blood, 102, 
2074-80. 
CHAN, S. L., LEE, M. C., TAN, K. 0., YANG, L. K., LEE, A. S., FLOTOW, 
H., FU, N. Y., BUTLER, M. S., SOEJARTO, D. D., BUSS, A. D. & 
YU, V. C. (2003b) Identification of chelerythrine as an inhibitor of 
BclXL function. J Bioi Chem, 278, 20453-6. 
CHANCE, B., SIES, H. & BOVERIS, A. (1979) Hydroperoxide metabolism in 
mammalian organs. Physiol Rev, 59, 527-605. 
CHANG, L. & KARIN, M. (2001) Mammalian MAP kinase signalling 
cascades. Nature, 410,37-40. 
CHAPMAN, R. S., LOURENCO, P. C., TONNER, E., FLINT, D. J., 
SELBERT, S., TAKEDA, K., AKIRA, S., CLARKE, A. R. & 
WATSON, C. J. (1999) Suppression of epithelial apo_ptosis and delayed 
mammary gland involution in mice with a conditional knockout of 
Stat3. Genes Dev, 13,2604-16. 
CHEN, X., XU, H., YUAN, P., FANG, F., HUSS, M., VEGA, V. B., WONG, 
E., ORLOV, Y. L., ZHANG, W., JIANG, J., LOH, Y. H., YEO, H. c., 
YEO, Z. X., NARANG, V., GOVINDARAJAN, K. R., LEONG, B., 
SHAHAB, A., RUAN, Y., BOURQUE, G., SUNG, W. K., CLARKE, 
N. D., WEI, C. L. & NG, H. H. (2008) Integration of external signaling 
pathways with the core transcriptional network in embryonic stem cells. 
Cell, 133, 1106-17. 
CHILDS, A. C., PHANEUF, S. L., DIRKS, A. 1., PHILLIPS, T. & 
LEEUWENBURGH, C. (2002) Doxorubicin treatment in vivo causes 
cytochrome C release and cardiomyocyte apoptosis, as well as 
increased mitochondrial efficiency, superoxide dismutase activity, and 
Bcl-2:Bax ratio. Cancer Res, 62,4592-8. 
CHINNAIY AN, A. M., O'ROURKE, K., TEWARI, M. & DIXIT, V. M. 
(1995) F ADD, a novel death domain-containing protein, interacts with 
the death domain ofFas and initiates apoptosis. Cell, 81,505-12. 
CHLOPCIKOVA, S., PSOTOVA, J. & MIKETOVA, P. (2001) Neonatal rat 
cardiomyocytes--a model for the study of morphological, biochemical 
and electrophysiological characteristics of the heart. Biomed Pap Med 
Fac Univ Palacky Olomouc Czech Repub, 145,49-55. 
CHOI, S. 0., CHO, Y. S., KIM, H. L. & PARK, J. W. (2007) ROS mediate the 
hypoxic repression of the hepcidin gene by inhibiting C/EBPalpha and 
STAT-.3. Biochem Biophys Res Commun, 356,312-7. 
188 
CHUA, P. 1., YIP, G. W. & BAY, B. H. (2009) Cell cycle arrest induced by 
hydrogen peroxide is associated with modulation of oxidative stress 
related genes in breast cancer cells. Exp Bioi Med (Maywood), 234, 
1086-94. 
CHUNG, C. D., LIAO, J., LIU, B., RAO, x., JAY, P., BERTA, P. & SHUAI, 
K. (1997a) Specific inhibition of Stat3 signal transduction by PIAS3. 
Science, 278, 1803-5. 
CHUNG, 1., UCHIDA, E., GRAMMER, T. C. & BLENIS, J. (1997b) STAT3 
serine phosphorylation by ERK-dependent and -independent pathways 
negatively modulates its tyrosine phosphorylation. Mol Cell Bioi, 17, 
6508-16. 
CLAVIJO, c., CHEN, J. L., KIM, K. J., REYLAND, M. E. & ANN, D. K. 
(2007) Protein kinase Cdelta-dependent and -independent signaling in 
genotoxic response to treatment of desferroxamine, a hypoxia-mimetic 
agent. Am J Physiol Cell Physiol, 292, C2150-60. 
CLA YCOMB, W. C. (1985) Long-term culture and characterization of the 
adult ventricular and atrial cardiac muscle cell. Basic Res Cardiol, 80 
Suppl2, 171-4. 
CLAYCOMB, W. C., LANSON, N. A., JR., STALLWORTH, B. S., 
EGELAND, D. B., DELCARPIO, J. B., BAHINSKI, A. & IZZO, N. J., 
JR. (1998) HL-l cells: a cardiac muscle cell line that contracts and 
retains phenotypic characteristics of the adult cardiomyocyte. Proc Natl 
A cad Sci V S A, 95, 2979-84. 
CORY, S. & ADAMS, J. M. (2002) The Bcl2 family: regulators of the cellular 
life-or-death switch. Nat Rev Cancer, 2,647-56. 
COWAN, D. B., POUTIAS, D. N., DEL NIDO, P. 1. & MCGOWAN, F. X., 
JR. (2000) CD 14-independent activation of cardiomyocyte signal 
transduction by bacterial endotoxin. Am J Physiol Heart Circ Physiol, 
279, H619-29. 
D'AUTREAUX, B. & TOLEDANO, M. B. (2007) ROS as signalling 
molecules: mechanisms that generate specificity in ROS homeostasis. 
Nat Rev Mol Cell Bioi, 8, 813-24 . 
. DALLE-DONNE, I., GIUST ARINI, D., COLOMBO, R., ROSSI, R. & 
MILZANI, A. (2003) Protein carbonylation in human diseases. Trends 
Mol Med, 9, 169-76. 
DANIAL, N. N. & KORSMEYER, S. J. (2004) Cell death: critical control 
points. Cell, 116, 205-19. 
DANIAL, N. N. & ROTHMAN, P. (2000) JAK-STAT signaling activated by 
Abl oncogenes. Oncogene, 19, 2523-31. 
189 
DARNELL, J. E., JR. (1997) STATs and gene regulation. Science, 277, 1630-
5. 
DECKER, T. & KOVARIK, P. (2000) Serine phosphorylation of STATs. 
Oncogene, 19,2628-37. 
DEISSEROTH, A. & DOUNCE, A. L. (1970) Catalase: Physical and chemical 
properties, mechanism of catalysis, and physiological role. Physiol Rev, 
50,319-75. 
DENNIS V. COKKINOS, C. P., GERD HEUSCH (2006) Myocardial 
Ischemia: From Mechanisms to Therapeutic Potential. 
DENU, J. M. & TANNER, K. G. (1998) Specific and reversible inactivation of 
protein tyrosine phosphatases by hydrogen peroxide: evidence for a 
sulfenic acid intermediate and implications for redox regulation. 
Biochemistry, 37,5633-42. 
DING, J. & KOPCHICK, J. J. (2011) Plasma biomarkers of mouse aging. Age 
(Dordr), 33,291-307. 
DODD, R. (2005) ubiquitylation system. IN UBIQUITYLATION (Ed. 
DROESCHER, M., BEGITT, A., MARG, A., ZACHARIAS, M. & 
VINKEMEIER, U. (2010) Cytokine-induced paracrystals prolong the 
activity of signal transducers and activators of transcription (STAT) and 
provide a model for the regulation of protein solubility by small 
ubiquitin-like modifier (SUMO). J Bioi Chem, 286, 18731-46. 
DUILIO, c., AMBROSIO, G., KUPPUSAMY, P., DIPAULA, A., BECKER, 
L. C. & ZWEIER, J. L. (2001) Neutrophils are primary source of 02 
radicals during reperfusion after prolonged myocardial ischemia. Am J 
Physiol Heart Cire Physiol, 280, H2649-57. 
DUNN, S. E. (2000) Insulin-like growth factor I stimulates angiogenesis and 
the production of vascular endothelial growth factor. Growth Horm 
IGF Res, 10 Suppl A, S41-2. 
EEFTING, F., RENSING, B., WIGMAN, 1., PANNEKOEK, W. 1., LIU, W. 
M., CRAMER, M. 1., LIPS, D. J. & DOEVENDANS, P. A. (2004) 
Role ofapoptosis in reperfusion injury. Cardiovasc Res, 61,414-26. 
EHRET, G. B., REICHENBACH, P., SCHINDLER, U., HORVATH, C. M., 
FRITZ, S., NABHOLZ, M. & BUCHER, P. (2001) DNA binding 
specificity of different STAT proteins. Comparison of in vitro 
specificity with natural target sites. J Bioi Chem, 276,6675-88. 
EILERS, A., GEORGELLIS, D., KLOSE, B., SCHINDLER, C., ZIEMIECKI, 
A., HARPUR, A. G., WILKS, A. F. & DECKER, T. (1995) 
Differentiation-regulated serine phosphorylation of STATI promotes 
GAF activation in macrophages. Mol Cell Bioi, 15, 3579-86. 
190 
EPLING-BURNETTE, P. K., LIU, J. H., CATLETT-FALCONE, R., 
TURKSON, J., OSHIRO, M., KOTHAPALLI, R., LI, Y., WANG, J. 
M., YANG-YEN, H. F., KARRAS, J., JOVE, R. & LOUGHRAN, T. 
P., JR. (2001) Inhibition of ST AT3 signaling leads to apoptosis of 
leukemic large granular lymphocytes and decreased Mcl-l expression. 
J Clin Invest, 107,351-62. 
FESTJENS, N., VANDEN BERGHE, T., CORNELIS, S. & 
VANDENABEELE, P. (2007) RIPl, a kinase on the crossroads of a 
cell's decision to live or die. Cell Death Differ, 14,400-10. 
FISCHER, u., JANICKE, R. U. & SCHULZE-OSTHOFF, K. (2003) Many 
cuts to ruin: a comprehensive update of caspase substrates. Cell Death 
Differ, 10, 76-100. 
FOLEY, T. D. & KINTNER, M. E. (2005) Brain PP2A is modified by thiol-
disulfide exchange and intermolecular disulfide formation. Biochem 
Biophys Res Commun, 330, 1224-9. 
FREEMAN, B. A. & CRAPO, J. D. (1982) Biology of disease: free radicals 
and tissue injury. Lab Invest, 47,412-26. 
FRIDOVICH, I. (1983) Superoxide radical: an endogenous toxicant. Annu Rev 
Pharmacol Toxicol, 23,239-57. 
FRIDOVICH, I. (1986) Biological effects of the superoxide radical. Arch 
Biochem Biophys, 247, 1-11. 
FRIED, M. & CROTHERS, D. M. (1981) Equilibria and kinetics of lac 
repressor-operator interactions by polyacrylamide gel electrophoresis. 
Nucleic Acids Res, 9, 6505-25. 
FRYER, R. M., WANG, Y., HSU, A. K. & GROSS, G. J. (2001) Essential 
activation of PKC-delta in opioid-initiated cardioprotection. Am J 
Physiol Heart Orc Physiol, 280, H1346-53. 
FUNAMOTO, M., FUJIO, Y., KUNISADA, K., NEGORO, S., TONE, E., 
OSUGI, T., HIROTA, H., IZUMI, M., YOSHIZAKI, K., WALSH, K., 
KISHIMOTO, T. & Y AMAUCHI-TAKIHARA, K. (2000) Signal 
transducer and activator of transcription 3 is required for glycoprotein 
130-mediated induction of vascular endothelial growth factor in cardiac 
myocytes. J Bioi Chem, 275, 10561-6. 
GARDNER, H. W. (1989) Oxygen radical chemistry of polyunsaturated fatty 
acids. Free Radic Bioi Med, 7, 65-86. 
GARIMORTH, K., WELTE, T. & DOPPLER, W. (1999) Generation of 
carboxy-terminally deleted forms of ST AT5 during preparation of cell 
extracts. Exp Cell Res, 246, 148-51. 
GARNER, M. M. & REVZIN, A. (1981) A gel electrophoresis method for 
quantifying the binding of proteins to specific DNA regIOns: 
191 
application to components of the Escherichia coli lactose operon 
regulatory system. Nucleic Acids Res, 9,3047-60. 
GARTSBEIN, M., ALT, A., HASHIMOTO, K., NAKAJIMA, K., KUROKl, 
T. & TENNENBAUM, T. (2006) The role of protein kinase C delta 
activation and STAT3 Ser727 phosphorylation in insulin-induced 
keratinocyte proliferation. J Cell Sci, 119, 470-81. 
GEISZT, M. & LETO, T. L. (2004) The Nox family of NAD(P)H oxidases: 
host defense and beyond. J BioI Chern, 279, 51715-8. 
GHOSH, S., PULINILKUNNIL, T., YUEN, G., KEWALRAMANI, G., AN, 
D., QI, D., ABRAHANI, A. & RODRIGUES, B. (2005) 
Cardiomyocyte apoptosis induced by short-term diabetes requires 
mitochondrial GSH depletion. Am J Physiol Heart Circ Physiol, 289, 
H768-76. 
GHOSH, S., TING, S., LAU, H., PULINILKUNNIL, T., AN, D., QI, D., 
ABRAHANI, M. A. & RODRIGUES, B. (2004) Increased efflux of 
glutathione conjugate in acutely diabetic cardiomyocytes. Can J 
Physiol Pharmacol, 82,879-87. 
GIESE, B., RODERBURG, C., SOMMERAUER, M., WORTMANN, S. B., 
METZ, S., HEINRICH, P. C. & MULLER-NEWEN, G. (2005) 
Dimerization of the cytokine receptors gp 130 and LIFR analysed in 
single cells. J Cell Sci, 118, 5129-40. 
GOLDSTEIN, B. J., MAHADEV, K. & WU, X. (2005) Redox paradox: 
insulin action is facilitated by insulin-stimulated reactive oxygen 
species with multiple potential signaling targets. Diabetes, 54, 311-21. 
GONG, J., TRAGANOS, F. & DARZYNKIEWICZ, Z. (1994) A selective 
procedure for DNA extraction from apoptotic cells applicable for gel 
electrophoresis and flow cytometry. Anal Biochem, 218,314-9. 
GONZALEZ, F. A., RADEN, D. L. & DAVIS, R. J. (1991) Identification of 
substrate recognition determinants for human ERKI and ERK2 protein 
kinases. J BioI Chern, 266,22159-63. 
GOTTLIEB, R. A., BURLESON, K. 0., KLONER, R. A., BABIOR, B. M. & 
ENGLER, R. L. (1994) Reperfusion injury induces apoptosis in rabbit 
cardiomyocytes. J Clin Invest, 94, 1621-8. 
GREGORIO, C. C. & ANTIN, P. B. (2000) To the heart of myofibril 
assembly. Trends Cell BioI, 10, 355-62. 
GRUNDY, S. M., BENJAMIN, I. J., BURKE, G. L., CHAIT, A., ECKEL, R. 
H., HOWARD, B. V., MITCH, W., SMITH, S. c., JR. & SOWERS, J. 
R. (1999) Diabetes and cardiovascular disease: a statement for 
healthcare professionals from the American Heart Association. 
Circulation, 100, 1134-46. 
192 
GUEHMANN, S., VORBRUEGGEN, G., KALKBRENNER, F. & 
MOELLlNG, K. (1992) Reduction of a conserved Cys is essential for 
Myb DNA-binding. Nucleic Acids Res, 20,2279-86. 
HAANEN, C. & VERMES, 1. (1995) Apoptosis and inflammation. Mediators 
Inflamm, 4,5-15. 
HABARA-OHKUBO, A. (1996) Differentiation of beating cardiac muscle 
cells from a derivative of P 19 embryonal carcinoma cells. Cell Struet 
Funet, 21, 101-10. 
HAHN, H. S., YUSSMAN, M. G., TOYOKAWA, T., MARREEZ, Y., 
BARRETT, T. J., HILTY, K. C., OSINSKA, H., ROBBINS, J. & 
DORN, G. W., 2ND (2002) Ischemic protection and myofibrillar 
cardiomyopathy: dose-dependent effects of in vivo deitaPKC 
inhibition. Cire Res, 91, 741-8. 
HENGARTNER, M. O. & HORVITZ, H. R. (1994) Programmed cell death in 
Caenorhabditis elegans. Curr Opin Genet Dev, 4, 581-6. 
HENZE, K. & MARTIN, W. (2003) Evolutionary biology: essence of 
mitochondria. Nature, 426, 127-8. 
HESCHELER, J., FLEISCHMANN, B. K., WARTENBERG, M., BLOCH, 
W., KOLOSSOV, E., JI, G., ADDICKS, K. & SAUER, H. (1999) 
Establishment of ionic channels and signalling cascades in the 
embryonic stem cell-derived primitive endoderm and cardiovascular 
system. Cells Tissues Organs, 165, 153-64. 
HESCHELER, J., MEYER, R., PLANT, S., KRAUTWURST, D., 
ROSENTHAL, W. & SCHULTZ, G. (1991) Morphological, 
biochemical, and electrophysiological characterization of a clonal cell 
(H9c2) line from rat heart. Cire Res, 69, 1476-86. 
HILFIKER-KLEINER, D., HILFIKER, A, FUCHS, M., KAMINSKI, K., 
SCHAEFER, A, SCHIEFFER, B., HILLMER, A., SCHMIEDL, A, 
DING, Z., PODEWSKI, E., POLl, V., SCHNEIDER, M. D., SCHULZ, 
R., PARK, J. K., WOLLERT, K. C. & DREXLER, H. (2004) Signal 
transducer and activator of transcription 3 is required for myocardial 
capillary growth, control of interstitial matrix deposition, and heart 
protection from ischemic injury. Cire Res, 95, 187-95. 
HO, AS., LlU, Y., KHAN, T. A, HSU, D. H., BAZAN, J. F. & MOORE, K. 
W. (1993) A receptor for interleukin 10 is related to interferon 
receptors. Proe Natl Aead Sci USA, 90, 11267-71. 
HOEY, T., ZHANG, S., SCHMIDT, N., YU, Q., RAMCHANDANI, S., XU, 
X., NAEGER, L. K., SUN, Y. L. & KAPLAN, M. H. (2003) Distinct 
requirements for the naturally occurring splice forms Stat4alpha and 
Stat4beta in IL-12 responses. EMBO J, 22,4237-48. 
193 
HORIUCHI, H., TATEGAKI, A., YAMASHITA, Y., HISAMATSU, H., 
OGAWA, M., NOGUCHI, T., AOSASA, M., KAWASHIMA, T., 
AKITA, S., NISHIMICHI, N., MITSUI, N., FURUSAWA, S. & 
MATSUDA, H. (2004) Chicken leukemia inhibitory factor maintains 
chicken embryonic stem cells in the undifferentiated state. J BioI Chern, 
279, 24514-20. 
HORVATH, C. M., WEN, Z. & DARNELL, J. E., JR. (1995) A STAT protein 
domain that determines DNA sequence recognition suggests a novel 
DNA-binding domain. Genes Dev, 9, 984-94. 
HOU, 1., SCHINDLER, U., HENZEL, W. 1., HO, T. C., BRASSEUR, M. & 
MCKNIGHT, S. L. (1994) An interleukin-4-induced transcription 
factor: IL-4 Stat. Science, 265, 1701-6. 
HOUWELING, A. c., SOMI, S., MAS SINK, M. P., GROENEN, M. A., 
MOORMAN, A. F. & CHRISTOFFELS, V. M. (2005) Comparative 
analysis of the natriuretic peptide precursor gene cluster in vertebrates 
reveals loss of ANF and retention of CNP-3 in chicken. Dev Dyn, 233, 
1076-82. 
HUDLICKA, O. & BROWN, M. D. (1996) Postnatal growth of the heart and 
its blood vessels. J Vasc Res, 33,266-87. 
HUMPHREY, R. K., BEATTIE, G. M., LOPEZ, A. D., BUCAY, N., KING, 
C. C., FIRPO, M. T., ROSE-JOHN, S. & HAYEK, A. (2004) 
Maintenance of pluripotency in human embryonic stem cells is STA T3 
independent. Stem Cells, 22,522-30. 
HUNTER, 1. J. & CHIEN, K. R. (1999) Signaling pathways for cardiac 
hypertrophy and failure. N Engl J Med, 341, 1276-83. 
HUNTER, T. (2000) Signaling--2000 and beyond. Cell, 100, 113-27. 
HUSSAIN, S. P., AGUILAR, F. & CERUTTI, P. (1994) Mutagenesis of codon 
248 of the human p53 tumor suppressor gene by N-ethyl-N-nitrosourea. 
Oncogene, 9, 13-8. 
HUTCHISON, K. A., MA TIC, G., MESHINCHI, S., BRESNICK, E. H. & 
PRATT, W. B. (1991) Redox manipulation of DNA binding activity 
and BuGR epitope reactivity of the glucocorticoid receptor. J BioI 
Chern, 266, 10505-9. 
IEMITSU, M., MIY AUCHI, T., MAEDA, S., SAKAI, S., KOBAYASHI, T., 
FUJII, N., MIYAZAKI, H., MATSUDA, M. & YAMAGUCHI, I. 
(2001) Physiological and pathological cardiac hypertrophy induce 
different molecular phenotypes in the rat. Am J Physiol Regul Integr 
Comp Physiol, 281, R2029-36. 
INAGAKI, K., HAHN, H. S., DORN, G. W., 2ND & MOCHLY-ROSEN, D. 
(2003). Additive protection of the ischemic heart ex vivo by combined 
194 
treatment with delta-protein kinase C inhibitor and epsilon-protein 
kinase C activator. Circulation, 108,869-75. 
ITOH, G., TAMURA, J., SUZUKI, M., SUZUKI, Y., IKEDA, H., KOIKE, M., 
NOMURA, M., JIE, T. & ITO, K. (1995) DNA fragmentation of 
human infarcted myocardial cells demonstrated by the nick end labeling 
method and DNA agarose gel electrophoresis. Am J Pathol, 146, 1325-
31. 
IVAN, M., KONDO, K., YANG, H., KIM, W., V ALIANDO, J., OHH, M., 
SALIC, A., ASARA, 1. M., LANE, W. S. & KAELIN, W. G., JR. 
(2001) HIFalpha targeted for VHL-mediated destruction by proline 
hydroxylation: implications for 02 sensing. Science, 292, 464-8. 
JACOBY, J. J., KALINOWSKI, A., LIU, M. G., ZHANG, S. S., GAO, Q., 
CHAI, G. x., JI, L., IWAMOTO, Y., LI, E., SCHNEIDER, M., 
RUSSELL, K. S. & FU, X. Y. (2003) Cardiomyocyte-restricted 
knockout of ST AT3 results in higher sensitivity to inflammation, 
cardiac fibrosis, and heart failure with advanced age. Proc Natl Acad 
Sci USA, 100, 12929-34. 
JAIN, N., ZHANG, T., FONG, S. L., LIM, C. P. &. CAO, X. (1998) 
Repression of Stat3 activity by activation of mitogen-activated protein 
kinase (MAPK). Oncogene, 17,3157-67. 
JAIN, N., ZHANG, T., KEE, W. H., LI, W. & CAO, X. (1999) Protein kinase 
C delta associates with and phosphorylates Stat3 in an interleukin-6-
dependent manner. J Bioi Chem, 274, 24392-400. 
JARRETA, D., ORUS, J., BARRIENTOS, A., MIRO, 0., ROIG, E., HERAS, 
M., MORAES, C. T., CARDELLACH, F. & CASADEMONT, J. 
(2000) Mitochondrial function in heart muscle from patients with 
idiopathic dilated cardiomyopathy. Cardiovasc Res, 45,860-5. 
JEREMIAS, I., KUPATT, C., MARTIN-VILLALBA, A., HABAZETTL, H., 
SCHENKEL, 1., BOEKSTEGERS, P. & DEBATIN, K. M. (2000) 
Involvement of CD95/Apol/Fas in cell death after myocardial 
ischemia. Circulation, 102,915-20. 
JIANG, B. H., SEMENZA, G. L., BAUER, C. & MARTI, H. H. (1996) 
Hypoxia-inducible factor 1 levels vary exponentially over a 
physiologically relevant range of 02 tension. Am J Physiol, 271, 
C1172-80. 
JOHN, S., VINKEMEIER, U., SOLDAINI, E., DARNELL, 1. E., JR. & 
LEONARD, W. 1. (1999) The significance of tetramerization in 
promoter recruitment by Stat5. Mol Cell Bioi, 19, 1910-8. 
KABIR, A. M., CLARK, J. E., TANNO, M., CAO, X., HOTHERSALL, 1. S., 
DASHNY AM, S., GOROG, D. A., BELLAHCENE, M., SHATTOCK, 
M. J. {k. MARBER, M. S. (2006) Cardioprotection initiated by reactive 
195 
oxygen species is dependent on activation of PKCepsilon. Am J Physiol 
Heart Circ Physiol, 291, HI893-9. 
KANG, B. H., PLESCIA, J., DOHI, T., ROSA, J., DOXSEY, S. J. & 
ALTIERI, D. C. (2007) Regulation of tumor cell mitochondrial 
homeostasis by an organelle-specific Hsp90 chaperone network. Cell, 
131,257-70. 
KANG, S. H., YU, M. 0., PARK, K. 1., CHI, S. G., PARK, D. H. & CHUNG, 
y. G. (2010) Activated STAT3 regulates hypoxia-induced angiogenesis 
and cell migration in human glioblastoma. Neurosurgery, 67, 1386-95; 
discussion 1395. 
KANTHASAMY, A. G., KITAZAWA, M., KANTHASAMY, A. & 
ANANTHARAM, v. (2003) Role of proteolytic activation of protein 
kinase Cdelta in oxidative stress-induced apoptosis. Antioxid Redox 
Signal, 5, 609-20. 
KATZ (2006) Physiology of the heart. 4th Edition, Lippincott Williams and 
Wilkins. 
KERR, J. F. (1965) A histochemical study of hypertrophy and ischaemic injury 
of rat liver with special reference to changes in lysosomes. J Pathol 
Bacteriol, 90,419-35. 
KERR, J. F., WYLLIE, A. H. & CURRIE, A. R. (1972) Apoptosis: a basic 
biological phenomenon with wide-ranging implications in tissue 
kinetics. Br J Cancer, 26,239-57. 
KHODADADI, P., MERSINIAS, THUMSER (2010) Applicability of the 
P 19CL6 cells as a model of cardiomyocytes - a transcriptome analysis. 
Health, 2, 24-32. 
KIDDER, B. L., YANG, 1. & PALMER, S. (2008) Stat3 and c-Myc genome-
wide promoter occupancy in embryonic stem cells. PLoS One, 3, 
e3932. 
KIM, H. 1., KIM, J. H., SHIN, Y. K., LEE, S. I. & AHN, K. M. (2009) A novel 
mutation in the linker domain of the signal transducer and activator of 
transcription 3 gene, p.Lys531Glu, in hyper-IgE syndrome. J Allergy 
CUn lmmunol, 123,956-8. 
KIM, J. H., PARK, S. H., PARK, S. G., CHOI, J. S., XIA, Y. & SUNG, J. H. 
(2011) The Pivotal Role of Reactive Oxygen Species Generation in the 
Hypoxia-Induced Stimulation of Adipose-Derived Stem Cells. Stem 
Cells Dev. 
KIM, T. K. & MANIATIS, T. (1996) Regulation of interferon-gamma-
activated STATI by the ubiquitin-proteasome pathway. Science, 273, 
1717-9. 
196 
KIMES, B. W. & BRANDT, B. L. (1976) Properties of a clonal muscle cell 
line from rat heart. Exp Cell Res, 98,367-81. 
KISCHKEL, F. C., HELLBARDT, S., BEHRMANN, I., GERMER, M., 
PAWLITA, M., KRAMMER, P. H. & PETER, M. E. (1995) 
Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a 
death-inducing signaling complex (DISC) with the receptor. EMBO J, 
14,5579-88. 
KLATT, P. & LAMAS, S. (2000) Regulation of protein function by S-
glutathiolation in response to oxidative and nitrosative stress. Eur J 
Biochern, 267,4928-44. 
KLINGMULLER, U., LORENZ, U., CANTLEY, L. C., NEEL, B. G. & 
LODISH, H. F. (1995) Specific recruitment of SH-PTP1 to the 
erythropoietin receptor causes inactivation of JAK2 and termination of 
proliferative signals. Cell, 80, 729-38. 
KORZUS, E., TORCHIA, J., ROSE, D. W., XU, L., KUROKA WA, R., 
MCINERNEY, E. M., MULLEN, T. M., GLASS, C. K. & 
ROSENFELD, M. G. (1998) Transcription factor-specific requirements 
for coactivators and their acetyltransferase functions .. Science, 279, 703-
7. 
KOTAMRAJU, S., KONOREV, E. A., JOSEPH, 1. & KALYANARAMAN, 
B. (2000) Doxorubicin-induced apoptosis in endothelial cells and 
cardiomyocytes is ameliorated by nitrone spin traps and ebselen. Role 
of reactive oxygen and nitrogen species. J BioI Chern, 275,33585-92. 
KRAMER, O. H., BAUS, D., KNAUER, S. K., STEIN, S., JAGER, E., 
STAUBER, R. H., GREZ, M., PFITZNER, E. & HEINZEL, T. (2006) 
Acetylation of Statl modulates NF-kappaB activity. Genes Dev, 20, 
473-85. 
KRAMER, O. H., KNAUER, S. K., GREINER, G., JANDT, E., 
REICHARDT, S., GUHRS, K. H., STAUBER, R. H., BOHMER, F. D. 
& HEINZEL, T. (2009) A phosphorylation-acetylation switch regulates 
STAT1 signaling. Genes Dev, 23,223-35. 
KREBS, D. L. & HILTON, D. 1. (2000) SOCS: physiological suppressors of 
cytokine signaling. J Cell Sci, 113 (Pt 16),2813-9. 
KREUZALER, P. A., STANISZEWSKA, A. D., LI, ·W., OMIDV AR, N., 
KEDJOUAR, B., TURKSON, 1., POLl, V., FLAVELL, R. A., 
CLARKSON, R. W. & WATSON, c. J. (2011) Stat3 controls 
lysosomal-mediated cell death in vivo. Nat Cell BioI, 13,303-9. 
KROEMER, G., EL-DEIRY, W. S., GOLSTEIN, P., PETER, M. E., VAUX, 
D., V ANDENABEELE, P., ZHIVOTOVSKY, B., 
BLAGOSKLONNY, M. V., MALORNI, W., KNIGHT, R. A., 
PIACENTINI, M., NAGATA, S. & MELINO, G. (2005) Classification 
197 
of cell death: recommendations of the Nomenclature Committee on 
Cell Death. Cell Death Differ, 12 Suppl2, 1463-7. 
KUKREJA, R. C. & HESS, M. L. (1992) The oxygen free radical system: from 
equations through membrane-protein interactions to cardiovascular 
injury and protection. Cardiovasc Res, 26,641-55. 
KUNISADA, K., NEGORO, S., TONE, E., FUNAMOTO, M., OSUGI, T., 
YAMADA, S., OKABE, M., KISHIMOTO, T. & Y AMAUCHI-
TAKIHARA, K. (2000) Signal transducer and activator of transcription 
3 in the heart transduces not only a hypertrophic signal but a protective 
signal against doxorubicin-induced cardiomyopathy. Proc Natl Acad 
Sci USA, 97,315-9. 
KWON, S. H., PIMENTEL, D. R., REMONDINO, A., SAWYER, D. B. & 
COLUCCI, W. S. (2003) H(2)O(2) regulates cardiac myocyte 
phenotype via concentration-dependent activation of distinct kinase 
pathways. J Mol Cell Cardia I, 35,615-21. 
LAHTEENVUO, 1. E., LAHTEENVUO, M. T., KIVELA, A., ROSENLEW, 
C., FALKEVALL, A., KLAR, J., HEIKURA, T., RISSANEN, T. T., 
V AHAKANGAS, E., KORPISALO, P., ENHOLM, B., CARMELIET, 
P., ALITALO, K., ERIKSSON, U. & YLA-HERTTUALA, S. (2009) 
Vascular endothelial growth factor-B induces myocardium-specific 
angiogenesis and arteriogenesis via vascular endothelial growth factor 
receptor-l- and neuropilin receptor-I-dependent mechanisms. 
Circulation, 119, 845-56. 
LAMB, P., SEIDEL, H. M., HASLAM, J., MILOCCO, L., KESSLER, L. V., 
STEIN, R. B. & ROSEN, 1. (1995) STAT protein complexes activated 
by interferon-gamma and gp 130 signaling molecules differ in their 
sequence preferences and transcriptional induction properties. Nucleic 
Acids Res, 23,3283-9. 
LAUGWITZ, K. L., MORETTI, A., WEIG, H. J., GILLITZER, A., 
PINKERNELL, K., OTT, T., PRAGST, I., ST ADELE, C., 
SEYFARTH, M., SCHOMIG, A. & UNGERER, M. (2001) Blocking 
caspase-activated apoptosis improves contractility in failing 
myocardium. Hum Gene Ther, 12,2051-63. 
LEE, C., PIAZZA, F., BRUTSAERT, S., VALENS, J., STREHLOW, I., 
JAROSINSKI, M., SARIS, C. & SCHINDLER, c. (1999) 
Characterization of the Stat5 protease. J Bioi Chern, 274,26767-75. 
LEVY, D. E. & DARNELL, J. E., JR. (2002) Stats: transcriptional control and 
biological impact. Nat Rev Mol Cell Bioi, 3, 651-62. 
LEVY, D. E. & LEE, c. K. (2002) What does Stat3 do? J Clin Invest, 109, 
1143-8. 
198 
LI, H., ZHU, H., XU, C. 1. & YUAN, J. (1998) Cleavage of BID by caspase 8 
mediates the mitochondrial damage in the Fas pathway of apoptosis. 
Cell, 94, 491-501. 
LI, L., CHEUNG, S. H., EVANS, E. L. & SHAW, P. E. Modulation of gene 
expression and tumor cell growth by redox modification of STAT3. 
Cancer Res, 70, 8222-32. 
LI, L., CHEUNG, S. H., EVANS, E. L. & SHAW, P. E. (2010) Modulation of 
gene expression and tumor cell growth by redox modification of 
STAT3. Cancer Res, 70,8222-32. 
LI, L. & SHAW, P. E. (2006) Elevated activity of STAT3C due to higher DNA 
binding affinity of phosphotyrosine dimer rather than covalent dimer 
formation. J BioI Chern, 281, 33172-81. 
LI, P., NI1HAWAN, D., BUDIHARDJO, I., SRINIVASULA, S. M., AHMAD, 
M., ALNEMRI, E. S. & WANG, X. (1997a) Cytochrome c and dATP-
dependent formation of Apaf-llcaspase-9 complex initiates an 
apoptotic protease cascade. Cell, 91,479-89. 
LI, W., ZHANG, J., BOTTARO, D. P. & PIERCE, J. H. (1997b) Identification 
of serine 643 of protein kinase C-delta as an important 
autophosphorylation site for its enzymatic activity. J BioI Chern, 272, 
24550-5. 
LI, Y., HUANG, T. T., CARLSON, E. J., MELOV, S., URSELL, P. C., 
OLSON, J. L., NOBLE, L. J., YOSHIMURA, M. P., BERGER, c., 
CHAN, P. H., WALLACE, D. C. & EPSTEIN, c. J. (1995) Dilated 
cardiomyopathy and neonatal lethality in mutant mice lacking 
manganese superoxide dismutase. Nat Genet, 11,376-81. 
LI, Y., ZHANG, H., LlAO, W., SONG, Y., MA, X., CHEN, C., LU, Z., LI, Z. 
& ZHANG, Y. (2011) Transactivated EGFR mediates alpha-AR-
induced ST AT3 activation and cardiac hypertrophy. Arn J Physiol 
Heart Circ Physiol, 301, H1941-51. 
LIM, C. P. & CAO, X. (1999) Serine phosphorylation and negative regulation 
of Stat3 by JNK. J BioI Chern, 274, 31055-61. 
LIM, H., FALLAVOLLlTA, 1. A., HARD, R., KERR, C. W. & CANTY, 1. 
M., JR. (1999) Profound apoptosis-mediated regional myocyte loss and 
compensatory hypertrophy in pigs with hibernating myocardium. 
Circulation, 100, 2380-6. 
LIPPI, G., FRANCHINI, M. & TARGHER, G. (2011) Arterial thrombus 
formation in cardiovascular disease. Nat Rev Cardiol, 8,502-12. 
LlU, B., LIAO, J., RAO, X., KUSHNER, S. A., CHUNG, C. D., CHANG, D. 
D. & SHUAI, K. (1998) Inhibition of Statl-mediated gene activation by 
P I A S ~ . . Proc Natl Acad Sci USA, 95, 10626-31. 
199 
LIU, G. S., THORNTON, J., VAN WINKLE, D. M., STANLEY, A. W., 
OLSSON, R. A. & DOWNEY, J. M. (1991) Protection against 
infarction afforded by preconditioning is mediated by A 1 adenosine 
receptors in rabbit heart. Circulation, 84, 350-6. 
LIU, M., ZHANG, P., CHEN, M., ZHANG, W., YU, L., YANG, X. C. & 
FAN, Q. (2011) Aging might increase myocardial ischemia / 
reperfusion-induced apoptosis in humans and rats. Age (Dordr). 
LIU, X., KIM, C. N., YANG, 1., JEMMERSON, R. & WANG, X. (1996) 
Induction of apoptotic program in cell-free extracts: requirement for 
dATP and cytochrome c. Cell, 86, 147-57. 
LOSCHEN, G., AZZI, A., RICHTER, C. & FLOHE, L. (1974) Superoxide 
radicals as precursors of mitochondrial hydrogen peroxide. FEBS Lett, 
42,68-72. 
LOSCHEN, G., FLOHE, L. & CHANCE, B. (1971) Respiratory chain linked 
H(2)O(2) production in pigeon heart mitochondria. FEBS Lett, 18, 261-
264. 
LU, Y., ZHOU, J., XU, C., LIN, H., XIAO, J., WANG, Z. & YANG, B. (2008) 
JAKISTAT and PI3K1 AKT pathways form a mutual transactivation 
loop and afford resistance to oxidative stress-induced apoptosis in 
cardiomyocytes. Cell Physio/ Biochem, 21,305-14. 
LUO, X., BUDIHARDJO, I., ZOU, H., SLAUGHTER, C. & WANG, X. 
(1998) Bid, a Bel2 interacting protein, mediates cytochrome c release 
from mitochondria in response to activation of cell surface death 
receptors. Cell, 94, 481-90. 
MACMILLAN-CROW, L. A., CROW, J. P. & THOMPSON, J. A. (1998) 
Peroxynitrite-mediated inactivation of manganese superoxide dismutase 
involves nitration and oxidation of critical tyrosine residues. 
Biochemistry, 37, 1613-22. 
MAK, T. W. & YEH, W. C. (2002) Signaling for survival and apoptosis in the 
immune system. Arthritis Res, 4 Suppl 3, S243-52. 
MARIN-GARCIA, J. & GOLDENTHAL, M. 1. (2002) Understanding the 
impact of mitochondrial defects in cardiovascular disease: a review. J 
Card Fail, 8,347-61. 
MARRERO, M. B., SCHIEFFER, B., PAXTON, W. G., HEERDT, L., BERK, 
B. c., DELAFONTAINE, P. & BERNSTEIN, K. E. (1995) Direct 
stimulation of Jak/STAT pathway by the angiotensin II ATI receptor. 
Nature, 375,247-50. 
MARTIN, M. E., CHINENOV, Y., YU, M., SCHMIDT, T. K. & YANG, X. 
Y. (1996) Redox regulation ofGA-binding protein-alpha DNA binding 
activity. J Bioi Chem, 271,25617-23. 
200 
MARZETTI, E., HWANG, J. C., LEES, H. A., WOHLGEMUTH, S. E., 
DUPONT-VERSTEEGDEN, E. E., CARTER, C. S., BERNABEI, R. 
& LEEUWENBURGH, C. (2009) Mitochondrial death effectors: 
relevance to sarcopenia and disuse muscle atrophy. Biochim Biophys 
Acta, 1800, 235-44. 
MATSUMOTO, A., MASUHARA, M., MITSUI, K., YOKOUCHI, M., 
OHTSUBO, M., MISAWA, H., MIYAJIMA, A. & YOSHIMURA, A. 
(1997) CIS, a cytokine inducible SH2 protein, is a target of the JAK-
ST AT5 pathway and modulates ST AT5 activation. Blood, 89, 3148-54. 
MATTA, c., JUHASZ, T., SZIJGYARTO, Z., KOLOZSVARI, B., 
SOMOGYI, C., NAGY, G., GERGELY, P. & ZAKANY, R. (2011) 
PKCdelta is a positive regulator of chondrogenesis in chicken high 
density micromass cell cultures. Biochimie, 93, 149-59. 
MATTSON, M. P. (2000) Apoptosis in neurodegenerative disorders. Nat Rev 
Mol Cell Bioi, 1, 120-9. 
MAYR, M., METZLER, B., CHUNG, Y. L., MCGREGOR, E., MAYR, U., 
TROY, H., HU, Y., LEITGES, M., PAC HINGER, 0., GRIFFITHS, J. 
R., DUNN, M. J. & XU, Q. (2004) Ischemh:; preconditioning 
exaggerates cardiac damage in PKC-delta null mice. Am J Physiol 
Heart Circ Physiol, 287, H946-56. 
MCBRIDE, H. M., NEUSPIEL, M. & W ASIAK, S. (2006) Mitochondria: 
more than just a powerhouse. Curr Bioi, 16, R551-60. 
MCDONALD, C. & REICH, N. C. (1999) Cooperation of the transcriptional 
coactivators CBP and p300 with Stat6. J Interferon Cytokine Res, 19, 
711-22. 
MCGILL, H. c., JR., MCMAHAN, C. A., HERDERICK, E. E., ZIESKE, A. 
W., MALCOM, G. T., TRACY, R. E. & STRONG, J. P. (2002) 
Obesity accelerates the progression of coronary atherosclerosis in 
young men. Circulation, 105,2712-8. 
MCNEILL, L. A., HEWITSON, K. S., GLEADLE, J. M., HORSFALL, L. E., 
OLDHAM, N. 1., MAXWELL, P. H., PUGH, C. W., RATCLIFFE, P. 
1. & SCHOFIELD, C. J. (2002) The use of dioxygen by HIF prolyl 
hydroxylase (PHD1). Bioorg Med Chem Lett, 12, 1547-50. 
MCWHINNEY, C. D., HUNT, R. A., CONRAD, K. M., DOSTAL, D. E. & 
BAKER, K. M. (1997) The type I angiotensin II receptor couples to 
Stat! and Stat3 activation through Jak2 kinase in neonatal rat cardiac 
myocytes. J Mol Cell Cardiol, 29,2513-24. 
MEDICALSYMPTOMSGUIDE (2009) Atherosclerosis symptoms. 
MELLOR, H. & PARKER, P. 1. (1998) The extended protein kinase C 
s u p e r ~ a m i l y . . Biochem J, 332 (Pt 2),281-92. 
201 
MENG, T. c., FUKADA, T. & TONKS, N. K. (2002) Reversible oxidation 
and inactivation of protein tyrosine phosphatases in vivo. Mol Cell, 9, 
387-99. 
MEYER, T., MARG, A, LEMKE, P., WIESNER, B. & VINKEMEIER, U. 
(2003) DNA binding controls inactivation and nuclear accumulation of 
the transcription factor Stat1. Genes Dev, 17, 1992-2005. 
MINEGISHI, Y., SAITO, M., TSUCHIYA, S., TSUGE, I., TAKADA, H., 
HARA, T., KAWAMURA, N., ARIGA, T., PASIC, S., STOJKOVIC, 
0., METIN, A. & KARASUYAMA, H. (2007) Dominant-negative 
mutations in the DNA-binding domain of STAT3 cause hyper-IgE 
syndrome. Nature, 448, 1058-62. 
MOCANU, M. M., BELL, R. M. & YELLON, D. M. (2002) PI3 kinase and 
not p42/p44 appears to be implicated in the protection conferred by 
ischemic preconditioning. J Mol Cell Cardia I, 34,661-8. 
MOWEN, K. A., TANG, 1., ZHU, W., SCHURTER, B. T., SHUAI, K., 
HERSCHMAN, H. R. & DAVID, M. (2001) Arginine methylation of 
STAT 1 modulates IFN alphalbeta-induced transcription. Cell, 104, 731-
41. 
MUI, A L., WAKAO, H., O'FARRELL, A M., HARADA, N. & MIYAJIMA, 
A (1995) Interleukin-3, granulocyte-macrophage colony stimulating 
factor and interleukin-5 transduce signals through two STAT5 
homologs. EMBO J, 14, 1166-75. 
MURPHY, M. P. (2009) How mitochondria produce reactive oxygen species. 
Biochem J, 417, 1-13. 
MURRIEL, C. L., CHURCHILL, E., INAGAKI, K., SZWEDA, L. I. & 
MOCHLY-ROSEN, D. (2004) Protein kinase Cdelta activation induces 
apoptosis in response to cardiac ischemia and reperfusion damage: a 
mechanism involving BAD and the mitochondria. J Bioi Chem, 279, 
47985-91. 
MURRY, C. E., JENNINGS, R. B. & REIMER, K. A (1986) Preconditioning 
with ischemia: a delay of lethal cell injury in ischemic myocardium. 
Circulation, 74, 1124-36 . 
. NAKA, T., NARAZAKI, M., HIRATA, M., MATSUMOTO, T., 
MINAMOTO, S., AONO, A, NISHIMOTO, N.:KAJITA, T., TAGA, 
T., YOSHIZAKI, K., AKIRA, S. & KISHIMOTO, T. (1997) Structure 
and function of a new STAT-induced STAT inhibitor. Nature, 387, 
924-9. 
NAKAJIMA, K., YAMANAKA, Y., NAKAE, K., KOJIMA, H., ICHIBA, M., 
KIUCHI, N., KITAOKA, T., FUKADA, T., HIBI, M. & HIRANO, T. 
(1996) A central role for Stat3 in IL-6-induced regulation of growth and 
d i f f e r ~ n t i a t i o n n in M 1 leukemia cells. EMBO J, 15, 3651-8. 
202 
NANDI, D., TAHILIANI, P., KUMAR, A. & CHANDU, D. (2006) The 
ubiquitin-proteasome system. J Biosci, 31, 137-55. 
NEEL, B. G., GU, H. & PAO, L. (2003) The 'Shp'ing news: SH2 domain-
containing tyrosine phosphatases in cell signaling. Trends Biochem Sci, 
28,284-93. 
NEGORO, S., KUNISADA, K., FUJIO, Y., FUNAMOTO, M., DARVILLE, 
M. I., EIZIRIK, D. L., OSUGI, T., IZUMI, M., OSHIMA, Y., 
NAKAOKA, Y., HIROTA, H., KISHIMOTO, T. & YAMAUCHI-
T AKIHARA, K. (2001) Activation of signal transducer and activator of 
transcription 3 protects cardiomyocytes from hypoxiaJreoxygenation-
induced oxidative stress through the upregulation of manganese 
superoxide dismutase. Circulation, 104, 979-81. 
NICHOLSON, S. E., WILLSON, T. A., FARLEY, A., STARR, R., ZHANG, 
1. G., BACA, M., ALEXANDER, W. S., METCALF, D., HILTON, D. 
1. & NICOLA, N. A. (1999) Mutational analyses of the SOCS proteins 
suggest a dual domain requirement but distinct mechanisms for 
inhibition ofLIF and IL-6 signal transduction. EMBO J, 18,375-85. 
NIJHAWAN, D., FANG, M., TRAER, E., ZHONG, Q., GAO, W., DU, F. & 
WANG, X. (2003) Elimination ofMcl-l is required for the initiation of 
apoptosis following ultraviolet irradiation. Genes Dev, 17, 1475-86. 
NOVICK, D., COHEN, B. & RUBINSTEIN, M. (1994) The human interferon 
alphalbeta receptor: characterization and molecular cloning. Cell, 77, 
391-400. 
OKAMURA, T., MIURA, T., TAKEMURA, G., FUJIWARA, H., 
IWAMOTO, H., KAWAMURA, S., KIMURA, M., IKEDA, Y., 
IW A TATE, M. & MA TSUZAKI, M. (2000) Effect of caspase 
inhibitors on myocardial infarct size and myocyte DNA fragmentation 
in the ischemia-reperfused rat heart. Cardiovasc Res, 45, 642-50. 
OLA YIOYE, M. A., BEUVINK, I., HORSCH, K., DALY, J. M. & HYNES, 
N. E. (1999) ErbB receptor-induced activation of stat transcription 
factors is mediated by Src tyrosine kinases. J Bioi Chem, 274, 17209-
18. 
OLIVETTI, G., ABBI, R., QUAIN I, F., KAJSTURA, J., CHENG, W., 
NIT AHARA, 1. A., QUAINI, E., DI LORETO, c.: BELTRAMI, C. A., 
KRAJEWSKI, S., REED, 1. C. & ANVERSA, P. (1997) Apoptosis in 
the failing human heart. N Engl J Med, 336, 1131-41. 
OLIVETTI, G., QUAINI, F., SALA, R., LAGRASTA, C., CORRADI, D., 
BONACINA, E., GAMBERT, S. R., CIGOLA, E. & ANVERSA, P. 
(1996) Acute myocardial infarction in humans is associated with 
activation of programmed myocyte cell death in the surviving portion 
of the heart. J Mol Cell Cardio/, 28, 2005-16. 
203 
OSHIMA, Y., FUJIO, Y., NAKANISHI, T., ITOH, N., YAMAMOTO, Y., 
NEGORO, S., TANAKA, K., KISHIMOTO, T., KAWASE, I. & 
AZUMA, 1. (2005) ST A T3 mediates cardioprotection against 
ischemialreperfusion injury through metallothionein induction in the 
heart. Cardia vase Res, 65,428-35. 
OTTAVIANI, G., LAVEZZI, A. M., ROSSI, L. & MATTURRI, L. (1999) 
Proliferating cell nuclear antigen (PCNA) and apoptosis in hyperacute 
and acute myocardial infarction. Eur J Histoehem, 43, 7-14. 
PARK, S. J., KIM, H. Y., KIM, H., PARK, S. M., JOE, E. H., JOU, I. & 
CHOI, Y. H. (2009) Oxidative stress induces lipid-raft-mediated 
activation of Src homology 2 domain-containing protein-tyrosine 
phosphatase 2 in astrocytes. Free Radie BioI Med, 46, 1694-702. 
PASTORE, A., PIEMONTE, F., LOCATELLI, M., LO RUSSO, A., GAETA, 
L. M., TOZZI, G. & FEDERICI, G. (2001) Determination of blood 
total, reduced, and oxidized glutathione in pediatric SUbjects. Clin 
Chem, 47, 1467-9. 
PAUKKU, K., VALGEIRSDOTTIR, S., SAHARINEN, P., BERGMAN, M., 
HELDIN, C. H. & SILVENNOINEN, O. (2000) Platelet-derived 
growth factor (PDGF)-induced activation of signal transducer and 
activator of transcription (Stat) 5 is mediated by PDGF beta-receptor 
and is not dependent on c-src, fyn, jakl or jak2 kinases. Bioehem J, 345 
Pt 3, 759-66. 
PAULSON, M., PISHARODY, S., PAN, L., GUADAGNO, S., MUI, A. L. & 
LEVY, D. E. (1999) Stat protein transactivation domains recruit 
p300/CBP through widely divergent sequences. J BioI Chem, 274, 
25343-9. 
PERLMAN, H., PAGLIARI, L. J., LIU, H., KOCH, A. E., HAINES, G. K., 
3RD & POPE, R. M. (2001) Rheumatoid arthritis synovial 
macrophages express the Fas-associated death domain-like interleukin-
1 beta-converting enzyme-inhibitory protein and are refractory to Fas-
mediated apoptosis. Arthritis Rheum, 44,21-30. 
PHILLIPS, D., REILLEY, M. 1., APONTE, A. M., WANG, G., BOJA, E., 
GUCEK, M. & BALABAN, R. S. (2010) Stoichiometry ofSTAT3 and 
mitochondrial proteins: Implications for the regulation of oxidative 
phosphorylation by protein-protein interactions . .J BioI Chem, 285, 
23532-6. 
PODEWSKI, E. K., HILFIKER-KLEINER, D., HILFIKER, A., 
MORAWIETZ, H., LICHTENBERG, A., WOLLERT, K. C. & 
DREXLER, H. (2003) Alterations in Janus kinase (JAK)-signal 
transducers and activators of transcription (STAT) signaling in patients. 
with end-stage dilated cardiomyopathy. Circulation, 107, 798-802. 
204 
PRANADA, A. L., METZ, S., HERRMANN, A., HEINRICH, P. C. & 
MULLER-NEWEN, G. (2004) Real time analysis of STAT3 
nucleocytoplasmic shuttling. J Bioi Chem, 279, 15114-23. 
PRIDGEON, 1. W., OLZMANN, J. A., CHIN, L. S. & LI, L. (2007) PINKI 
protects against oxidative stress by phosphorylating mitochondrial 
chaperone TRAPl. PLoS Bioi, 5, e172. 
PUGH, C. W., TAN, C. c., JONES, R. W. & RATCLIFFE, P. 1. (1991) 
Functional analysis of an oxygen-regulated transcriptional enhancer 
lying 3' to the mouse erythropoietin gene. Proc Natl Acad Sci USA, 
88, 10553-7. 
QIU, H., LIZANO, P., LAURE, L., SUI, X., RASHED, E., PARK, J. Y., 
HONG, C., GAO, S., HOLLE, E., MORIN, D., DHAR, S. K., 
WAGNER, T., BERDEAUX, A., TIAN, B., VA TNER, S. F. & 
DEPRE, C. (2011) Hll kinase/heat shock protein 22 deletion impairs 
both nuclear and mitochondrial functions of ST AT3 and accelerates the 
transition into heart failure on cardiac overload. Circulation, 124, 406-
15. 
RAJEWSKY, K., GU, H., KUHN, R., BETZ, U. A., MULLER, W., ROES, 1. 
& SCHWENK, F. (1996) Conditional gene targeting. J Clin Invest, 98, 
600-3. 
RAY, S., BOLDOGH, I. & BRASIER, A. R. (2005) STAT3 NH2-terminal 
acetylation is activated by the hepatic acute-phase response and 
required for IL-6 induction of angiotensinogen. Gastroenterology, 129, 
1616-32. 
REDDY, E. P., KORAPATI, A., CHATURVEDI, P. & RANE, S. (2000) IL-3 
signaling and the role of Src kinases, JAKs and ST ATs: a covert liaison 
unveiled. Oncogene, 19,2532-47. 
RISTER, M. & BAEHNER, R. L. (1976) The alteration of superoxide 
dismutase, catalase, glutathione peroxidase, and NAD(P)H cytochrome 
c reductase in guinea pig polymorphonuclear leukocytes and alveolar 
macrophages during hyperoxia. J Clin Invest, 58, 1174-84. 
ROBIN, M. A., PRABU, S. K., RAZA, H., ANANDATHEERTHA V ARADA, 
H. K. & AVADHANI, N. G. (2003) Phosphorylation enhances 
mitochondrial targeting of GST A4-4 through increased affinity for 
binding to cytoplasmic Hsp70. J Bioi Chem, 278, 18960-70. 
ROSSE, C., LINCH, M., KERMORGANT, S., CAMERON, A. J., 
BOECKELER, K. & PARKER, P. 1. (2010) PKC and the control of 
localized signal dynamics. Nat Rev Mol Cell Bioi, 11, 103-12. 
ROSSI, F. & ZATTI, M. (1964) Biochemical aspects of phagocytosis in 
polymorphonuclear leucocytes. NADH and NADPH oxidation by the 
granules of resting and phagocytizing cells. Experientia, 20, 21-3. 
205 
RUDNICKI, M. A., JACKOWSKI, G., SAGGIN, L. & MCBURNEY, M. W. 
(1990) Actin and myosin expression during development of cardiac 
muscle from cultured embryonal carcinoma cells. Dev Bioi, 138, 348-
58. 
SABBAH, H. N., SHAROV, V., RIDDLE, J. M., KONO, T., LESCH, M. & 
GOLDSTEIN, S. (1992) Mitochondrial abnormalities in myocardium 
of dogs with chronic heart failure. J Mol Cell Cardiol, 24, 1333-47. 
SABIA, P. 1., POWERS, E. R., RAGOSTA, M., SAREMBOCK, I. 1., 
BURWELL, L. R. & KAUL, S. (1992) An association between 
collateral blood flow and myocardial viability in patients with recent 
myocardial infarction. N Engl J Med, 327, 1825-31. 
SAFRAN, M. & KAELIN, W. G., JR. (2003) HIF hydroxylation and the 
mammalian oxygen-sensing pathway. J Clin Invest, Ill, 779-83. 
SANDIN, A., DAGNELL, M., GONON, A., PERNOW, J., STANGL, V., 
ASPENSTROM, P., KAPPERT, K. & OSTMAN, A. (2011) Hypoxia 
followed by re-oxygenation induces oxidation of tyrosine phosphatases. 
Cell Signal, 23, 820-6. 
SANO, S., IT AMI, S., TAKEDA, K., TARUTANI, M., YAMAGUCHI, Y., 
MIURA, H., YOSHIKAWA, K., AKIRA, S. & TAKEDA, J. (1999) 
Keratinocyte-specific ablation of Stat3 exhibits impaired skin 
remodeling, but does not affect skin morphogenesis. EMBO J, 18, 
4657-68. 
SARASTE, A., PULKKI, K., KALLAJOKI, M., HENRIKSEN, K., 
PARVINEN, M. & VOIPIO-PULKKI, L. M. (1997) Apoptosis in 
human acute myocardial infarction. Circulation, 95,320-3. 
SATO, N., YAMAMOTO, T., SEKINE, Y., YUMIOKA, T., JUNICHO, A., 
FUSE, H. & MATSUDA, T. (2003) Involvement of heat-shock protein 
90 in the interleukin-6-mediated signaling pathway through STAT3. 
Biochem Biophys Res Commun, 300,847-52. 
SCARBOROUGH, P., BHATNAGAR, P., WICKRAMASINGHE, K., 
SMOLINA, K., MITCHELL, c., RAYNER, M. (2010) Coronary heart 
disease statistics 2010 edition. British Heart Foundation: London. 
'SCHAEFER, L. K., REN, Z., FULLER, G. N. & SCHAEFER, T. S. (2002) 
Constitutive activation of Stat3alpha in brain tumors: localization to 
tumor endothelial cells and activation by the endothelial tyrosine kinase 
receptor (VEGFR-2). Oncogene, 21,2058-65. 
SCHAEFER, T. S., SANDERS, L. K. & NATHANS, D. (1995) Cooperative 
transcriptional activity of Jun and Stat3 beta, a short form of Stat3. 
Proc Natl Acad Sci USA, 92,9097-101. 
206 
SCHINDLER, C. & DARNELL, 1. E., JR. (1995) Transcriptional responses to 
polypeptide ligands: the JAK-STAT pathway. Annu Rev Biochem, 64, 
621-51. 
SCHINDLER, c., FU, X. Y., IMPROTA, T., AEBERSOLD, R. & DARNELL, 
J. E., JR. (1992a) Proteins of transcription factor ISGF-3: one gene 
encodes the 91-and 84-kDa ISGF-3 proteins that are activated by 
interferon alpha. Proc Natl A cad Sci USA, 89, 7836-9. 
SCHINDLER, C., SHUAI, K., PREZIOSO, V. R. & DARNELL, 1. E., JR. 
(1992b) Interferon-dependent tyrosine phosphorylation of a latent 
cytoplasmic transcription factor. Science, 257, 809-13. 
SCHMIDT, D. & MULLER, S. (2003) PIAS/SUMO: new partners m 
transcriptional regulation. Cell Mol Life Sci, 60,2561-74. 
SCHRADER, M. & FAHIMI, H. D. (2004) Mammalian peroxisomes and 
reactive oxygen species. Histochem Cell Bioi, 122,383-93. 
SEARLE, J., KERR, J. F. & BISHOP, C. 1. (1982) Necrosis and apoptosis: 
distinct modes of cell death with fundamentally different significance. 
Pathol Annu, 17 Pt 2, 229-59. 
SEKIY A, M., HIRAISHI, A., TOUY AMA, M. & SAKAMOTO, K. (2008) 
Oxidative stress induced lipid accumulation via SREBPlc activation in 
HepG2 cells. Biochem Biophys Res Commun, 375,602-7. 
SELZER, A. (1992) Understanding heart disease, Berkeley and Los Angeles, 
California. 
SEMENZA, G. L. (2004) 02-regulated gene expression: transcriptional control 
of cardiorespiratory physiology by HIF-l. J Appl Physiol, 96, 1173-7; 
discussion 1170-2. 
SETATI, M. M., PRINSLOO, E., LONGSHAW, V. M., MURRAY, P. A., 
EDGAR, D. H. & BLATCH, G. L. (2010) Leukemia inhibitory factor 
promotes Hsp90 association with ST AT3 in mouse embryonic stem 
cells. fUBME Life, 62, 61-6. 
SHANKARANARAYANAN, P., CHAITIDIS, P., KUHN, H. & NIGAM, S. 
(2001) Acetylation by histone acetyltransferase CREB-binding 
proteinlp300 of ST AT6 is required for transcriptional activation of the 
15-lipoxygenase-l gene. J Bioi Chem, 276,42753-60. 
SHAROV, V. G., GOUSSEV, A., LESCH, M., GOLDSTEIN, S. & SABBAH, 
H. N. (1998) Abnormal mitochondrial function in myocardium of dogs 
with chronic heart failure. J Mol Cell Cardiol, 30, 1757-62. 
SHELTON, S. 1. (2009) A role for Serum Response Factor in the phenotypic 
maintenance and survival of cardiomyocytes following exposure to 
hypoxia. Thesis submitted to the University of Nottingham. 
207 
SHEN, Y., SCHLESSINGER, K., ZHU, X., MEFFRE, E., QUIMBY, F., 
LEVY, D. E. & DARNELL, J. E., JR. (2004) Essential role ofSTAT3 
in postnatal survival and growth revealed by mice lacking STAT3 
serine 727 phosphorylation. Mol Cell BioI, 24, 407-19. 
SHERMAN, M. A., SECOR, V. H. & BROWN, M. A. (1999) IL-4 
preferentially activates a novel ST AT6 isoform in mast cells. J 
lmmunol, 162,2703-8. 
SHUAI, K., HORVATH, C. M., HUANG, L. H., QURESHI, S. A., 
COWBURN, D. & DARNELL, J. E., JR. (1994) Interferon activation 
of the transcription factor Stat91 involves dimerization through SH2-
phosphotyrosyl peptide interactions. Cell, 76, 821-8. 
SHUAI, K. & LIU, B. (2003) Regulation of JAK-STAT signalling in the 
immune system. Nat Rev lmmunol, 3, 900-11. 
SHUAI, K. & LIU, B. (2005) Regulation of gene-activation pathways by PIAS 
proteins in the immune system. Nat Rev lmmunol, 5,593-605. 
SHUAI, K., SCHINDLER, c., PREZIOSO, V. R. & DARNELL, J. E., JR. 
(1992) Activation of transcription by IFN-gamma: tyrosine 
phosphorylation of a 91-kD DNA binding protein. Science, 258, 1808-
12. 
SILVENNOINEN, 0., SCHINDLER, C., SCHLESSINGER, J. & LEVY, D. 
E. (1993) Ras-independent growth factor signaling by transcription 
factor tyrosine phosphorylation. Science, 261, 1736-9. 
SIMON, A. R., RAI, U., FANBURG, B. L. & COCHRAN, B. H. (1998) 
Activation of the JAK-STAT pathway by reactive oxygen species. Am J 
Physiol, 275, CI640-52. 
SIWIK, D. A., TZORTZIS, J. D., PIMENTAL, D. R., CHANG, D. L., 
PAGANO, P. 1., SINGH, K., SAWYER, D. B. & COLUCCI, W. S. 
(1999) Inhibition of copper-zinc superoxide dismutase induces cell 
growth, hypertrophic phenotype, and apoptosis in neonatal rat cardiac 
myocytes in vitro. Circ Res, 85, 147-53. 
SKERJANC, 1. S. (1999) Cardiac and skeletal muscle development in P19 
embryonal carcinoma cells. Trends Cardiovasc Med, 9, 139-43. 
SMITH, R. M., SULEMAN, N., LACERDA, L., OPIE,·L. H., AKIRA, S., 
CHIEN, K. R. & SACK, M. N. (2004) Genetic depletion of cardiac 
myocyte STAT -3 abolishes classical preconditioning. Cardiovasc Res, 
63,611-6. 
SNYDER, M., HUANG, X. Y. & ZHANG, J. J. (20lO) Stat3 directly controls 
the expression of Tbx5, Nkx2.5, and GATA4 and is essential for 
cardiomyocyte differentiation of Pl9CL6 cells. J Bioi Chern, 285, 
23639-46. 
208 
SOHAL, R. S. (2002) Role of oxidative stress and protein oxidation in the 
aging process. Free Radic BioI Med, 33,37-44. 
SOLTOFF, S. P. (2007) Rottlerin: an inappropriate and ineffective inhibitor of 
PKCdelta. Trends Pharmacol Sci, 28, 453-8. 
SONNENBLICK, STROBECK lE., CAPASSO 1.M. & S.M., F. (1983) 
Ventricular hypertrophy: models and methods. Perspectives in 
cardiovascular research, 8, 13-20. 
STADTMAN, E. R. (1995) Role of oxidized amino acids in protein breakdown 
and stability. Methods Enzymol, 258,379-93. 
STAMLER, 1., NEATON, 1 D. & WENTWORTH, D. N. (1989) Blood 
pressure (systolic and diastolic) and risk of fatal coronary heart disease. 
Hypertension, 13,12-12. 
STEINBERG, D., PARTHASARATHY, S., CAREW, T. E., KHOO, 1. C. & 
WITZTUM, 1. L. (1989) Beyond cholesterol. Modifications of low-
density lipoprotein that increase its atherogenicity. N Engl J Med, 320, 
915-24. 
STEINBERG, S. F. (2008) Structural basis of protein kinase C isoform 
function. Physiol Rev, 88, 1341-78. 
STEPHANOU, A. & LATCHMAN, D. S. (1999) Transcriptional regulation of 
the heat shock protein genes by STAT family transcription factors. 
Gene Expr, 7, 311-9. 
STOUT, R. W. (1987) Ageing and atherosclerosis. Age Ageing, 16,65-72. 
SUGDEN, P. H. & CLERK, A. (2006) Oxidative stress and growth-regulating 
intracellular signaling pathways in cardiac myocytes. Antioxid Redox 
Signal, 8,2111-24. 
TAKAHASHI, T., SCHUNKERT, H., ISOYAMA, S., WEI, 1. Y., NADAL-
GINARD, B., GROSSMAN, W. & IZUMO, S. (1992) Age-related 
differences in the expression of proto-oncogene and contractile protein 
genes in response to pressure overload in the rat myocardium. J Clin 
Invest, 89, 939-46. 
TAKEDA, K., CLAUSEN, B. E., KAISHO, T., TSUJIMURA, T., TERADA, 
N., FORSTER, I. & AKIRA, S. (1999) Enhancea Thl activity and 
development of chronic enterocolitis in mice devoid of Stat3 in 
macrophages and neutrophils. Immunity, 10,39-49. 
TAKEDA, K., KAISHO, T., YOSHIDA, N., TAKEDA, l, KISHIMOTO, T. 
& AKIRA, S. (1998) Stat3 activation is responsible for IL-6-dependent 
T cell proliferation through preventing apoptosis: generation and 
characterization of T cell-specific Stat3-deficient mice. J Immunol, 161, 
4652-60. 
209 
TAKEDA, K., NOGUCHI, K., SHI, W., TANAKA, T., MATSUMOTO, M., 
YOSHIDA, N., KISHIMOTO, T. & AKIRA, S. (1997) Targeted 
disruption of the mouse Stat3 gene leads to early embryonic lethality. 
Proc Natl Acad Sci USA, 94,3801-4. 
TANG, H., YAN, c., CAO, J., SARMA, J. V., HAURA, E. B., WU, M. & 
GAO, H. (2011) An essential role for Stat3 in regulating IgG immune 
complex-induced pulmonary inflammation. F ASEB J, 25, 4292-300. 
TEN HOEVE, J., DE JESUS IBARRA-SANCHEZ, M., FU, Y., ZHU, W., 
TREMBLAY, M., DAVID, M. & SHUAI, K. (2002) Identification of a 
nuclear Stat! protein tyrosine phosphatase. Mol Cell Bioi, 22, 5662-8. 
THAVEAU, F., ZOLL, 1., ROUYER, 0., CHAFKE, N., KRETZ, J. G., 
PIQUARD, F. & GENY, B. (2007) Ischemic preconditioning 
specifically restores complexes I and II activities of the mitochondrial 
respiratory chain in ischemic skeletal muscle. J Vasc Surg, 46, 541-7; 
discussion 547. 
THOMPSON, C. B. (1995) Apoptosis in the pathogenesis and treatment of 
disease. Science, 267, 1456-62. 
THORPE, P. E., HUNTER, W. J., 3RD, ZHAN, X. X., DOVGAN, P. S. & 
AGRAWAL, D. K. (1996) A noninjury, diet-induced swine model of 
atherosclerosis for cardiovascular-interventional research. Angiology, 
47,849-57. 
TOLEDANO, M. B. & LEONARD, W. 1. (1991) Modulation of transcription 
factor NF-kappa B binding activity by oxidation-reduction in vitro. 
Proc Natl Acad Sci USA, 88, 4328-32. 
TONG, H., CHEN, W., STEENBERGEN, C. & MURPHY, E. (2000) 
Ischemic preconditioning activates phosphatidylinositol-3-kinase 
upstream of protein kinase C. Circ Res, 87,309-15. 
TSAI, C. T., LAI, L. P., KUO, K. T., HWANG, J. J., HSIEH, C. S., HSU, K. 
L., TSENG, C. D., TSENG, Y. Z., CHIANG, F. T. & LIN, 1. L. (2008) 
Angiotensin II activates signal transducer and activators of transcription 
3 via Rac 1 in atrial myocytes and fibroblasts: implication for the 
therapeutic effect of statin in atrial structural remodeling. Circulation, 
117,344-55. 
TSUTSUI, H. (2001) Oxidative stress in heart failure: the role of mitochondria. 
Intern Med, 40, 1177-82. 
TURKSON, 1. (2004) STAT proteins as novel targets for cancer drug 
discovery. Expert Opin Ther Targets, 8,409-22. 
TURKSON, J., BOWMAN, T., ADNANE, J., ZHANG, Y., DJEU, J. Y., 
SEKHARAM, M., FRANK, D. A., HOLZMAN, L. B., WU, 1., SEBTI, 
S. & J ~ V E , , R. (1999) Requirement for RaslRacl-mediated p38 and c-
210 
Jun N-tenninal kinase signaling in StaG transcriptional activity induced 
by the Src oncoprotein. Mol Cell BioI, 19,7519-28. 
TURRENS, J. F. (2003) Mitochondrial fonnation of reactive oxygen species. J 
Physiol, 552, 335-44. 
TURRENS,1. F. & BOVERIS, A. (1980) Generation of superoxide anion by 
the NADH dehydrogenase of bovine heart mitochondria. Biochem J, 
191,421-7. 
UNGUREANU, D., SAHARINEN, P., JUNTTILA, 1., HILTON, D. J. & 
SILVENNOINEN, O. (2002) Regulation of Jak2 through the ubiquitin-
proteasome pathway involves phosphorylation of Jak2 on Y1007 and 
interaction with SOCS-1. Mol Cell BioI, 22, 3316-26. 
UNGUREANU, D., VANHATUPA, S., KOTAJA, N., YANG, 1., 
AITTOMAKI, S., JANNE, O. A., PALVIMO, 1. J. & 
SILVENNOINEN, O. (2003) PIAS proteins promote SUMO-1 
conjugation to STATl. Blood, 102,3311-3. 
VAN DER HEYDEN, M. A. & DEFIZE, L. H. (2003) Twenty one years of 
P19 cells: what an embryonal carcinoma cell line taught us about 
cardiomyocyte differentiation. Cardiovasc Res, 58, 292-302. 
VAN PUIJENBROEK, A. A., VAN DER SAAG, P. T. & COFFER, P. J. 
(1999) Cytokine signal transduction in P 19 embryonal carcinoma cells: 
regulation of StaG-mediated transactivation occurs independently of 
p21ras-Erk signaling. Exp Cell Res, 251,465-76. 
VANDEN HOEK, T. L., BECKER, L. B., SHAO, Z., LI, C. & 
SCHUMACKER, P. T. (1998) Reactive oxygen species released from 
mitochondria during brief hypoxia induce preconditioning in 
cardiomyocytes. J BioI Chem, 273, 18092-8. 
VANDEN HOEK, T. L., LI, C., SHAO, Z., SCHUMACKER, P. T. & 
BECKER, L. B. (1997) Significant levels of oxidants are generated by 
isolated cardiomyocytes during ischemia prior to reperfusion. J Mol 
Cell Cardiol, 29,2571-83. 
VEALS, S. A., SCHINDLER, C., LEONARD, D., FU, X. Y., AEBERSOLD, 
R., DARNELL, J. E., JR. & LEVY, D. E. (1992) Subunit of an alpha-
interferon-responsive transcription factor is related to interferon 
regulatory factor and Myb families of DNA-binding proteins. Mol Cell 
BioI, 12,3315-24. 
VIGNAIS, M. L. & GILMAN, M. (1999) Distinct mechanisms of activation of 
Stat! and Stat3 by platelet-derived growth factor receptor in a cell-free 
system. Mol Cell BioI, 19,3727-35. 
VINKEMEIER, U., MOAREFI, I., DARNELL, 1. E., JR. & KURIYAN, 1. 
(1998) Structure of the amino-tenninal protein interaction domain of 
STAT-4. Science, 279, 1048-52. 
211 
VON HARSDORF, R., LI, P. F. & DIETZ, R. (1999) Signaling pathways in 
reactive oxygen species-induced cardiomyocyte apoptosis. Circulation, 
99, 2934-41. 
WAGNER, B. J., HAYES, T. E., HOBAN, C. 1. & COCHRAN, B. H. (1990) 
The SIF binding element confers sislPDGF inducibility onto the c-fos 
promoter. EMBO J, 9,4477-84. 
WAKAO, H., GOUILLEUX, F. & GRONER, B. (1994) Mammary gland 
factor (MGF) is a novel member of the cytokine regulated transcription 
factor gene family and confers the prolactin response. EMBO J, 13, 
2182-91. 
WALLERSTEDT, E., SMITH, U. & ANDERSSON, C. X. (2010) Protein 
kinase C-delta is involved in the inflammatory effect of IL-6 in mouse 
adipose cells. Diabetologia, 53, 946-54. 
WANG, D., MORIGGL, R., STRAVOPODIS, D., CARPINO, N., MARINE, 
J. C., TEGLUND, S., FENG, J. & IHLE, J. N. (2000) A small 
amphipathic alpha-helical region is required for transcriptional 
activities and proteasome-dependent turnover of the tyrosine-
phosphorylated Stat5. EMBOJ, 19,392-9. 
WANG, D., STRA VOPODIS, D., TEGLUND, S., KITAZA WA, J. & IHLE, J. 
N. (1996) Naturally occurring dominant negative variants ofStat5. Mol 
Cell Bioi, 16, 6141-8. 
WANG, G., QIAN, P., JACKSON, F. R., QIAN, G. & WU, G. (2008) 
Sequential activation of JAKs, STATs and xanthine 
dehydrogenase/oxidase by hypoxia in lung microvascular endothelial 
cells. Int J Biochem Cell Bioi, 40, 461-70. 
WANG, Y. & ASHRAF, M. (1999) Role of protein kinase C in mitochondrial 
KA TP channel-mediated protection against Ca2+ overload injury in rat 
myocardium. Circ Res, 84, 1156-65. 
WEBER, J. R. (1991) Left Ventricular Hypertrophy: Its Prevalence, Etiology, 
and Significance. Clin. Cardia!., 14, 13-17. 
WEBER, K. T. & BRILLA, c. G. (1991) Pathological hypertrophy and cardiac 
interstitium. Fibrosis and renin-angiotensin-aldosterone system. 
Circulation, 83, 1849-65. 
WEGENKA, U. M., BUSCHMANN, J., LUTTICKEN, c., HEINRICH, P. C. 
& HORN, F. (1993) Acute-phase response factor, a nuclear factor 
binding to acute-phase response elements, is rapidly activated by 
interleukin-6 at the posttranslationallevel. Mol Cell Bioi, 13, 276-88. 
WEGRZYN, J., POTLA, R., CHWAE, Y. 1., SEPURI, N. B., ZHANG, Q., 
KOECK, T., DERECKA, M., SZCZEPANEK, K., SZELAG, M., 
GORNICKA, A., MOH, A., MOGHADDAS, S., CHEN, Q., BOBBILI, 
S., CICilY, J., DULAK, 1., BAKER, D. P., WOLFMAN, A., 
212 
STUEHR, D., HASSAN, M. 0., FU, X. Y., A V ADHANI, N., DRAKE, 
J. I., FAWCETT, P., LESNEFSKY, E. J. & LARNER, A. C. (2009) 
Function of mitochondrial Stat3 in cellular respiration. Science, 323, 
793-7. 
WEN, Z. & DARNELL, 1. E., JR. (1997) Mapping of Stat3 serine 
phosphorylation to a single residue (727) and evidence that serine 
phosphorylation has no influence on DNA binding of Statl and Stat3. 
Nucleic Acids Res, 25,2062-7. 
WEN, Z., ZHONG, Z. & DARNELL, J. E., JR. (1995) Maximal activation of 
transcription by Stat 1 and Stat3 requires both tyrosine and serine 
phosphorylation. Cell, 82, 241-50. 
WHELAN, R. S., KAPLINSKlY, V. & KlTSIS, R. N. (2010) Cell death in the 
pathogenesis of heart disease: mechanisms and significance. Annu Rev 
Physiol, 72, 19-44. 
WHITE, F. c., CARROLL, S. M., MAGNET, A. & BLOOR, C. M. (1992) 
Coronary collateral development in swine after coronary artery 
occlusion. Circ Res, 71, 1490-500. 
WHO (2008) The global burden of sisease 2004 update. 
WIBOM, R., HAGENFELDT, L. & VON DOBELN, U. (2002) Measurement 
of A TP production and respiratory chain enzyme activities in 
mitochondria isolated from small muscle biopsy samples. Anal 
Biochem, 311, 139-51. 
WITZTUM, 1. L. & STEINBERG, D. (1991) Role of oxidized low density 
lipoprotein in atherogenesis. J Clin Invest, 88, 1785-92. 
WOBUS, A. M., KLEPPISCH, T., MALTSEV, V. & HESCHELER, J. (1994) 
Cardiomyocyte-like cells differentiated in vitro from embryonic 
carcinoma cells P 19 are characterized by functional expression of 
adrenoceptors and Ca2+ channels. In Vitro Cell Dev Bioi Anim, 30A, 
425-34. 
WOETMANN, A., NIELSEN, M., CHRISTENSEN, S. T., BROCKDORFF, 
J., KAL TOFT, K., ENGEL, A. M., SKOV, S., BRENDER, c., 
GEISLER, c., SVEJGAARD, A., RYGAARD, 1., LEICK, V. & 
ODUM, N. (1999) Inhibition of protein phospha!ase 2A induces 
serine/threonine phosphorylation, subcellular redistribution, and 
functional inhibition of STAT3. Proc Natl Acad Sci USA, 96, 10620-
5. 
WYLLIE, A. H. (1997) Apoptosis and carcinogenesis. Eur J Cell Bioi, 73, 
189-97. 
XIE, Y., KOLE, S., PRECHT, P., PAZIN, M. 1. & BERNIER, M. (2009) S-
g l u t a t h i o ~ y l a t i o n n impairs signal transducer and activator of 
transcription 3 activation and signaling. Endocrinology, 150, 1122-31. 
213 
xu, P., WANG, J., KODAVATIGANTI, R., ZENG, Y. & KASS, I. S. (2004) 
Activation of protein kinase C contributes to the isoflurane-induced 
improvement of functional and metabolic recovery in isolated ischemic 
rat hearts. Anesth Analg, 99, 993-1000, table of contents. 
xu, X., SUN, Y. L. & HOEY, T. (1996) Cooperative DNA binding and 
sequence-selective recognition conferred by the STAT amino-terminal 
domain. Science, 273, 794-7. 
XUAN, Y. T., GUO, Y., HAN, H., ZHU, Y. & BOLLI, R. (2001) An essential 
role of the JAK-STAT pathway in ischemic preconditioning. Proc Natl 
Acad Sci V SA, 98,9050-5. 
Y AJIMA, D., MOTANI, H., HAY AKA WA, M., SATO, Y., SATO, K. & 
IW ASE, H. (2009) The relationship between cell membrane damage 
and lipid peroxidation under the condition of hypoxia-reoxygenation: 
analysis of the mechanism using antioxidants and electron transport 
inhibitors. Cell Biochem Funct, 27,338-43. 
YAMAMOTO, K., QUELLE, F. W., THIERFELDER, W. E., KREIDER, B. 
L., GILBERT, D. 1., JENKINS, N. A., COPELAND, N. G., 
SILVENNOINEN, O. & IHLE, J. N. (1994) Stat4, a-novel gamma 
interferon activation site-binding protein expressed in early myeloid 
differentiation. Mol Cell Bioi, 14,4342-9. 
YAMASHITA, H., XU, J., ERWIN, R A., FARRAR, W. L., KIRKEN, R A. 
& RUI, H. (1998) Differential control of the phosphorylation state of 
proline-juxtaposed serine residues Ser725 of Stat5a and Ser730 of 
Stat5b in prolactin-sensitive cells. J Bioi Chem, 273, 30218-24. 
YANG, B. c., ZANDER, D. S. & MEHTA, J. L. (1999a) Hypoxia-
reoxygenation-induced apoptosis in cultured adult rat myocytes and the 
protective effect of platelets and transforming growth factor-beta(I). J 
Pharmacal Exp Ther, 291, 733-8. 
YANG, E., WEN, Z., HASPEL, R. L., ZHANG, J. J. & DARNELL, J. E., JR 
(1999b) The linker domain of Statl is required for gamma interferon-
driven transcription. Mol Cell Bioi, 19, 5106-12. 
YANG, J., HUANG, J., DASGUPTA, M., SEARS, N., MIYAGI, M., WANG, 
B., CHANCE, M. R, CHEN, X., DU, Y., WANG, Y., AN, L., WANG, 
Q., LU, T., ZHANG, X., WANG, Z. & STARK; G. R. (2010) 
Reversible methylation of promoter-bound ST AT3 by histone-
modifying enzymes. Proc Natl Acad Sci USA, 107,21499-504. 
YAOITA, H., OGAWA, K., MAEHARA, K. & MARUYAMA, Y. (1998) 
Attenuation of ischemia/reperfusion injury in rats by a caspase 
inhibitor. Circulation, 97,276-81. 
YASUKAWA, H., HOSHIJIMA, M., GU, Y., NAKAMURA, T., 
PRADERVAND, S., HANADA, T., HANAKAWA, Y., 
YOSHIMURA, A., ROSS, 1., JR. & CHIEN, K. R. (2001) Suppressor 
214 
of cytokine signaling-3 is a biomechanical stress-inducible gene that 
suppresses gp 130-mediated cardiac myocyte hypertrophy and survival 
pathways. J Clin Invest, 108, 1459-67. 
YELLON, D. M. & DANA, A. (2000) The preconditioning phenomenon: A 
tool for the scientist or a clinical reality? Circ Res, 87,543-50. 
YOKOGAMI, K., WAKISAKA, S., AVRUCH, J. & REEVES, S. A. (2000) 
Serine phosphorylation and maximal activation of ST A T3 during 
CNTF signaling is mediated by the rapamycin target mTOR. Curr BioI, 
10,47-50. 
YOSHIDA, K. (2007) PKCdelta signaling: mechanisms of DNA damage 
response and apoptosis. Cell Signal, 19, 892-901. 
YOUNG, L. H., BALIN, B. J. & WEIS, M. T. (2005) Go 6983: a fast acting 
protein kinase C inhibitor that attenuates myocardial 
ischemiaireperfusion injury. Cardiovasc Drug Rev, 23,255-72. 
YU, C. L. & BURAKOFF, S. 1. (1997) Involvement of proteasomes in 
regulating Jak-STAT pathways upon interleukin-2 stimulation. J BioI 
Chern, 272, 14017-20. 
YU, C. L., MEYER, D. J., CAMPBELL, G. S., LARNER, A. c., CARTER-
SU, c., SCHWARTZ, 1. & JOVE, R. (1995) Enhanced DNA-binding 
activity of a Stat3-related protein in cells transformed by the Src 
oncoprotein. Science, 269,81-3. 
YU, H. & JOVE, R. (2004) The STATs of cancer--new molecular targets come 
of age. Nat Rev Cancer, 4,97-105. 
YUE, H., LI, W., DESNOYER, R. & KARNIK, S. S. (2010) Role of nuclear 
unphosphorylated ST AT3 in angiotensin II type 1 receptor-induced 
cardiac hypertrophy. Cardiovasc Res, 85,90-9. 
YUE, Y., QIN, Q., COHEN, M. V., DOWNEY, 1. M. & CRITZ, S. D. (2002) 
The relative order of mK(ATP) channels, free radicals and p38 MAPK 
in preconditioning's protective pathway in rat heart. Cardiovasc Res, 
55,681-9. 
ZHANG, 1. J., VINKEMEIER, U., GU, W., CHAKRAVARTI, D., 
HORVATH, C. M. & DARNELL, 1. E., JR. (199.6) Two contact 
regions between Statl and CBP/p300 in interferon gamma signaling. 
Proc Natl Acad Sci USA, 93, 15092-6. 
ZHANG, J. J., ZHAO, Y., CHAIT, B. T., LATHEM, W. W., RITZI, M., 
KNIPPERS, R. & DARNELL, J. E., JR. (1998) Ser727-dependent 
recruitment of MCM5 by Statlalpha in IFN-gamma-induced 
transcriptional activation. EMBO J, 17, 6963-71. 
ZHANG, T., K E ~ , , W. H., SEOW, K. T., FUNG, W. & CAO, X. (2000) The 
coiled-coil domain of Stat3 is essential for its SH2 domain-mediated 
215 
receptor binding and subsequent activation induced by epidermal 
growth factor and interleukin-6. Mol Cell Bioi, 20, 7132-9. 
ZHANG, X., BLENIS, J., LI, H. C., SCHINDLER, C. & CHEN-KIANG, S. 
(1995) Requirement of serine phosphorylation for formation of STAT-
promoter complexes. Science, 267, 1990-4. 
ZHANG, X., GUO, A., YU, J., POSSEMATO, A., CHEN, Y., ZHENG, W., 
POLAKIEWICZ, R. D., KINZLER, K. W., VOGELSTEIN, B., 
VELCULESCU, V. E. & WANG, Z. 1. (2007) Identification ofSTAT3 
as a substrate of receptor protein tyrosine phosphatase T. Proc Natl 
A cad Sci USA, 104, 4060-4. 
ZHANG, x., WRZESZCZYNSKA, M. H., HORVATH, C. M. & DARNELL, 
J. E., JR. (1999) Interacting regions in Stat3 and c-Jun that participate 
in cooperative transcriptional activation. Mol Cell Bioi, 19,7138-46. 
ZHANG, Y., MARCILLAT, 0., GIULIVI, C., ERNSTER, L. & DAVIES, K. 
1. (1990) The oxidative inactivation of mitochondrial electron transport 
chain components and ATPase. J Bioi Chem, 265, 16330-6. 
ZHAO, M., LIU, F., WANG, J. Y., ZHANG, W. Y., GAO, F. H. & JIANG, B. 
(2011) [Effects of JAK2/ST AT3 signaling pathway on angiogenesis in 
non-small cell lung cancer]. Zhonghua Yi Xue Za Zhi, 91, 375-81. 
ZHAO, X., HE, G., CHEN, Y. R., PANDIAN, R. P., KUPPUSAMY, P. & 
ZWEIER, J. L. (2005) Endothelium-derived nitric oxide regulates 
postischemic myocardial oxygenation and oxygen consumption by 
modulation of mitochondrial electron transport. Circulation, 111,2966-
72. 
ZHONG, Z., WEN, Z. & DARNELL, J. E., JR. (1994) Stat3: a STAT family 
member activated by tyrosine phosphorylation in response to epidermal 
growth factor and interleukin-6. Science, 264,95-8. 
ZHOU, H., NEWNUM, A. B., MARTIN, 1. R., LI, P., NELSON, M. T., MOH, 
A., FU, X. Y., YOKOTA, H. & LI, J. (2011) Osteoblastlosteocyte-
specific inactivation of Stat3 decreases load-driven bone formation and 
accumulates reactive oxygen species. Bone, 49, 404-11. 
ZHOU, L. & TOO, H. P. (2011) Mitochondrial localized STAT3 is involved in 
NGF induced neurite outgrowth. PLoS One, 6, e21680. 
ZIMMERMAN, A. N. & HULSMANN, W. C. (1966) Paradoxical influence of 
calcium ions on the permeability of the cell membranes of the isolated 
rat heart. Nature, 211, 646-7. 
ZOROV, D. B., JUHASZOV A, M. & SOLLOTT, S. 1. (2006) Mitochondrial 
ROS-induced ROS release: an update and review. Biochim Biophys 
Acta, 1757,509-17. 
ZOU, Y., TAKANO, H., MIZUKAMI, M., AKAZAWA, H., QIN, Y., TOKO, 
H., SAKAMOTO, M., MINAMINO, T., NAGAI, T. & KOMURO, 1. 
(2003) Leukemia inhibitory factor enhances survival of cardiomyocytes 
216 
and induces regeneration of myocardium after myocardial infarction. 
Circulation, 108, 748-53. 
ZWEIER, J. L., FLAHERTY, J. T. & WEISFELDT, M. L. (1987) Direct 
measurement of free radical generation following reperfusion of 
ischemic myocardium. Proc Natl A cad Sci USA, 84, 1404-7. 
217 
Appendices 
Clone charts 
Abbreviation: pRc/eMV STAT3Wt Flag 
Description: Mouse wild-type STAT3 cDNA expression vector. Diagnostic 
Restriction Digest with BamHI (3.2kb, 2.8kb, and 2.0kb) 
Size: Vector: 5500bp 
Insert: 2600bp 
Resistances: Ampicillin 
Bacterial Strain: NM522 
Constructed by: (Horvath et al., 1995) 
Method: Due to a stop codon error made when tagging the Stat3 clone 
with FLAG (DYKDDDDK) additional residues precede (SR) and follow the 
tag (GPYSIVSPKe STOP). The ApaI cloning site is GGG eee, whIch encodes 
the G and P residues coming after the FLAG tag. Therefore, if the insert is 
removed with a NotI and ApaI digestion, it will not have a stop codon 
included. 
Special Remarks: Diagnostic Restriction Digest with BamHI (3.2kb, 2.8kb, 
and 2.0kb). 
Notl 
t 
pRc/CMV STAT3Wt Flag 
218 
Abbreviation: pRc/CMV STAT3c3s Flag 
Description: Mouse STAT3 cDNA expression vector. C418S, C426S and 
C468S. Residues changed to serine render as redox-insenstive. 
Size: Vector: 5500bp 
Insert: 2600bp 
Resistances: Ampicillin 
Bacterial Strain: NM522 
Constructed by: (Li et al., 2010) 
Method: Due to a stop codon error made when tagging the Stat3 clone 
with FLAG (DYKDDDDK) additional residues precede (SR) and follow the 
tag (GPYSIVSPKC STOP). The ApaI cloning site is GGG CCC, which encodes 
the G and P residues coming after the FLAG tag. Therefore, if the insert is 
removed with a NotI and ApaI digestion, it will not have a stop codon 
included. C418S, C426S and C468S mutations were introduced into the 
pRcjCMV STAT3wt Flag vector via site-directed mutagenesis. 
Special Remarks: Diagnostic Restriction Digest with BamHI (3.2kb, 2.8kb, 
and 2.0kb). 
Map: 
Notl 
l 
pRc/CMV STAT3c3S Flag 
f\ 
ApaI Flag 
219 
Abbreviation: pRcjeMV STAT3 s727A Flag 
Description: Mouse STAT3 cDNA expression vector. Residues changed to 
Ala prevent serine phosphorylation of this molelcule. 
Size: Vector: 5500bp 
Insert: 2600bp 
Resistances: Ampicillin 
Bacterial Strain: NM522 
Constructed by: (Wen and Darnell, 1997, Bromberg et aI., 1999) 
Method: Due to a stop codon error made when tagging the Stat3 clone 
with FLAG (DYKDDDDK) additional residues precede (SR) and follow the 
tag (GPYSIVSPKe STOP). The ApaI cloning site is GGG eee, which encodes 
the G and P residues coming after the FLAG tag. Therefore, if the insert is 
removed with a Notl and ApaI digestion, it will not have a stop codon 
included 
Special Remarks: Diagnostic Restriction Digest with Bam HI (3.2kb, 2.Skb, 
and 2.0kb). 
Map: 
NotI 
t 
pRc/CMV STAT3S727 A Flag 
t'\ 
ApaJ Flag 
220 
Abbreviation: pRcjCMV STAT3C Flag 
Description: Mouse STAT3 eDNA expression vector. A662C and N664C 
mutants renders as constitutively active. 
Size: Vector: 5500bp 
Insert: 2600bp 
Resistances: Ampicillin 
Bacterial Strain: NM522 
Constructed by: (Bromberg et al., 1999) 
Method: Due to a stop codon error made when tagging the Stat3 clone 
with FLAG (DYKDDDDK) additional residues precede (SR) and follow the 
tag (GPYSIVSPKC STOP). The ApaI cloning site is GGG CCC, which encodes 
the G and P residues coming after the FLAG tag. Therefore, if the insert is 
removed with a NotI and ApaI digestion, it will not have a stop codon 
included 
Special Remarks: Diagnostic Restriction Digest with BamHI (3.2kb, 2.8kb, 
and 2.0kb). . 
Map: 
NotI 
t 
pRc/CMV STAT3C Flag 
t' ApaJ Flag 
221 
Abbreviation: pRcjCMV STATs727D Flag 
Description: Mouse STAT3 cDNA expression vector. Residues changed to 
Asp renders the molecule as phospho-mimetic. 
Size: Vector: 5500bp 
Insert: 2600bp 
Resistances: Ampicillin 
Bacterial Strain: NM522 
Constructed by: Emma Evans 
Method: Due to a stop codon error made when tagging the Stat3 clone 
with FLAG (DYKDDDDK) additional residues precede (SR) and follow the 
tag (GPYSIVSPKe STOP). The ApaI cloning site is GGG eee, which encodes 
the G and P residues coming after the FLAG tag. Therefore, if the insert is 
removed with a NotI and ApaI digestion, it will not have a stop codon 
included. Serine to Aspartic acid mutation generated using site-directed 
mutagenesis. 
Special Remarks: Diagnostic Restriction Digest with BamHI (3.Zkb, 2.8kb, 
and 2.0kb). 
Map: 
NoH 
t 
pRc/CMV STATs727D Flag 
t" ApaJ Flag 
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Abbreviation: pRcjeMV STATs727E Flag 
Description: Mouse STAT3 cDNA expression vector. Residues changed to 
Glu renders the molecule as phospho-mimetic. 
Size: Vector: 5500bp 
Insert: 2600bp 
Resistances: Ampicillin 
Bacterial Strain: NM522 
Constructed by: Emma Evans 
Method: Due to a stop codon error made when tagging the Stat3 clone 
with FLAG (DYKDDDDK) additional residues precede (SR) and follow the 
tag (GPYSIVSPKe STOP). The ApaI cloning site is GGG eee, which encodes 
the G and P residues coming after the FLAG tag. Therefore, if the insert is 
removed with a NotI and ApaI digestion, it will not have a stop codon 
included. Serine to glutamic acid mutation generated using site-directed 
mutagenesis. 
Special Remarks: Diagnostic Restriction Digest with BamHI (3 .2kb, 2.8kb, 
and 2.0kb). 
Map: 
Notl 
t 
pRc/CMV STATs727E Flag 
t' ApaI Flag 
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